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ABSTRACT 
 
There is biochemical evidence that the acute phase protein, a1-antichymotrypsin 
(ACT), is involved in Alzheimer’s disease (AD), the most common form of 
dementia.  Inflammation increases the level of ACT in the plasma, and it has 
been suggested that AD provokes chronic neuroinflammation.  One of the key 
proteins in AD is ß-amyloid which associates with ACT in the senile plaques 
characteristic of AD.  Studies to demonstrate a genetic association between 
polymorphisms in the ACT gene and AD have, to date, been inconclusive and 
contradictory.  The discovery, in our laboratory, of a single nucleotide 
polymorphism in the promoter region of ACT suggested a new marker to test 
for a genetic association between ACT and AD. 
To determine if the ACT promoter polymorphism had a functional effect which 
could modify the risk of AD, the promoter region was cloned into reporter 
constructs and transfected into mammalian cells in culture.  These included 
hepatocytes, astrocytes, neuronal cells and mixed population neural cells, and 
these were stimulated with oncostatin M.  In astrocytes, the T allele of the 
promoter allele demonstrates 208% and 146% higher activity than the G allele 
under basal and stimulated conditions, respectively.  In neuronal cells these 
values are 37% and 46%.  Electrophoretic mobility shift assays demonstrated 
differences in binding affinity of a DNA-binding protein, probably TFIIB, and 
the two alleles of the ACT promoter polymorphism.  However, an analysis of 
ACT promoter genotypes in AD cases (n= 389) and controls (n= 335) revealed 
no significant difference in the distribution of genotypes between cases and 
controls (p= 0.250), nor did any ACT promoter geno type appear to modify the 
age of onset of AD (p= 0.997).  The association between the ACT –51bp 
polymorphism and early onset AD was not investigated, due to the small 
number of EOAD cases in the population studied. 
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1 INTRODUCTION 
 
1.1 General Overview 
 
A vast body of information has been accumulated about Alzheimer’s disease in 
the past century. A number of factors have been discovered that contribute to 
the aetiology and pathology of this disease, and advances in several branches of 
biomedical sciences have led to a greater understanding of this condition. As an 
example the progress made in molecular biology has led to a number of genes 
being implicated in the aetiology and pathology of Alzheimer’s disease, and this 
understanding improves hope of producing treatments, and possibly cures and 
preventative measures to combat the disease. 
This introduction is intended to give a summary of some of the advances in the 
molecular pathology related to Alzheimer’s disease. The focus of this thesis will 
be on a1-antichymotrypsin also known as SERPINA3, and it’s role in AD.
1.2 Alzheimer’s Disease 
1.2.1 Features and Scale of Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most common cause of dementia in the elderly 
population accounting for 50 – 70% of all cases (Borchelt, 1998; Kelly, 2000).  
It afflicts an estimated 10% of people over the age of 65, with the incidence and 
prevalence doubling every 5 years, past the age of 60, with the proportion rising 
to 50% of those older than 85. AD reduces life expectancy, and has a marked 
effect on the quality of life of sufferers and family (Gracon and Emmerling, 
2001). According to the most recent data available, AD is the third most 
expensive disease after heart disease and cancer in the USA.  When the direct 
and indirect costs of caring for the estimated 4 million Americans suffering 
from this disease are calculated $100 billion a year is spent on the 
1.2 Alzheimer’s Disease 
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disease (Leifer, 2003).  Studies in the US that counted cause of death on death 
certificates showed that there are 50,000 deaths per year caused by AD, making 
it the eighth leading cause of death in the US, although these figures are likely 
to be an underestimate (Fu et al., 2004). There is no reliable way, at present of 
predicting who is at risk, or when symptoms will develop. In addition the age 
group at risk is the fastest growing sector of the world population, and at the 
present rate of growth, by the year 2050 there will be a worldwide incidence of 
30 million patients with AD (Gracon and Emmerling, 2001). The progress of 
the disease can be divided into three phases; early, middle and late (Kelly, 2000) 
(See table 1.2.1). 
 
Phase Symptom 
Absent mindedness, difficulty recalling names / words 
Increasing forgetfulness 
Difficulty learning new information 
Disorientation in unfamiliar surroundings 
Minor, but uncharacteristic, lapses in judgement and behaviour 
Early 
Reduction in social activities 
Obvious loss of cognitive skills and marked memory loss 
Deterioration in verbal skills: range and content of speech diminishes 
Increased behavioural disturbance, characterised by; frustration, 
impatience, restlessness, and verbal or physical aggression 
Obvious decline in social skills 
Middle 
Emergence of psychotic phenomena; paranoid delusions and 
hallucinations 
Speech becomes monosyllabic and later disappears 
Fleeting psychotic symptoms, because of superimposed delirium 
Behavioural and emotional disturbance 
Loss of bladder and bowel control 
Late 
Mobility deteriorates with a shuffling gait or involuntary movements 
Table 1.2.1: The progression of symptoms in AD, from (Gracon and Emmerling, 2001; 
Kelly, 2000). 
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The symptoms of AD are not uniform, and may be present in a greater or lesser 
degree in individuals. Depression and anxiety are common in the early clinical 
stages in mildly impaired patients, while severely impaired patients may have 
delusions, hallucinations, paranoia, agitation, hostility and aggression (Gracon 
and Emmerling, 2001). 
The chief histopathological characteristics of AD are extracellular senile 
plaques (SPs) and intracellular neurofibrillary tangles (NFTs). The pathology is 
most profound in the limbic system, the temporal, frontal and association 
neurocortices, as well as the basal forebrain areas (Friedland et al., 2001).  
These areas are involved in learning, memory, emotion, judgment, and language 
(Selkoe, 1999). 
Diffuse plaques are present in normal ageing brain, but can develop into senile 
plaques (Burnett, 2000). The number of senile plaques in AD patients is greater 
than in ordinary ageing brains (Howlett et al., 2001). Senile plaques form 
around degenerating nerve endings, which become surrounded by a ß-amyloid 
(Aß) central core (Howlett et al., 1995). In AD the amyloid is mainly Aß1-42 and 
the core also contains heparan sulphate proteoglycan, a1antichymotrypsin (ACT, 
also called SERPINA3), a2macroglobulin (a2M), apolipoprotein E, complement 
factors C1q, C3d, C4d and components of dying cells (Gracon and Emmerling, 
2001). Around this are activated microglia, astrocytes, and dystrophic neurites 
(Burnett, 2000). Senile plaque count does not correlate with severity of 
dementia, but plaque count in specific brain areas correlates with degree and 
type of mental impairment (Cummings and Mega, 1996). Plaques may be 
present for 10 years before AD is clinically detectable (Carr et al., 1997; 
Zubenko, 1997). The Aß in senile plaques has been the focus of much study into 
AD, although recent research has focussed on soluble, intracellular Aß 
oligomers between 4 and 12kDa (Dahlgren et al., 2002; Delacourte et al., 2002; 
Walsh et al., 2002b; Walsh et al., 2000; Yang et al., 1999).  The processing of 
the amyloid precursor protein (APP), which also results in APP-C-terminal 
fragments (APP-CTFs), generates these oligomers.  This is thought to trigger 
the tau pathology, as a decrease in APP-CTFs correlates with an increase in tau 
pathology, however, the mechanism for this is unknown (Sergeant et al., 2002). 
1.2 Alzheimer’s Disease 
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Neurofibrillary tangles (NFT) are an interneuronal structure. They consist of 
paired helical fragments, containing microtubule associated tau protein and 
glycolipids (Gracon and Emmerling, 2001).  Tau participation is dependent on 
the degree to which that protein has been phosphorylated, which is controlled by 
at least eight protein kinases and various phosphatases (Burnett, 2000; Imahori 
et al., 1998).  An increase in intracellular calcium concentration leads to the 
formation of NFTs and the loss of calcium homeostasis may be a common 
factor in senile plaque and NFT formation (Cummings and Mega, 1996). 
In it’s abnormally hyperphosphorylated state tau forms paired helices that 
disrupt microtubule formation and cause cell death. NFTs accumulate in 
response to a variety of degenerative, toxic and traumatic insults to the brain. 
The density of NFTs in the neocortex correlates with the severity of dementia.  
Age related deposits are present in the hippocampus and inferior temporal 
cortex of non-demented elderly people (Burnett, 2000).  NFTs only develop in a 
few types of cortical pyramidal cells, starting in the entorhinal cortex.  The 
destructive processes then spread in a predictable fashion to the isocortex 
(Braak et al., 1993). 
1.2.2 Pathology of Alzheimer’s Disease 
Although definitive diagnosis of AD can only be made on autopsy, often 
decades after the onset of disease (Gracon and Emmerling, 2001; Kelly, 2000; 
Walker, 2000), there are gross changes to the brain during the course of the 
disease.  These include a decrease in brain weight, brain atrophy, specifically in 
the cortex and hippocampus, and the selective loss of the medial temporal lobe 
(Gracon and Emmerling, 2001). It can be seen that these changes take place in 
the brain and so, are difficult to study, as extraction of live tissue is almost 
impossible.  In addition, the brain decreases in weight during normal ageing, 
from about the 5th decade in females, and the 6th in males (Burnett, 2000). AD 
affects the rate and pattern of weight loss in the brain.  There is progressive 
neuronal shrinkage and death, that affects the hippocampus, brain stem, basal 
forebrain and temporoparietal areas of the neocortex and this leads to diffuse 
1.2 Alzheimer’s Disease 
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cortical atrophy and, later, dilated ventricles, which are characteristic of AD 
(Burnett, 2000) (See figure 1.2.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.1: Diagrams of the human brain, showing some of the areas affected by 
Alzheimer’s disease.  Sections highlighted in red are some of those that show neuronal 
shrinkage, while the blue areas are amongst those that decrease in mass. 
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There are histopathological changes to the brain during AD as well. These 
include synaptic loss, and granulovacuolar degeneration, as well as neuronal 
cell death, amyloid plaque formation and amyloid angiopathy, and NFT 
formation, consisting of paired helical fragments of hyperphosphorylated tau 
protein and glycolipids.  There are also changes that indicate an inflammatory 
response, such as the activation of microglia and astrocytes.  The most 
consistent change in AD brains is cholinergic loss in CA1 region of 
hippocampus, but the timing and its connection in relation to the onset of 
symptoms is unknown (Gracon and Emmerling, 2001).  Cell death in the 
forebrain and stem cell nuclei leads to decreased synthesis of neurotransmitters. 
Cholinergic cells project from the basal forebrain into the cortex and 
hippocampus, areas that are involved in AD (Gracon and Emmerling, 2001). 
The cholinergic system is involved in memory and learning, and neuronal loss 
in the nucleus basilis of Meynert (nbM), and loss of choline acetyltransferase 
(CAT) activity correlates with plaque formation, possibly by promoting the 
amyloidogenic metabolic pathway of APP (see 1.2.2) (Burnett, 2000). The 
cholinergic deficits associated with AD include the atrophy of cells in nbM, a 
loss of cholinergic cortical neurones, decreased CAT synthesis, which leads to 
decreased acetyl choline synthesis, a decrease in nicotinic receptor density, and 
possibly a functional change of the muscarinic receptors (Burnett, 2000). The 
loss of cholinergic neurones, and the disruption of choline activity may 
contribute to memory and cognitive changes, and these neurones are believed to 
be especially sensitive to Aß1-42 compared with other cell types (Gracon and 
Emmerling, 2001). 
The direct causes of neuronal damage are thought to come about from a number 
of sources.  These include direct toxic effects of Aß, in particular oligomers of 
Aß1-42 (Sergeant et al., 2003), free radicals that promote Aß, disruption to cells 
caused by NFT formation, altered cell membrane function, leading to calcium 
influx.  These factors can promote Aß and NFT formation (Cummings and 
Mega, 1996), as well as immune mechanisms resulting in the cell lysis due to 
complement activation (Burnett, 2000). 
1.2 Alzheimer’s Disease 
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It is believed that there are a number of amyloid isoforms found in AD, 
including insoluble Aß40 and soluble Aß42 oligomers (Delacourte et al., 2002).  
In this spectrum of Aß isoforms, it has been found that oligomers are 10 times 
more neurotoxic than insoluble fibrils and 40 times more neurotoxic than the 
unaggregated peptide.  Oligomers of Aß42 are more toxic than Aß40, and Aß42 
oligomers correlate with the severity of neurodegeneration in AD (Dahlgren et 
al., 2002).  The oligomeric form of Aß is produced intracellularly, especially in 
neural cells (Walsh et al., 2000) and can be induced by exogenous Aß fibrils 
(Yang et al., 1999).  Aß oligomers are able to inhibit hippocampal long-term 
potentiation in rat brains, and in mouse models, dysfunctional amyloid 
processing appears to precede tau pathology in pre-clinical AD (Sergeant et al., 
2003).  Dysfunction of amyloid precursor protein processing has an effect on 
neuron to neuron propagation of tau pathology (Delacourte et al., 2002), 
indicating that Aß production may be one of the earlier events in AD aetiology.  
The balance between production and clearance of Aß is altered in AD (Evin and 
Weidemann, 2002). 
Diagnosis of AD can only be made post mortem, for a number of reasons.  It is 
rare that patients present a classical form of AD, but instead they show mixed 
pathologies, and there are unresolved issues about the pathological classification 
of all the main dementias (Walker, 2000). There are two conditions in particular 
which overlap with AD; vascular dementia, and dementia with Lewy bodies 
(Gorelick et al., 1996). In addition, there are a number of conditions that can be 
confused with AD on clinical examination.  These include; pseudodementia, 
delirium, fronto-temporal dementia, alcohol related dementia, toxic and drug 
encephalopathies, normal pressure hydrocephalus, chronic subdural haematoma, 
certain infectious diseases, Cruetzfeldt-Jakob disease and various endocrine and 
metabolic disorders (Walker, 2000) all in addition to vascular dementia and 
dementia with Lewy bodies. 
1.2.3 Causes and Risk Factors of Alzheimer’s Disease 
Although there is no known specific cause of AD in most patients (Burnett, 
2000), there are a number of risk factors associated with AD, and these can be 
1.2 Alzheimer’s Disease 
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placed into various categories. Demographic factors, psychological factors, 
medical factors, environmental factors and genetic factors are all thought to play 
a role in the development of AD. Demographic factors are probably the most 
important category of risk factors for AD. The most important risk factor for 
AD is increased age.  An increase in age results in more time for cells to be 
exposed to toxins, and greater neuronal cell death (Burnett, 2000). Ischaemic 
events, hypoxic events, oxidative stress, free radical generation, inflammation 
and repair occur all through life, and this leads to loss of neurones and synapses, 
and decreased cortical acetylcholine levels.  The situation is exacerbated by 
increased concentrations of Aß1-42 (Gracon and Emmerling, 2001; Licastro, 
2001; Licastro et al., 2001). Even accounting for the effects of longevity, 
women have a greater risk for AD, although there is a decreased incidence of 
AD in women who undergo hormone replacement therapy, and oestrogen has 
been linked to improved cognitive performance (Richard and Amouyel, 2001). 
It has been reported that low educational levels and poor linguistic skills 
increases susceptibility to AD as an increase in educational levels indicates 
greater cerebral reserve and stronger synaptic connections (Snowdon et al., 
1997). A history of depression leads to an increased risk of late onset AD, and 
the depressive episodes can occur up to 10 years before the onset of AD 
(Burnett, 2000).  Depression and AD are both associated with over activity of 
the hypothalamus – pituitary – adrenal axis, with an increase in circulating 
levels of cortisol (Burnett, 2000). In rats and primates increases in corticosteroid 
levels can cause hippocampal damage, which worsens with age. 
There are medical conditions that can alter the risk of developing AD (see table 
1.2.2). The excessive microvascular pathology and blood-brain barrier 
abnormalities seen in AD have challenged the traditional division between AD 
and vascular dementia, and has led to the implication of blood vessel 
abnormalities in the pathogenesis of AD (Burnett, 2000).  While blood pressure 
decreases immediately before the onset of dementia, hypertension early in life is 
a risk factor for the disease (Kilander et al., 1998). 
1.2 Alzheimer’s Disease 
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Medical condition Reference 
Hyper- and hypotension Gracon & Emmerling, 2001 
Hyperthyroidism van Duijn, et al, 1992 
Epilepsy van Duijn, et al, 1992 
Hypercholesterolaemia Gracon & Emmerling, 2001 
Coronary artery disease Gracon & Emmerling, 2001 
Atherosclerosis Gracon & Emmerling, 2001 
Cerebrovascular disease Gracon & Emmerling, 2001 
Atrial fibrillation Gracon & Emmerling, 2001 
Down’s syndrome Richard & Amouyel, 2001 
Parkinson’s disease Richard & Amouyel, 2001 
Damage to endothelial cells Gracon & Emmerling, 2001 
Damage to blood-brain barrier Gracon & Emmerling, 2001 
Table 1.2.2: Medical factors that increase the risk of AD. 
Head injury involving loss of consciousness is also a risk factor for AD (van 
Duijn et al., 1992).  The risk may be greatest during the pre-symptomatic phase 
of AD when the capacity for recovery is reduced.  On post mortem an over-
expression of APP has been observed, and NFT and senile plaques have been 
found in the brains of boxers with dementia pugilistica. In addition, Aß 
deposition has been found in 33% of people who die after severe brain injury, 
and the combination of head injury, and an apolipoprotein E ε4 allele (see 
below) leads to a 10 fold greater risk of AD (Mayeux and Ottman, 1998). 
Another medical condition that can modify the risk of AD is diabetes.  It has 
been shown that experimentally induced diabetes results in memory deficits, 
and hyperglycaemia and hyperinsulinaemia could increase the vulnerability of 
neurones to damage by pathological events, for instance; hypoxia, 
hypoglycaemia or Aß deposition (Messier and Gagnon, 1996). In addition, 
adults with mature onset diabetes mellitus have a 1.7 fold increase in their risk 
of dementia, rising to 2 fold greater in men (Leibson et al., 1997). 
Nutrition and toxins can also alter the chances of developing AD, although a 
significant effect of toxins as risk factors has yet to be conclusively 
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demonstrated (Burnett, 2000). Heavy metal poisoning has long been considered 
to play a role in the development of AD.  It has been suggested that redox 
metals such as copper, iron and zinc may play a role in both Aß and tau 
pathologies (Cuajungco and Faget, 2003; Shin et al., 2003; Sparks and Schreurs, 
2003).  It is thought that aluminium may enter cells and interfere with 
production of Aß, induce aggregation of Aß and contribute to the formation of 
NFTs, by a mechanism yet to be fully demonstrated.  Conversely, occupational 
exposure to solvents and lead may result in a sma ll drop in the risk of 
developing AD (Burnett, 2000).  Other toxins thought to modify the risk of 
developing AD are heavy alcohol consumption, which lowers the risk of AD, at 
a cost of increasing the likelihood of developing other forms of dementia, and 
controversially, an increased number of cigarettes smoked per day may lead to a 
lower risk of developing AD (Burnett, 2000). Differences in nutrition have been 
shown to modulate the risk of AD.  A deficiency of thiamine leads to vascular 
endothelial cell changes, which lead to local leakage and local Aß expression.  
High fat diets, and high blood cholesterol increases the risk of AD, while 
lowering these decreases the risk of AD.  High cholesterol levels are believed to 
interfere with a-secretase production, and therefore favour the production of 
Aß1-42 (Burnett, 2000). Providing support to the theory that AD can result due to 
a build up of damage by free-radicals and reactive oxygen species over life, a 
diet high in anti-oxidants might provide some benefit in lowering the risk of 
developing AD (Behl and Moosmann, 2002; Burnett, 2000; Carr et al., 1997; 
Goodman et al., 1994; Lauderback et al., 2002). 
The theory of neuronal reserve is used to explain the finding that having a small 
head circumference leads to a more rapid progression of AD (Schofield et al., 
1995). This theory states that a small head circumference, a small brain size, a 
low IQ or a lack of education are indicative of a lower number of synapses, 
decreased neuronal plasticity, and therefore a diminished ability to establish 
alternative circuitry to bypass damaged pathways, and therefore a more rapid 
onset of symptoms (Gracon and Emmerling, 2001). 
The long-term use of non-steroidal anti- inflammatory drugs (NSAIDs), such as 
ibuprofen, indomethacin or dapsone, reduces risk by delaying the onset of 
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symptoms, probably mediated by decreasing the levels of microglial cell 
activation by Aß, and providing support for the belief that AD is an 
inflammatory disease (Gracon and Emmerling, 2001; Richard and Amouyel, 
2001). 
Many non-demented elderly patients come to autopsy with pathologies that 
significantly resemble AD, and it has been hypothesised that there is a final 
common pathway between genetically determined AD, familial AD, sporadic 
AD, Down’s syndrome and normal ageing.  It is also believed that ones genetic 
background may determine the cause of dementia, although mutation accounts 
directly for less than 5% of AD cases, there are a large number of putative 
genetic risk modulators for AD.  The genes known to cause familial 
Alzheimer’s disease are listed in table 1.2.3, while those thought to promote 
sporadic Alzheimer’s disease are listed in table 1.2.4. 
 
Chromosome Gene 
Number of 
pathogenic 
mutations  
Effect of mutation 
21 
Amyloid 
Precursor 
Protein 
12 
Promotes amyloidogenic 
metabolism and Aß deposition 
1 Presenilin 2 10 Promotes Aß deposition 
14 Presenilin 1 135 Promotes Aß deposition 
Table 1.2.3: Amyloid-processing genes directly implicated in Alzheimer’s disease.  A list of 
the pathogenic mutations implicated in familial Alzheimer’s disease can be found on the 
Alzheimer disease & Frontotemporal Dementia Mutations Database (www. 
molgen.ua.ac.be/ADMutations). 
 
Mutations in the genes listed in table 1.2.3 are known to cause familial early 
onset AD.  These genes are all involved in the processing of amyloid precursor 
protein to ß-amyloid, which is central to the pathogenesis of AD.  Only one 
gene has been proven to alter the risk of AD, the lipid transporter 
apolipoprotein E  (APOE) gene (Rocchi et al., 2003; Saunders et al., 1993).  
Table 1.2.4 lists some of the genes that have been suggested as AD 
1.2 Alzheimer’s Disease 
12 
  
susceptibility genes, that modify the risk of late onset sporadic and familial AD.  
This is not a complete list and as more knowledge is gained to determine the 
mechanisms of AD aetiology and pathology other genes will be added to the list 
of genes linked to AD.  Indeed, as high throughput genotyping becomes more 
readily ava ilable the number of potential candidate genes are being discovered 
with increasing frequency (Bertram et al., 2000; Blacker et al., 2003; Tanzi and 
Bertram, 2001), although care is required to validate such studies, to avoid 
false-positive associations (Emahazion et al., 2001). 
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Gene Chromosome Role 
Interleukin-6 1q21 Regulation of inflammatory response 
Nicastrin 1q23 Component of ?-secretase 
Transferrin C2 3q21 Inhibits lipid peroxidation 
Neprilysin 3q21-q27 Degrades Aß 
Butyrylcholinesterase 3q26.1-26.2 Maturation of plaques 
Nitric Oxide Synthase 7q35 Regulates production of nitric oxide 
N-Acetyltransferase 8p23.1-21.3 De-toxification of exogenous toxins 
Very Low Density Lipoprotein 
Receptor 
9p23 Alters lipoprotein metabolism 
Insulin Degrading Enzyme 10q23-q25 Degrades Aß 
Cathepsin D 11p15.5 Cleaves APP, degrades tau protein 
LBP-1c/CP2/LSF Transcriptional 
Factor 
12q13 Protective effect 
a2-Macroglobulin 12q13.3-p12.3 Clearance and degradation of Aß 
Low Density Lipoprotein Receptor-
Related Protein 
12q13-q14 Production and clearance of Aß 
Presenilin 1 Promoter 14q24 Regulates PS1 activity 
a1-Antichymotrypsin 14q32.1 Promotes Aß fibrilisation 
5-HT (Serotonin) Transporter 17q11.1-q12 Involved in serotonin transmission 
Bleomycin Hydrolase 17q11.1q12 Secretion of Aß 
Angiotensin Converting Enzyme 17q23 Inhibits Aß aggregation 
Myeloperoxidase 17q23.1 Oxidation induced damage 
Transforming Growth Factor – ß1 19q13.1-q13.3 Modulates cellular response to injury 
Apolipoprotein E (Apo E)  19q32.2 Aß deposition 
Apo E Promoter 19q32.2 Regulates Apo E  
Cystatin C 20p11.2 Co-localises with Aß 
Table 1.2.4 : Susceptibility genes in Alzheimer's disease (Combarros et al., 2002; Ling et 
al., 2003; Nicholl et al., 1999; Rocchi et al., 2003). 
1.2.3.1 Apolipoprotein E 
The Apolipoprotein E (APOE) gene is found on chromosome 19, and codes for 
the major serum lipoprotein involved in cholesterol metabolism (Lendon et al., 
1997).  The apolipoprotein consists of 299 amino acids (Berr et al., 1994), 
making it far too big to cross the blood brain barrier, but it is synthesised in the 
brain, mainly by astrocytes (Lambert et al., 1997; Lendon et al., 1997).  
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Apolipoprotein E level has been identified as being a risk factor for 
hypercholesteraemia (Berr et al., 1994) and the e4 allelic variant of 
Apolipoprotein E gene is the single most common genetic determinant of AD 
susceptibility (Lendon et al., 1997).  The gene has three alleles, ε2, ε3, and ε4 
resulting from polymorphisms at positions 112 and 158, with ε4 associated with 
a greater risk of developing late onset AD (Lendon et al., 1997).  For ε4 
heterozygotes the risk of developing AD is 2 to 4 fold greater, and ε4 
homozygotes the risk is 5 to 18 fold higher for developing AD compared to 
those with other APOE alleles (Rojas-Fernandez et al., 2002).  While the 
mechanism by which APOE alleles lead to AD is unknown, the pathology could 
result from the absence of ε3 allele, or the presence of the ε4 allele, although the 
risk of AD appears to rise in a dose dependent manner with the number of ε4 
alleles present.  The more ε4 alleles present, the lower the age of onset of AD 
and the greater the rate of Aß deposition (Artiga et al., 1998; Burnett, 2000; 
Lendon et al., 1997).  In addition to this, the same studies have demonstrated a 
protective effect of ε2 alleles (Artiga et al., 1998; Burnett, 2000; Lendon et al., 
1997).  It is known that lipoproteins that contain the e4 isoform of the protein 
are cleared more effectively from the blood (Lendon et al., 1997).  There have 
been suggestions that e4 facilitates the deposition of Aß (Burnett, 2000), or that 
since ApoE binds to tau protein (Burnett, 2000), the isoform may influence 
formation of NFTs, for example e3 decreases the level of tau protein 
phosphorylation, so that e4 promotes the assembly of paired helices, and NFT 
formation (Berr et al., 1994).  Another suggestion is that APOE alleles interact 
with other genetic or environmental factors, such as brain injury (Lendon et al., 
1997; Snowdon et al., 1997). The expression of ApoE increases with neuronal 
damage, and it is possible that it may be part of a compensatory mechanism to 
replace synapses (Lambert et al., 1997).  The risk of AD could be related to 
ApoE expression rate, and it is known that levels of ApoE expression rise after 
insult.  It is also the case that different alleles are expressed at different rates 
(Lambert et al., 1997).  It is possible that the additional risk of AD associated 
with e4 may not be entirely due to intrinsic biochemical properties of isoforms 
of ApoE, but instead results from the expression rate (Artiga et al., 1998).  The 
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level of ApoE expression rises with the ε3 allele over ε4, in both patients and 
controls (Lambert et al., 1997).  In addition there are polymorphisms in the 
regulatory regions of the APOE gene, such as that at position –491, that is in 
linkage disequilibrium with APOE polymorphisms, and can alter APOE 
expression (Thome et al., 1995).  The APOE –491 promoter polymorphism is 
not thought to be in direct association with AD, but this polymorphism could act 
as a genetic modifier for AD risk, although other studies suggest otherwise 
(Licastro et al., 1999b).  This promoter polymorphism is not the only modifying 
factor associated with APOE, while genetic factors are not the sole type of risk 
modifiers that act in tandem with the APOE gene.  Aside from the synergy 
between APOE e4 and brain injury, other biological factors can act with this 
gene to influence risk of developing AD.  There is an inverse relationship 
between number of ε4 alleles and residual brain choline acetyltransferase 
activity and nicotinic receptor density (Poirier et al., 1995), which may have an 
implication on the responsiveness of cholinomimetic therapies (Burnett, 2000), 
as well as providing information about the causes of AD.  
1.2.3.2 The Presenilins 
Two related genes accounting for a number of cases of early onset familial AD 
are the presenilins, PS1 and PS2.  They are located on chromosome 14 and 
chromosome 1 (Citron, 2001; Levy-Lahad et al., 1995; Rogaev et al., 1995; 
Sherrington et al., 1995). The presenilins belong to a family of genes with a 
high degree of interspecies conservation.  PS1 is composed of 12 exons, and is 
about 75kb in length, with open reading frames in exons 3 to 12.  PS2 is greater 
than 90kb in length, and is arranged into 10 exons (Citron, 2001). The 
presenilin genes, although sharing 67% sequence homology are not the product 
of recent gene duplication (Levy-Lahad et al., 1996). 
The majority of cases of familial AD accounted for by the two presenilins are 
caused by mutations of PS1 (Rogaev et al., 1995; Schellenberg, 1995; 
Sherrington et al., 1996; Sherrington et al., 1995). PS1 encodes a 467 amino 
acid polypeptide, predicted to contain seven to nine transmembrane spanning 
domains (Sherrington et al., 1995). In mammalian cells it was found that the 
1.2 Alzheimer’s Disease 
16 
  
polypeptide spans the cell membrane eight times. There are three hydrophilic 
domains, an N-terminus, a C-terminus and a loop, that project into the 
cytoplasm.  The N-terminus and loop domains of PS1/2 have a consensus 
sequence for phosphorylation by cytosolic kinases (Arai et al., 2001). PS1/2 
both undergo endoproteolytic processing which asymmetrically cleaves the 
proteins into C- and N-terminal fragments.  Concentrations of these fragments 
do not increase in parallel with increases in mRNA and full length polypeptide 
(Citron et al., 1992; Haass and De Strooper, 1999; Mercken et al., 1996; 
Thinakaran et al., 1996).  The 43kDa precursor protein is cleaved to a 27kDa N-
terminal fragment and a 17kDa C-terminal fragment in various human organs, 
including the cortex, cerebellum, thyroid, lung, heart, liver, spleen, pancreas, 
kidneys, adrenal glands, testis and muscles (Arai et al., 2001).  The cleavage 
occurs between amino acids 260 and 320.  Familial AD-linked mutations result 
in alternative splicing which causes a deletion in exon 9, which codes for amino 
acids 290 to 319, and this prevents cleavage (Arai et al., 2001). With the 
exception of exon 9 mutants, there is little full length PS1 found, only 
fragments, and this is the only disease- linked mutation that dramatically alters 
proteolytic processing of PS1. 
A gene with a high degree of sequence homology to PS1 was identified on 
chromosome 1, and was identified as PS2.  Mutations of PS2 are a rare cause of 
familial AD, but links between familial AD and markers on chromosome 1 have 
been made in Volga German and Italian pedigrees (Burnett, 2000). 
Presenilin 1 is a foetal protein, and is present in a much higher concentration in 
the cerebral cortices of foetuses compared to adults, but the concentration 
decreases rapidly during development (Okochi et al., 1998).  In the human 
foetal cerebral cortex the concentration of PS1 is 300fmol / mg, but this drops to 
14fmol / mg by adulthood (Okochi et al., 1998). Evidence of the importance of 
PS1 in development comes from the finding that PS1 null mice die at the foetal 
stage of development (Wong et al., 1997). 
There is a high degree of homology between PS1/2 and the Caenorhabditis 
elegans protein SEL-12 (Arai et al., 2001).  SEL-12 facilitates signalling 
mediated by the LIN 12 / Notch family of receptors (Levitan and Greenwald, 
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1995; Levy-Lahad et al., 1995).  A decrease in SEL-12 leads to an egg- laying 
defect in C. elegans, which can be reversed by PS1/2, and it is thought that 
SEL-12 is interchangeable with the presenilins. SEL-12 also reveals that 
familial AD-linked PS1 mutations do not eliminate PS1 function, as there are 6 
independent familial AD-linked PS1 mutations that can restore “missing” SEL-
12 activity (Arai et al., 2001). 
Transfection studies and transgenic mice (expressing PS1/2 and APP) 
experiments show that familial AD-linked PS variants influence APP processing 
(see section 1.2.3.3), which leads to an increase in the insoluble form of ß-
amyloid, Aß1-42 (Arai et al., 2001; Gracon and Emmerling, 2001). It has been 
suggested that PS1 and PS2 may be the γ-secretases that proteolytically cleave 
the amyloid precursor protein, and can influence the production of Aß1-42 (De 
Strooper, 2000).  More recent work has argued that ?-secretase is a complex of 
different proteins (De Strooper and Annaert, 2001; Esler and Wolfe, 2001; 
Octave et al., 2000), and that PS1 and PS2 are components of that complex, 
possibly even forming the active site of ?-secretase.  It is believed that the ?-
secretase complex is formed after leaving the endoplasmic reticulum (Maltese et 
al., 2001).  Although evidence is starting to mount in favour of the theory that ?-
secretase is a complex of proteins there is still debate over this.  The main points 
of contention are as follows: 
(i) The spatial paradox.  The PS’s predominantly localise to intracellular 
ER and Golgi-associated compartments, but PS cleavage of Notch and 
APP occurs at cell surface.  How is it possible for a complex located in 
one region of the cell to cleave a protein found in another?  (Cupers et 
al., 2001; Fortini, 2001) 
(ii) Notch-1 processing is highly selective, APP processing is relaxed, 
allowing for the production of different products.  If ?-secretase is a 
single entity, it must be extremely unusual to be able to generate 
different lengths of Aß (Sisodia et al., 2001). 
Although these two points are difficult to address, they can be reconciled with 
the theory that the presenilins are involved in ?-secretase processing.  The 
evidence in favour of this hypothesis is strong. 
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(i) PS mutations modulate Aß production, and alter ?-secretase activity.  
Primary neurones from PS1 knockout mice embryos have been cultured.  
When transfected with APP, these cultures revealed a marked decrease 
in ?-secretase activity, the maturation and distribution of APP was not 
affected, nor was a- or ß- APP release. Substrates of ?-secretase 
increased dramatically in these cultures.  Compared to their PS1+ 
littermates, Aß production decreased 20%.  PS 1/2 double knockout 
mice were devoid of all ?-secretase activity (Esler and Wolfe, 2001). 
(ii) There is evidence of direct interaction between PS1 and APP, as they co-
immunoprecipitate.  The substitution of conserved aspartate residues of 
presenilins reduces ?-secretase activity in the cell.  Compounds that 
inhibit ?-secretase activity bind directly to presenilins (Cupers et al., 
2001; Maltese et al., 2001) 
(iii) Database comparisons have identified conserved PS motifs similar to 
bacterial proteases (Fortini, 2001). 
(iv)  The generation of ß-amyloids from a presenilin 1/APP fragment was 
blocked by a ?-secretase inhibitor (Shizuka-Ikeda et al., 2002). 
1.2.3.3 Amyloid Precursor Protein 
Beta-amyloid (Aß), one of the key components of senile plaques, is a 39 – 43 
amino acid amyloidogenic peptide, derived from the proteolytic processing of 
the amyloid precursor processing (APP) gene, found on chromosome 21 
(Wasco, 2001). The APP gene is composed of 18 exons, of which three can 
undergo alternate transcription, to produce different mRNA species, including 
APP695, APP751, and APP770. The APP gene contains a Kunitz protein inhibitor 
(KPI) domain, and a domain with homology to the MRC Ox-2 antigen (Roberts 
et al., 1995; Wasco, 2001).  The APP mRNA transcripts are widely, and 
possibly, ubiquitously, expressed, and display tissue specific and developmental 
regulation.  Their transcription is low in the lungs and liver, but high in the 
heart, brain and kidneys.  There is specificity to the transcript locations, but all 
APP transcripts are found in the brain (Wasco, 2001). Amyloid precursor 
proteins (APPs) show features of cell membrane receptor proteins.  They have 
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extracellular, transmembrane and intracellular domains (Roberts et al., 1995), 
and can exist either as an integral membrane-associated type I or after 
proteolytic cleavage, a secreted protein (sAPP) (Wasco, 2001).  Both forms of 
the protein exhibit extensive post-translational modifications.  APP exists in 
three isoforms of 770, 751 and 695 amino acids, which may or may not contain 
a 57aa insert with homology to the Kunitz family of proteinase inhibitors.  In 
addition, the cytoplasmic tail of APP undergoes Thr and Tyr phosphorylation, 
which can alter the affinity for APP with other proteins, such as growth factor 
receptor-bound protein 2 (Goldgaber et al., 1987; Kang et al., 1987; Oltersdorf 
et al., 1989; Podlisny et al., 1990; Tanzi et al., 1987; Van Nostrand et al., 1989; 
Zhou et al., 2004).  The function of the amyloid precursor protein has not been 
determined, but recent research has suggested that the sAPP could be a 
transcription activator, since it forms a multimeric complex with the nuclear 
adapter protein Fe65 and the histone acetyltransferase Tip60 (Cao and Sudhof, 
2001). The precursor protein can be metabolised by one of at least two 
pathways, which produce APP fragments.  These fragments may, or may not 
contain Aß (Wasco, 2001).  The pathways involve a-secretase, ß-secretase, and 
γ-secretase.  The a-secretase pathway, which is the major pathway, involves 
cleavage at the Aß domain, and cleavage at this point precludes the formation of 
Aß (Howlett et al., 2000). The ß-secretase pathway leads to cleavage at the N-
terminal and produces a C-terminal fragment, which can then be cleaved by γ-
secretase, which produces Aß (Golde et al., 1992; Knops et al., 1992; Seubert et 
al., 1992) (Figure 1.2.2). 
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Figure 1.2.2: Cartoon showing processing of the Amyloid Precursor Protein by a-, ß- and 
?-secretases.  The amyloid precursor protein is shown in light blue, with the ß-amyloid 
domain shown in purple.  Black lines bracket the position of the transmembrane domain.  
The approximate positions of the APP cleavage sites are shown. 
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1.2.4 Amyloid Precursor Protein and Amyloid ß Production 
It is likely that the pathways shown in figure 1.2.2 need to be balanced to keep 
Aß below pathological levels, since both pathways occur in healthy brain 
(Burnett, 2000).  Aß is a normal product of neuronal cells and is found in the 
CSF and plasma, although in AD it fibrilises to form insoluble deposits in 
parenchyma and vasculature of vulnerable brain regions (Howlett et al., 2000). 
10% of the Aß produced is the relatively insoluble Aß1-42, which preferentially 
aggregates into the ß-pleat configuration.  Until recently, it had been thought 
that the insoluble aggregated form of Aß was toxic to neurones and caused 
apoptotic cell death and that the soluble form had little toxicity (Burnett, 2000; 
Howlett et al., 1995; Simmons et al., 1994).  Newer evidence, however, points 
to smaller Aß chains, oligomers, as possessing neurotoxic properties, with 
aggregated Aß forming a reservoir of Aß molecules (Kayed et al., 2003; 
Lambert et al., 2001; Walsh et al., 2002a; Walsh et al., 2000).  Mutations in the 
APP gene can increase Aß production (Howlett et al., 2000), and lead to a 
decrease in the potentially neuroprotective sAPPa (Mattson et al., 1992). 
Mutations in the APP gene were the first familial AD gene defects to be 
reported (Chartier-Harlin et al., 1991; Goate et al., 1991; Hendriks et al., 1992; 
Levy et al., 1990a; Levy et al., 1990b; Mullan et al., 1992; Murrell et al., 1991), 
but these mutations cause a small proportion of early onset familial AD (Tanzi 
et al., 1992).  There are at least twelve APP mutations, currently known to cause 
AD in an autosomal dominant manner in families with early onset AD (Wasco, 
2001).  All favour Aß1-42 production over Aß1-40, and all are located within 
exons 16 or 17 of the gene, exons which code for the Aß domain (see figure 
1.2.3). 
Finally, sufferers of Down’s syndrome (trisomy 21), have three copies of the 
APP gene, and show Aß deposits as early as 12 years old (before developing 
other AD pathologies), and can go on to develop AD (Iwatsubo et al., 1995; 
Singleton et al., 2004). 
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Figure 1.2.3: The Aß region of the Amyloid Precursor Protein.  Purple section is the Aß 
domain, arrows show secretase (a -, ß-, and ?-) cleavage sites.   The shaded box represents 
the membrane domain.  Lines show positions of FAD associated coding mutations, with 
text to describe amino acid position, the name of the mutation and red letters describing 
amino acid substitution. 
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1.2.4.1 Amyloid ß Turnover 
The role of Aß in the pathology of AD has meant that a good deal of attention 
has focussed on the metabolism of APP to Aß in the attempt to elucidate the 
mechanism of AD pathogenesis.  There are several different ways believed to 
reduce the Aß load in the brain.  These involve reducing the amount of Aß 
being produced, preventing Aß from causing harm, or clearing Aß from the 
brain before it can cause any damage. 
The level of amyloid in the brain is the result of a balance between biosynthesis 
from APP, via the amyloidogenic pathway, and its catabolism by a number of 
proposed proteolytic enzymes (see figure 1.2.4) (Evin and Weidemann, 2002).  
Recently, research has focussed on the clearance of Aß42 from the brain.  This 
area had been somewhat neglected, in favour of learning about the processes of 
Aß42 synthesis, but the discovery of a family of metalloendoproteases that 
degrade amyloid fibrils has led to increased interest in Aß42 clearence.  It has 
also been demonstrated that astrocytes in the brains of adult mice are attracted 
to Aß by monocyte chemoattractant protein-1, which is present in SPs, and can 
bind and degrade Aß in vitro (Wyss-Coray et al., 2003).  The amyloid-
degrading enzymes include insulin-degrading enzyme (IDE) (Chesneau et al., 
2000; Vekrellis et al., 2000), metalloendopeptidase EC 3.4.24.15 (Yamin et al., 
1999), neprilysin (Iwata et al., 2001) and endothelin-converting enzyme-1 
(Eckman et al., 2001).   
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Figure 1.2.4: Generation and clearance of Aß.  Red arrows show the amyloidogenic 
pathway, green arrows show the non-amyloidogenic pathway, blue arrows depict 
proteolytic cleavage.  Red ellipses show Aß or the Aß domain in APP, and the red 
fragments represent degraded Aß. 
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Neprilysin (NEP) is a 90-110 k-Da plasma membrane glycoprotein, composed 
of a short N-terminal cytoplasmic region, a membrane-spanning section and a 
large C-terminal extracellular, catalytic domain, containing a zinc-binding motif 
(Carson and Turner, 2002).  The active site of NEP is not accessible to large 
peptides and proteins, but it is able to interact with Aß42.  While NEP is 
primarily expressed in the kidney, it is also present in the brain, at low levels 
(Barnes et al., 1995), although expression in the brain of some members of the 
NEP family is modified after nerve injury, suggesting a neuroprotective role 
(Carson and Turner, 2002).  NEP has been demonstrated to degrade amyloid in 
vivo (Mohajeri et al., 2002).  Inhibition or deletion of the NEP gene results in 
~25 to 35% decrease in Aß degradation by the membrane fraction of rat brain, 
suggesting that NEP degrades insoluble membrane-bound Aß (Suh and Checler, 
2002).  In the brains of young neprilysin-deficient mice, the steady-state levels 
of Aß are elevated, but not greatly, and there was no effect on plaque formation, 
which, given the rapid turnover of Aß in the brain, would indicate that 
neprilysin is not the major degrader of Aß.  It is likely that other Aß-clearing 
pathways can compensate for a lack of neprilysin. 
In the majority of cases of familial AD, mutations in genes encoding APP and 
the presenilins increase Aß production and deposition.  Most cases of AD are 
sporadic, and in these cases consistently elevated plasma levels of Aß are not 
observed (Scheuner et al., 1996), which might indicate that a change in Aß 
degradation or clearance may be the cause of increased deposition. 
Evidence to support the amyloid model of AD pathology, in which the 
generation of Aß42 is an early and essential step in the pathological cascade 
which results in the neuronal damage characteristic of AD, comes from the 
discovery of cytokine- like properties of Aß.  It has been shown that Aß is able 
to directly activate the alternative and classical complement pathway, trigger the 
formation of covalent complexes with the complement component C3, and 
generate the cytokine- like C5a fragment, as well as being able to mediate 
production of the proinflammatory C5b-9 membrane attack complex (Bradt et 
al., 1998).  It has been known for some time that inflammation occurs in the 
brains of AD patients, and there had been speculation that Aß could trigger 
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inflammation, along with degenerating neuronal tissue.  These ideas were taken 
further with the publication of a paper which demonstrated that a 105 aa 
carboxyl-terminal fragment (CT105) of APP, as well as Aß42, can induce 
proinflammatory cytokines (Rah et al., 2001).  At relatively low concentrations 
CT105 can induce IL-1ß, TNF-a and nitric oxide (NO), which are not induced 
by Aß.  Carboxyl-terminal fragments of APP have been isolated from 
lymphoblastoid cells obtained from patients with early- or late-onset AD 
(Matsumoto, 1994). 
 
1.2.5 Properties of Aß 
In it’s normal physiological role, unprocessed, full length APP is believed to 
function as a kinesin-1 membrane receptor, with a role in axonal transport 
(Kamal et al., 2001).  The non-amyloidogenic proteolytic processing of APP 
generates C-terminal fragments, which can influence gene expression by acting 
as a transcription factor (Cao and Sudhof, 2001).  In contrast, there has been a 
tendency to view Aß as a dangerous by-product of inappropriate APP 
processing, with only a pathological role.  There is evidence, however, that this 
is not the case.  The finding that Aß is present in the cerebrospinal fluid and 
plasma of healthy individuals throughout their lives has been known for more 
than 10 years (Seubert et al., 1992).  A number of physiological roles have been 
proposed for Aß.  One suggestion was that Aß could act as a physiological 
regulator of ion channel function in rat neurons (Ramsden et al., 2002; Ramsden 
et al., 2001).  However, it is yet to be proven that endogenous Aß has a role on 
brain function after secretion from neurons.  It has recently been shown that 
neuronal activity results in Aß secretion and Aß can downregulate excitory 
synaptic transmission.  Previous work has shown that several factors, including 
neurotransmitters and neuronal depolarisation modulate the generation of APP 
secretory products (Mills and Reiner, 1999; Nitsch et al., 1993).  It has been 
proposed that neuronal activity enhances ß-secretase-mediated cleavage of APP, 
leading to an increase in Aß secretion (Kamenetz et al., 2003).  This is likely to 
be triggered by a signalling cascade initiated by the opening of NMDA 
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receptors, coupled with an influx of Ca2+ into the postsynaptic terminal 
(Esteban, 2004).  Clinical studies have shown that benzodiazepines, which 
enhance inhibitory transmission, reducing excitatory drive, and memantine, an 
NMDA receptor agonist, protected against cognitive decline in Alzheimer’s 
disease (Fastbom et al., 1998; Winblad and Poritis, 1999). 
Aß is able to depress fast excitatory synaptic transmission, mediated by AMPA 
and NMDA receptors, but not inhibitory transmission, mediated by GABA 
receptors (Kamenetz et al., 2003).  Additionally, Aß is able to affect not only 
the neuron producing Aß, but also neighbouring cells.  Aß production impairs 
long-term potentiation (LTP), an indicator of learning and memory function.  
The effects of Aß on synaptic transmission were apparent at levels of Aß 
production well below those necessary for plaque formation, reinforcing the 
theory that the initial stages of AD are asymptomatic, and take place early in 
life. 
It has also been shown that Aß and Aß fragments have cytokine-like and 
inflammatory properties. Aß peptides have been shown to activate the classical 
and alternative complement pathway, both directly and indirectly.  Complexes 
of Aß with activation products of the complement component C3 can generate 
the cytokine- like C5a complement activation fragment, and mediate the 
formation of the proinflammatory C5b-9 membrane attack complex (Bradt et 
al., 1998; Halliday et al., 2000; McGeer and McGeer, 2001a).  In cultured rat 
astrocytes, the ability of Aß to induce glial cell activation in concert with other 
proteins found in senile plaques is enhanced.  Some of the proteins that can 
activate cultured rat glial cells when acting with Aß include ACT and 
interleukin-1ß (IL-1ß) (Hu and Van Eldik, 1999).  This work has been taken 
further, and it has been demonstrated that in cultured human glioma cells Aß on 
its own can induce tumour necrosis factor-a (TNF-a), and IL-6.  A mixture of 
ACT and Aß did not induce IL-6, but caused a much stronger induction of TNF-
a (Sun et al., 2002).  Other evidence suggests that it is not the enitre Aß peptide 
that induces a cytokine response, but only a fragment (see section 1.2.6.1) (Rah 
et al., 2001).  This indicates that inflammation in AD is a self-perpetuating 
chronic state.  It has been suggested that the cytokine-like properties of Aß 
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provide a link between the seemingly disparate pathologies of AD, plaque 
formation, tau protein fibril tangle formation, and neuroinflammation (Lukiw 
and Bazan, 2000). 
Aß-induced oxidative stress has recently emerged as an important new theory.  
It is believed that Aß may be responsible for the generation of reactive oxygen 
species (ROS) (Hensley et al., 1994).  There is evidence that Aß in proto- or 
fibrillar form disturbs the membrane environment of metabolic pathway 
enzymes.  This could lead to increased leakage from redox chains that increase 
ROS toxicity (Goodman et al., 1994).  There is a possible synergy between 
oxidative stress and apoptosis (Howlett et al., 2000), as APP production 
increases after neuronal injury and oxidative stress (Burnett, 2000).  APP 
production also increases after ischaemic stress, and cytotoxic events that lead 
to increased intracellular calcium levels (Burnett, 2000). 
The possibility that Aß has both a physiological and a pathological role is in 
accordance with the hypothesis that in familial forms of neurodegenerative 
diseases, variation occurs in the coding regions of genes, whilst in sporadic 
forms, genetic variations are found in the regulatory regions of genes.  This 
theory explains that a normal protein that is overexpressed, or is not cleared at a 
sufficient rate will be deposited, in a way that may have pathological 
consequences (Singleton et al., 2004). 
 
1.2.6 Therapeutic Strategies for Alzheimer’s Disease 
There are still many unanswered questions about Alzheimer’s disease. For 
example, is there a specific ‘trigger’ that causes the disease, setting in motion 
the production of Aß1-42, the inappropriate phosphorylation of tau protein, and 
from there the development of neurofibrillary tangles and senile plaques?  What 
common pathway leads to the formation of senile plaques and neurofibrillary 
tangles?  Would the clearance of Aß1-42 fibrils be of benefit to sufferers of AD? 
On a more fundamental level, is AD an inflammatory condition, and if it is, 
would the use of anti- inflammatory drugs alleviate, or prevent neuronal damage 
in AD? 
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At present there is only one class of drug available for the treatment of AD, the 
acetylcholinesterase (AChE) inhibitors.  These compounds are unable to halt, or 
reverse the progress of AD they can merely mask the symptoms, making their 
value limited.  There are a large number of therapeutic strategies in different 
stages of design and testing, that have been proposed to either halt the progress 
of AD or to prevent it’s occurrence altogether.  Some of these therapies are 
already undergoing clinical trials, some are at the pre-clinical trial stage, and 
some are untested theories.  Although therapies like inhibitors of protein kinase 
cdk-5, MAPK and cathepsins have been proposed that target tau protein 
phosphorylation, this section will focus mainly on strategies that disrupt the 
amyloidogenic pathway, as evidence is emerging that this is the earlier 
pathological process (Delacourte et al., 2002; Sergeant et al., 2002).  The recent 
creation of a C. elegans model for studying AD-like neurological changes and 
the discovery that oxidative stress precedes Aß fibril formation also 
demonstrates the early impact of APP processing on AD pathogenesis (Drake et 
al., 2003; Link et al., 2003). 
A number of AD therapies are available or undergoing trials.  These therapies 
are listed in table 1.2.5, and those in the most advanced stages of development 
are described below. 
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 Suppression of Symptoms 
Acetylcholinesterase Inhibitors 
Improves mental state scores in 
short term 
In use 
Psychotropic drugs 
Suppress behavioural 
symptoms; anxiety, apathy, 
agitation, aggressiveness, 
depression, serious delusions, 
hallucinations 
In use 
Neuroprotective Strategies 
Anti-oxidants 
Delays time to entry of nursing 
home 
Small clinical trials 
Non-steroidal anti-inflammatories 
Blunt neurotoxic effects of 
inflammatory and acute phase 
responses 
Epidemiological studies and clinical 
trials 
Calcium channel modulators Limits neurotoxic effects of Aß Theoretical 
Free-radical scavengers Reduces oxidative damage Theoretical 
Metal ion chelators Inhibits Aß accumulation Clinical trials 
Inhibition of Aß Production 
ß-secretase inhibitors Prevents secretion of Aß Drug design stage 
?-secretase inhibitors 
Decrease formation of Aß 
oligomers 
Animal trials 
Aß clearance 
Active immunisation Provoke T-cell response to Aß Clinical trials halted 
Passive immunisation Provokes humoral response to Aß Animal trials 
Immunoconjugate immunisation Provokes B-cell response to Aß Animal trials 
a-Secretase Stimulation 
Stimulation of neurotransmitter 
systems 
Lowers cortical Aß, increase sAPPa 
secretion 
Animal trials 
Cholesterol-lowering agents Inhibits Aß formation 
Retrospective epidemiological 
studies, animal trials 
Table 1.2.5: An overview of therapeutic strategies available or proposed for AD (Cherny, 
et al., 2001; Leissring, et al., 2000; Moller, 1998; Sramek and Cutler, 1999). 
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1.2.6.1 Acetylcholinesterase Inhibitors 
It has been shown that cholinergic signalling and transmission in the cerebral 
cortex and hippocampus is disrupted in the brains of AD patients (Cutler and 
Sramek, 2001).  These areas of the brain are associated with memory and 
intellect, and so damage to these areas is an obvious place to look to discover 
the cause of the memory and intellectual deficits found in AD.  In addition to its 
role in transmission, cholinergic stimulation has also been shown to enhance the 
non-amyloidogenic pathway of APP processing, increasing production of 
sAPPa, which has a neuroprotective role (Suh and Checler, 2002).  A number of 
compounds that restore or boost the function of cholinergic signalling have been 
considered for use in AD therapy, and some of these are licensed for use in the 
treatment of AD, such as tacrine hydrochloride (Cognex), which is rarely used, 
due to the severity of side effects, donepezil hydrochloride (Aricept), 
rivastigmine tartrate (Exelon) and galantamine (Reminyl) (Suh and Checler, 
2002).  These compounds are all acetylcholinesterase inhibitors, which inhibit 
the enzyme which hydrolyses acetylcholine (ACh), and therefore increase the 
amount of ACh available to neurones (Cutler and Sramek, 2001).  These drugs 
slow progression of AD, but do not restore cognitive ability. 
1.2.6.2 Antioxidants 
There is evidence to suggest that oxidative damage to neurones is important in 
AD pathogenesis (Drake et al., 2003; Gahtan and Overmier, 1999; Guo et al., 
1999; Lavrovsky et al., 2000).  The use of antioxidants and free radical 
scavengers has been suggested to limit the damage caused by AD, and pre-
clinical studies have shown some beneficial effects (Butterfield, 2001).  Ginkgo 
biloba extract has been shown to protect neurones from oxidative stress, 
possibly caused by Aß effects on mitochondria (Luo et al., 2002).  Another 
compound being investigated is melatonin, which is known to have both anti-
oxidant and anti-amyloidogenic properties, which decreased neuronal damage in 
experimental models (Suh and Checler, 2002).  Vitamin E has also been used in 
small clinical trials to attempt to limit the progress of AD (Behl and Moosmann, 
2002).  Vitamin E is an anti-oxidant and free radical scavenger.  Clinical trials 
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showed no significant effect on cognitive ability, but it may have other 
beneficial health effects, as it delayed the time to entry to care homes. 
1.2.6.3 Vaccines 
The processing of APP to generate Aß is believed to be central to the 
pathogenesis of AD (Sergeant et al., 2002; Walsh et al., 2002a).  AD patients 
accumulate Aß plaques at a greater rate than unaffected individuals, and the 
reasons for this are unclear.  It has been suggested that AD patients either 
generate too much Aß peptide, or that they are less able to clear the peptide 
(Singleton et al., 2004).  In other words the normal equilibrium of Aß is 
disrupted in AD patients resulting in excess Aß remaining in the brain tissues.  
If this hypothesis is correct, it can be assumed that reducing the synthesis of Aß 
or increasing its clearance will be beneficial to AD patients.  Recently 
techniques to stimulate Aß clearance with anti-Aß antibodies have been 
proposed (Schenk et al., 2001). 
There are two methods of introducing anti-Aß antibodies into the brain: active 
vaccination and passive immunisation.  The first strategy, active vaccination, 
which involves introducing a fragment of Aß, or a synthetic Aß to provoke an 
immune response, has got as far as clinical trials.  The other form, passive 
immunisation, where antibodies raised against parts of Aß are administered has 
mainly been used to study the mechanism of active immunisation.  The results 
of experiments with passive immunisation had led some to believe that this 
would be a preferable therapeutic strategy for AD.  
Active immunisation, whereby an immune response is triggered by introducing 
fragments of Aß, synthetic Aß42 or other plaque-associated peptides, has been 
studied in transgenic mice models, and progressed to clinical trials.  Early 
experiments used the PDAPP mouse model; a mini-APP gene coupled with the 
platelet-derived growth factor promoter, containing the FAD mutation 
Val717Phe.  Experiments on mice given synthetic Aß42 before and after 
developing Aß deposits showed a decrease in hippocampal plaques versus 
controls, a decrease in dystrophic neurites and astrocytosis (Games et al., 1995; 
Schenk et al., 1999; Selkoe and Schenk, 2003; Weiner et al., 2000). 
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In younger animals, the build up of Aß plaques was almost completely 
inhibited, and in older animals existing plaques were reduced (Schenk et al., 
1999).  It was demonstrated that mice that develop learning deficits as a result 
of mutant APP with accompanying Aß build up, showed an improvement in 
cognitive abilities after treatment with Aß vaccination (Janus et al., 2000; 
Morgan et al., 2000).  
Aß production was not affected by active immunisation, but pre-existing 
plaques were cleared, and formation of plaques was inhibited in these 
experiments.  Studies using different transgenic mouse models showed no 
learning deficits and improved cognitive performances, comparable to non-
transgenic mice, when compared with transgenic mice in the control group 
(Janus et al., 2000; Morgan et al., 2000).  No adverse effects to active 
immunisation were reported in mouse models.  Immunisation with Aß results in 
antibodies (Ab) associated with extracellular dense-cored plaques and reduced 
Aß plaque deposition, while total brain Aß levels remain unchanged.  Ab is 
directed against Aß in the ß-sheet conformation, not soluble forms of Aß 
(Selkoe and Schenk, 2003).  The mechanism involved in clearing Aß from the 
brain is unknown.  It has been suggested that Fc-mediated microglial 
phagocytosis is involved (Schenk et al., 1999).  Some plaques in immunised 
mice were decorated with IgG, and co-localised with microglia.  Microglia / 
monocytes were located near the remaining plaques.  This mechanism is 
consistent with observations made after passive immunisation (Bard et al., 
2000). 
Passive immunisation involves generating anti-Aß monoclonal antibodies, and 
introducing these to transgenic mice.  This approach has been used to gain an 
insight into the mechanisms involved in active immunisation, but could possibly 
be used in future as a treatment.   
Experiments with 8-10 month old transgenic mice bred to produce Aß plaques 
were treated for 4-5 months with various anti-Aß antibodies.  The antibodies 
used were 10D5, 21F12, polyclonal IgG and the mean cortical Aß was 
compared after 6 months treatment (table 1.2.6) 
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Antibody 10D5 21F12 IgG Control 
Target Aß1-5 Aß33-42 Aß - 
Mean cortical Aß ng/g tissue 6,200 13,580 4,890 13,800 
Table 1.2.6: Mean cortical Aß levels in PDAPP transgenic mice after 6 months from the 
start of peripheral antibody administration (Bard et al., 2000). 
 
Following this slightly older mice (11.5 – 12 months) were treated with mAb 
3D6 (anti-Aß1-5) or 16C11 (anti-tau protein).  The effects of 3D6 were similar to 
10D5, but there was no effect shown with 16C11 (Bard et al., 2000). 
mAb directed against Aß13-28 does not bind to Aß plaques, but decreases brain 
Aß burden, shifting CNS-plasma Aß equilibrium and acting as a peripheral sink 
for amyloid.  This effect was seen, although not as strongly, with 3D6 and 10D5 
(DeMattos et al., 2001; DeMattos et al., 2002).  In addition to this, experiments 
using agents with a high affinity to Aß that are unrelated to antibodies or 
immune-modulators, gelsolin and ganglioside GM1, were shown to reduce 
levels of Aß in the brain when administered peripherally to PDAPP mice 
(Matsuoka et al., 2003).  These agents do not easily cross the blood-brain 
barrier, and add weight to the hypothesis that altering the equilibrium between 
CNS-plasma Aß could be an effective therapeutic strategy. 
Another set of experiments that demonstrate a possible mode of action for 
immunisation therapies used antibodies raised against Aß1-28, which prevented 
the fibrillar aggregation of Aß (Solomon et al., 1997; Solomon et al., 1996).  
Another study to investigate the mechanism of Aß clearance after immunisation 
has raised the possibility of a way of providing a diagnostic test for AD.  The 
antibody 10D5 was labelled with various fluorescent molecules such as 
Thioflavine-S and fluorescein, and directly applied to the cortex of transgenic 
mice.  This permitted the direct observation of Aß plaques, and studying the 
same brain region over 3 days revealed the clearance of these plaques by 
microglial phagocytosis (Bacskai et al., 2001). 
The mechanisms revealed by passive immunisation; prevention of fibrilisation, 
microglial phagocytosis, and removal of Aß from the CNS into the plasma are 
1.2 Alzheimer’s Disease 
35 
  
not mutually exclusive, and one, or all of them could occur after active or 
passive immunisation. 
In late 1999 development began on a human form of the vaccine.  This was 
based on a synthetic human Aß42 peptide, and completed phase I trials with 
small numbers of patients.  Phase II trials began in the USA and Europe, on a 
group of patients, in 2001.  This was a double-blind, placebo-controlled study 
involving 360 patients, but after several months, in February 2002, the trial was 
halted when 15 patients that had received the vaccine developed encephalitis, 
with symptoms of CNS inflammation (Imbimbo, 2002a; Imbimbo, 2002b).  
While studies are underway to determine what caused this response (Imbimbo, 
2002b), other vaccination strategies are being developed.  These include other 
active vaccinations, as before, but with an altered route of administration 
(Weiner et al., 2000) or different adjuvants, (Levey, 2000), or using modified 
Aß epitopes (Imbimbo, 2002a; Sigurdsson et al., 2001), or fusion proteins, 
immunogenic conjugates of Aß (Schenk et al., 2001).  
The mechanism by which the active Aß vaccination works is unclear, although 
there are theories as to what may happen.  Ex vivo assays in brain sections from 
transgenic mice and AD patients demonstrated antibodies against Aß in plaques.  
The antibody triggered microglial cells to clear plaques through phagocytosis 
and peptide degradation, indicating that antibody can cross the blood-brain 
barrier (BBB) (Bard et al., 2000).   
In vivo studies have shown that anti-Aß antibodies applied directly to the cortex 
of transgenic mice can provoke the clearance of Aß (Bacskai et al., 2001).  
Another proposal for the mechanism of Aß vaccination is that the antibodies 
sequester peripheral Aß, creating an Aß sink.  This causes Aß to leave the CNS, 
resulting in a clearance of Aß oligomers and proto-fibrils from the brain 
(DeMattos et al., 2001; Vehmas et al., 2001). 
The findings of these experiments has led to the possibility that the problems 
found in clinical trials of active immunisation may not have ended hopes of an 
immunisation therapy for AD.  Modifying the antigen, altering the route of 
administration, or changing the adjuvant used in active immunisation may 
reduce the risks of adverse side effects.  Alternatively, a passive immunisation 
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therapy may present a lower risk approach, especially if immunisation takes 
place long before development of AD in a younger, healthier population than 
that involved in the failed clinical trials.  Finally, using agents that sequester Aß 
in the plasma, but are not immune-related molecules, might be a safer treatment.  
The story of AD immunisation is not over, although more work will be needed 
than might have been anticipated. 
1.2.6.4 Anti-Inflammatory Drugs 
Retrospective studies investigating non-steroidal anti- inflammatory (NSAID) 
use in AD patients have suggested a possible therapeutic benefit in delaying the 
onset of AD (Rich et al., 1995), and epidemiological studies have found that 
there is a reduced frequency of AD in leprosy and arthritis patients taking 
NSAIDs (Halliday et al., 2000; Mackenzie and Munoz, 1998; McGeer et al., 
1996).  It has been shown that people taking NSAIDs whilst showing clinical 
signs of AD later in life suffer from less severe AD (Cutler and Sramek, 2001; 
Suh and Checler, 2002).  These findings agree with the hypothesis that 
inflammation is a key feature in the progression of AD. Many of the studies into 
the effects of NSAIDs on AD have been epidemiological, and therefore provide 
no evidence of the mechanism of how they work in alleviating the symptoms, or 
preventing the pathogenesis of the disease (Andersen et al., 1995; Flynn and 
Theesen, 1999; Halliday et al., 2000; McGeer et al., 1996; Rich et al., 1995; 
Sramek and Cutler, 1999; Stewart et al., 1997).  The epidemiological studies 
indicate that long-term NSAID use reduces the risk of AD in subjects younger 
than 85 years of age (in 't Veld et al., 1998).  Some studies have been carried out 
using different models to examine the effects of different NSAIDs on cell 
degeneration.  Animal models have been carried out on rats that have been 
given chronic lipopolysaccharide (LPS) infusions to induce the effects of 
chronic neuroinflammation.  These studies, using NO-flurbiprofen (NFP) 
suggested that NSAID therapy should start before inflammatory processes 
develop, and that NFP can reduce the density and active state of microglial cells 
in rats with chronic inflammation (Hauss-Wegrzyniak et al., 1999a; Hauss-
Wegrzyniak et al., 1999b).  Other studies have used transgenic mice that 
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overexpress APP.  When treated with ibuprofen, a reductio n was seen in the 
final levels of IL-1ß and glial fibrillary acidic protein.  In addition, the number 
and area of Aß deposits and ubiquitin- labelled neurites was reduced (Lim et al., 
2000).  Another study, using the spice curcumin, which is not an NSAID, but 
has antioxidant properties, in the same strain of transgenic mice, showed a 
reduction IL-1ß, insoluble Aß, soluble Aß and plaque burden.  The membrane-
associated APP levels were not reduced (Lim et al., 2001).  An NSAID with 
anti-oxidant properties, S-2474, has been investigated using primary cultures of 
rat cortical neurones.  S-2474 is a COX-2 inhibitor, and was demonstrated to 
prevent Aß-induced cell death.  In this study, it was shown that Aß25-35 was 
generating prostaglandin D(2) (PGD(2)) and free radicals which cause cell 
death.  S-2474 exhibits a protective effect either by suppressing PGD(2) or free-
radical damage. 
Several clinical trials with various anti- inflammatory drugs, such as 
indomethacin, dicloflenac and prednisone, have taken place, but these have 
shown mixed results (Aisen et al., 2000; Bruce-Jones et al., 1994; Mallet and 
Kuyumjian, 1998; Rogers et al., 1998; Rojas-Fernandez and Mallery, 1998; 
Scharf et al., 1999).  A new generation of NSAIDs is under development, the 
COX-2 inhibitors, which are expected to target the dysfunctional inflammatory 
pathways of AD (McGeer and McGeer, 2001a). 
 It has been reasoned that since the formation of SPs is the result of chronic 
neuroinflammation, NSAIDs may prevent the build up of SPs.  A study has 
compared brain pathology in post-mortem brain tissue of elderly non-demented 
patients with a history of chronic long-term NSAID use, with a control group of 
non-demented patients that had no history of any conditions that would 
necessitate the long-term use of NSAIDs (Mackenzie and Munoz, 1998).  This 
study showed no difference in the mean number of plaques between the two 
groups, but did show that control patients with SPs had almost three times the 
number of activated microglia as patients with SPs that did take NSAIDs.  This 
would suggest that NSAIDs suppress microglial activity in the brain, rather than 
suppress the formation of plaques.  Animal models have shown NSAID 
treatment to be beneficial in several neurodegenerative diseases, but do not 
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make clear whether these effects are due to the actions of COX inhibitors or 
direct anti- inflammatory properties (Moore and O'Banion, 2002). 
Following modest results in small-scale clinical trials, large multi-centre drug 
trials have been established to determine the efficacy of NSAIDs in the 
treatment of AD.  These trials are not yet complete (Moore and O'Banion, 
2002). 
One proposed strategy for preventing Aß peptide triggered complement proteins 
from causing neuronal damage would be to introduce anti-sense mRNA to APP 
into the affected areas of the brain.  Anti-sense mRNA can cross the blood-brain 
barrier, and reduces learning and memory deficits in aged mice, if it is coupled 
to an oligonucleotide transport system (Banks et al., 2001). 
1.2.6.5 Oestrogen 
The sex hormone oestrogen is known to affect intracellular signal transduction 
cascades, and can have a neuroprotective effect (Suh and Checler, 2002).  
Several studies have shown that being female is a risk factor for AD (Carr et al., 
1997), and small scale trials have indicated that oestrogen replacement therapy 
can improve cognition in AD patients (Cutler and Sramek, 2001).  Research has 
linked Parkinson’s disease and AD with oestrogen levels, which decreases 
rapidly after the menopause (Suh and Checler, 2002), but the mechanism for it’s 
actions is unclear.  The effect, which seems to be preventative, is possibly due 
to anti-oxidant properties of oestrogen (Behl and Moosmann, 2002), but it might 
also be due to the role it plays in modifying inflammation, or by acting on IL-6, 
or signal transduction via the MAPK pathway (Suh and Checler, 2002).  Other 
studies have shown that oestrogen can promote non-amyloidogenic processing 
of APP (Hooper and Turner, 2002).  A number of large-scale trials are being 
undertaken, that may settle the question of the benefits of oestrogen replacement 
therapy in AD treatment (Cutler and Sramek, 2001). 
 
1.2.6.6 Beta-secretase Inhibitors 
In the amyloidogenic-processing pathway of APP, two factors are of critical 
importance: ß-secretase and ?-secretase.  In this pathway, APP is first cleaved 
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by ß-secretase, then ?-secretase, resulting in the formation of Aß, so the 
suppression of either would theoretically prevent the pathogenesis of AD.  The 
major enzyme responsible for ß-secretase cleavage has been shown to be ß-site 
APP cleavage enzyme 1 (BACE1) (Cai et al., 2001; Vassar, 2001; Vassar et al., 
1999).  Although a homologous enzyme, BACE2, has been found, inhibition of 
BACE1 appears sufficient to reduce AD pathology in mice (Luo et al., 2001; 
Vassar, 2001).  The development of an effective BACE1 inhibitor for use by 
AD patients has become an important goal in the search for effective AD 
therapies, as it has been shown that BACE can produce toxic fragments of APP 
even if ?-secretase cleavage of APP has been blocked (Suh and Checler, 2002). 
Several BACE1 inhibitors have been found, and one class is capable of 
inhibiting both ß- and ?-secretase cleavage.  These inhibitors have been shown 
to cross the blood-brain barrier, and are undergoing pre-clinical trials to 
determine toxicity and tolerance (Suh and Checler, 2002). 
1.2.6.7 Gamma-secretase Inhibitors  
Attention has focussed on ?-secretase, as a potential target for therapy (Beher 
and Shearman, 2002; De Strooper et al., 1998; Esler et al., 2000; Schenk et al., 
2001; Selkoe, 1998; Tsai et al., 2002; Zhang et al., 2000), but there have been 
suggestions that since it may not be involved in normal cell signalling, ß-
secretase may be a better target (Howlett et al., 2000; Selkoe, 2001).  It has been 
discovered, however, that compounds can be developed that would inhibit ?-
secretase cleavage of APP, but maintain Notch signalling (Beher and Shearman, 
2002; Petit et al., 2001), as it appears that the Notch signalling and APP 
processing mechanisms of ?-secretase are not entirely homologous (Beher et al., 
2001; Lichtenthaler et al., 2002; Rozmahel et al., 2002). 
An off-shoot into research looking at ?-secretase/presenilin activity in AD has 
been the discovery that reduced PS1 activity alters calcium channel modulation 
(Yoo et al., 2000).  This corresponds to earlier findings, that associated Aß with 
the destabilisation of calcium homeostasis, resulting in neuronal damage 
(Mattson et al., 1992).  A number of compounds that inhibit amyloidogenic APP 
processing, but maintain a sufficient level of Notch processing are currently 
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being investigated for efficacy and toxicity in cultured cell and animal models 
(Suh and Checler, 2002). 
Another method of decreasing amyloidogenesis would be to increase the 
activity of a-secretase.  The protease plasmin seems to increase APP processing 
at the a-secretase cleavage site, and degrade APP fragments, which if verified 
would suggest another target for AD therapy (Carson and Turner, 2002; 
Ledesma et al., 2000; Periz and Fortini, 2000). 
1.2.6.8 Other Therapeutic Strategies 
Some drugs that are licensed for the treatment of other conditions have been 
shown to have beneficial effects in the treatment of AD, in addition to the anti-
inflammatory drugs, discussed above.  These include cholesterol- lowering 
drugs, such as simvastatin and lovastatin, which have been shown to lower the 
levels of Aß42 and Aß40 in the CSF and brain homogenates from guinea pigs 
(Fassbender et al., 2001).  The finding that cholesterol- lowering drugs may be 
beneficial in the treatment of AD is related to the cholesterol transport protein 
apolipoprotein E being a recognised risk factor for AD (Pappolla et al., 2002; 
Poirier, 2003; Poirier et al., 1995; Puglielli et al., 2003).  Clinical trials have 
begun on treating AD with cholesterol- lowering drugs (Puglielli et al., 2003; 
Suh and Checler, 2002).  Another drug believed to have therapeutic benefits in 
AD is the antibiotic clioquinol (Helmuth, 2000).  This antibiotic is a metal ion 
chelator, which is believed to be able to have a neuroprotective effect, although 
the mechanism of this is unclear.  Several metal ions have been shown to 
promote plaque formation (Cherny et al., 2001; Chong and Suh, 1995; 
Dominguez and Strooper, 2002; Kawahara et al., 2001), but as it is believed that 
Aß plaques are the result, not the cause, of neural degeneration in AD, this is 
unlikely to be the mechanism by which metal ions cause neuronal damage. 
In addition to therapeutic interventions that are intended to halt, or prevent AD, 
a number of treatments to ameliorate or temporarily suppress certain debilitating 
symptoms are available.  AD can result in behavioural disturbances, including 
anxiety, apathy, agitation, aggressiveness, depression, delusions and 
hallucinations (Mayeux and Sano, 1999).  Various anxiolytics, such as 
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benzodiazepines, can be used to suppress these symptoms, but a worsening of 
dementia often outweighs the ir benefits.   Non-phenothiazine antipsychotic 
agents, such as haloperidol, are more usually used.  For patients with 
depression, low doses of selective serotonin re-uptake inhibitors are sometimes 
prescribed, although these may temporarily heighten cognitive defects.  In cases 
of marked apathy, stimulants, such as methylphenidate, can be used.  
Anticonvulsants, such as carbamazepine, are administered for anxiety and 
agitation. 
Another possible strategy for AD therapy would be to utilise the Aß degrading 
properties of neprilysin.  This strategy does not interfere with the processing of 
APP or signalling pathways (see figure 1.2.4).  The restricted location of the 
active site limits potential substrates to less than 50 k-Da, reducing the number 
of inappropriate interactions that could result in side effects that could occur 
with inhibiting APP processing.  In addition, neprilysin preferentially degrades 
abundant substrates, such as the large amounts of Aß found in pathological 
conditions (Fukami et al., 2002). 
 
1.2.7 Evidence of Inflammation in Alzheimer’s Disease 
There is evidence to support the view that inflammatory- like, if not actual 
inflammatory, processes take place during the pathology of Alzheimer’s 
disease. Strong evidence comes from the observations of several proteins 
involved in inflammation, such as a1-antichymotrypsin and apolipoprotein E, 
being associated with amyloid plaques (Durany et al., 2000; Rebeck et al., 1995; 
Styren et al., 1998). In addition, a number of epidemiological studies revealed 
that anti- inflammatory drug treatment correlates to a negative risk of AD 
(Andersen et al., 1995; McGeer et al., 1996; Rich et al., 1995).  These studies 
were followed up by animal experiments and clinical trials of non steroidal anti-
inflammatory (NSAID) treatments (Hauss-Wegrzyniak et al., 1999a; Lim et al., 
2001; Lim et al., 2000; Scharf et al., 1999; Yagami et al., 2001).  It has also 
been demonstrated that Aß plays a role in initiating inflammatory responses 
(Cotman et al., 1996; Kalaria et al., 1996).  The study of inflammation is 
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detailed and complex, and the processes of neuroinflammation in AD are 
bewilderingly complex, even though the humoral immune response appears to 
take little or no part. Of the pathways that are involved in AD, the complement, 
cytokine, chemokine, acute phase response and so on, most research has 
focussed on the acute phase response, which will be investigated more closely 
as part of this thesis. The acute phase is a highly sophisticated and complex 
response, involving numerous reactions and interactions, and only those 
relevant to this body of work will be detailed here.  There are a number of 
reviews that summarise the major research into neuroinflammation, e.g. 
Akiyama, et al., 2000. 
There is evidence to show that neuroinflammation is a prominent feature of 
Alzheimer’s disease, which has important implications for therapy.  In addition 
to the epidemiological studies that identified a reduced risk for AD in patients 
treated with anti- inflammatory drugs (Andersen et al., 1995; Halliday et al., 
2000; McGeer et al., 1996) and longitudinal studies showing that consumption 
of anti- inflammatory drugs lowers the risk of AD in younger patients (Halliday 
et al., 2000), other lines of evidence support this theory.  Degenerating tissue, 
which is a feature of AD is a classical stimulant of inflammation (Akiyama et 
al., 2000).  Cultured microglia and astrocytes, which localise to SPs 
(Eikelenboom and Veerhuis, 1996; Halliday et al., 2000; McGeer and McGeer, 
1995) are known to produce inflammatory molecules, such as cytokines, 
complement factors and acute phase proteins (Eikelenboom and Veerhuis, 1996; 
McGeer and McGeer, 1995).  There is also evidence of increased platelet 
activation in AD (Halliday et al., 2000).  Polymorphisms in genes for 
inflammatory molecules, including IL-1a, IL-1ß, a2-macroglobulin and ACT 
are known to modulate the risk of AD (Franceschi et al., 2001; McGeer and 
McGeer, 2001b; Morgan et al., 2001; Rocchi et al., 2003; Scacchi et al., 2001), 
IL-1, for instance, has been shown to upregulate the translation of APP (Potter 
et al., 2001). 
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1.2.8 The Acute Phase Response and Inflammation 
As a result of an insult, such as injury, trauma or infection of a tissue a series of 
tightly regulated responses is initiated by the body in an attempt to limit the 
damage caused, and restore normal homeostasis.  These responses are 
collectively known as inflammation, and the early and immediate set of 
reactions induced is known as the acute phase response.  The acute phase 
response begins in the region of the insult, but can lead to the activation of 
genes in organs far from the original site (Baumann and Gauldie, 1994; 
Trowbridge and Emling, 1997). 
The acute phase response is made up of many systemic and metabolic changes, 
and is initiated in response to tissue damage, infection, malignant disease or 
immunological disorders.  These traumas unbalance the normal homeostasis and 
the purpose of the acute phase response is to restore homeostasis (Slaviero et al., 
2003).  To achieve this the acute phase response increases local neutrophil 
levels, which activate complement and coagulation pathways, and upregulates 
the production of acute phase proteins (Baumann and Gauldie, 1994).  The 
symptoms of the acute phase response include fever and fatigue, and it normally 
lasts for a few days, until homeostasis is restored (Slaviero et al., 2003).  If 
inflammation is chronic or recurring, the acute phase response can persist, and 
contribute to the pathology of disease (Balkwill and Mantovani, 2001). 
The acute phase response is the result of complex phagocyte-derived 
endogenous mediators, in particular the cytokines, a family of over 80 proteins.  
Cytokines are small (8-40kDa) and soluble and are crucial to the activation, 
development and determination of the extent of the immune response.  They act 
at pico- or femtomolar concentrations, and their production is generally 
transient and inducible (Slaviero et al., 2003).  A number of cytokines are 
involved in inflammation and the acute phase response, the proinflammatory 
cytokines, which includes tumour necrosis factor a (TNFa), some interleukins 
(IL-1, IL-6) and interferons (Trowbridge and Emling, 1997).  The inflammatory 
response to stimuli involves the synthesis and release of a number of factors, 
including cytokines, inflammatory mediators, e.g., histamine, bradyk inin and 
prostagladins, and hormones, such as cortisol and corticotrophin (Slaviero et al., 
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2003).  These factors activate inflammatory cells, such as macrophages, which 
can initiate the acute phase response through the release of TNFa and IL-1 
(Baumann and Gauldie, 1994).  These cytokines act locally and distally, and 
result in more factors being synthesised, such as second phase cytokines, like 
IL-6, chemokines, for instance IL-8, macrophage inflammatory protein and 
monocyte chemoattractant protein (Baumann and Gauldie, 1994; Slaviero et al., 
2003).  These factors circulate to other tissues and modulate the expression of 
acute-phase proteins, such as fibrilogen, a1-acid glycoprotein, a2-
macroglobulin, a1-antitrypsin and a1-antichymotrypsin (See table 1.2.7). Some 
acute phase proteins can increase in concentration by as much as 200 times 
during the acute phase, like C-reactive protein and serum amyloid A (Slaviero et 
al., 2003).  In addition to these other proteins, like phospholipase A, 
cyclooxygenase 2 and inducible nitric oxide synthase can also be upregulated. 
 
Acute Phase Protein or 
Family 
Role in inflammation 
Ceruloplasmin Scavenges oxygen radicals generated by leukocytes  
Protease inhibitors Inhibit proteases responsible for wide ranging reactions; i.e. 
degrading collagen, re-modelling tissue 
C-reactive protein Binds to bacteria and produces capsular swelling 
Transferrin A major iron transport protein 
 Table 1.2.7: Examples of acute phase proteins, from (Trowbridge and Emling, 1997). 
 
In the brain microglia, which can perform a similar function to macrophages, 
respond to interferon-? and TNF by expressing the major histocompatibility 
complex (MHC) class I and II molecules, which allows the microglia to 
function as antigen-presenting cells.  The microglia are the first cells to respond 
to injury and infection in the brain, and recruit astrocytes by secreting acute-
phase proteins, especially complement proteins, but also cytokines, such as IL-
1ß and TNF-a (Halliday et al., 2000).  The astrocytes react by releasing other 
complement proteins and acute-phase proteins, including ACT and a2-
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macroglobulin, neural growth factors and cytokines, including IL-6 (Halliday et 
al., 2000). 
The major pathway for transcriptional activation of acute phase proteins 
involves the Janus kinases (JAK) and signal transduction and activation of 
transcription (STAT), especially STAT3.  Another pathway is the mitogen-
activated protein kinases, which induce various nuclear factors including 
CCAAT enhancer binding proteins (C/EBP), also called nuclear factor (NF) 
interleukin 6a (NF-IL6a), NFkB and hepatocyte NF’s, HNF1 and HNF4.  The 
C/EBP family includes C/EBPß, C/EBP? also called NF-IL6ß, and C/EBPa.  
C/EBPß, one of the factors that upregulates a1-acid glycoprotein (Chiu et al., 
2002) is, like STAT3 and STAT5, a pro-inflammatory signal transcription 
factor.  Some cytokines are known to have an anti- inflammatory effect, such as 
IL-2, IL-4 and IL-10, and these counter the pro- inflammatory cytokines to 
maintain homeostasis (Jeschke et al., 2002).  There are also anti- inflammatory 
signal transduction factors, such as the suppressors of cytokine signalling 
(SOCS), such as SOCS-1, -2, -3, or regulated on activation, normally T-cell 
expressed and secreted (RANTES) (Jeschke et al., 2002).  SOC-3, for instance, 
suppresses IL-6 (Croker et al., 2003).  No single signalling pathway is solely 
responsib le for upregulating acute phase proteins, and there is a substantial 
overlap and co-operation between signal pathways (Slaviero et al., 2003).  As an 
example, IL-6 receptors include a sub-unit, gp130, that is capable of signal 
transduction via the JAK pathway, creating docking sites for cytoplasmic 
proteins with a Src homology domain-2, such as the STAT factors.  STATs then 
form homo- and heterodimers which migrate to the nucleus and upregulate gene 
transcription via STAT responsive elements in promoters (Croker et al., 2003).  
STATs may also be activated by receptors that are unrelated to cytokines, like 
the activation of STAT3 by hepatitis type C virus core protein, or angiotensin II 
which activates the STAT/JAK pathway (Minoguchi et al., 2003). 
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1.3 Serpins 
 
1.3.1 Molecular Biology of Serpins 
Serine Protease Inhibitors (serpins) are a protein superfamily, found in higher 
eukaryotes and viruses (Gettins, 2000; Irving et al., 2000), composed mainly of 
enzymes that use serine residues for nucleophilic catalysis of their target 
molecule (Turgeon and Houenou, 1997).  There are several hundred members of 
this superfamily (Gettins, 2000; Irving et al., 2000).  There are some molecules 
classified as serpins, that have no protease inhibitory function, such as 
ovalbumin, maspin and HSP47, due to their homology with the inhibitory 
serpins (Whisstock et al., 1998).  Alpha-1-antichymotrypsin is a typical serpin, 
with inhibitory activity against proteases. 
Serpins are variably glycosylated single chain proteins (Potempa et al., 1994), 
between 350 – 400 amino acids in length (Irving et al., 2000), with a conserved 
domain structure of between 370 – 390 amino acid residues (Potempa et al., 
1994) that form three ß-sheets and nine a-helices (Whisstock et al., 1998).  The 
inhibitory serpins interact with their target protease at a reactive site loop (RSL), 
30 – 40 amino acids from the carboxyl terminus.  This area is exposed on the 
surface of the serpin, and is susceptible to proteolysis (Potempa et al., 1994). 
As mentioned earlier, the main function of most of the serpins is the inhibition 
of serine proteases.  They are involved in various complex physiological 
processes, and play a vital role in the control of events associated with 
connective tissue turnover, coagulation, fibrinolysis, complement activation, 
and inflammatory reactions, amongst others, in humans (Gettins, 2000; Potempa 
et al., 1994).  They can be found in both intra- and extracellular environments 
(Gettins, 2000). 
Serpins do not inhibit their target molecules by cleavage, but instead use a 
process that is analogous to a mouse trap (Carrell and Lomas, 1997).  In the 
stressed state, the serpin can be likened to a primed mouse trap, with the RSL as 
bait (Carrell and Lomas, 1997).  The inhibition involves profound 
conformational change by the serpin, and is initiated by reaction of the active 
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serine with the serpin’s RSL (Huntington et al., 2000).  This results in the 
cleavage of the RSL, which upon cleavage moves 71Å, to the opposite pole of 
the serpin, taking the protease with it, trapping the target (Carrell and Lomas, 
1997; Huntington et al., 2000).  This is possible because serpins can exist in two 
states; the stressed labile configuration (S), or an ordered, heat stable, relaxed 
form (R).  The molecule can move between these forms due to a “hinge” in the 
RSL (Potempa et al., 1994).  This manoeuvre results in a 37% loss of protease 
structure (Huntington et al., 2000), but is an irreversible form of inhibition 
(Gettins, 2000).  Once cleaved, ACT contains two chains, A and B, of 337 and 
35 amino acids respectively (see figure 1.3.1) 
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Figure 1.3.1: The structure of the mature, cleaved a1-antichymotrypsin protein.  Purple 
sections are the 337 amino acid A chain, pink sections are the 35 amino acid B chain.  
Diagram obtained from National Center for Biotechnology Information, with permission  
 
In AD, ACT can act as a “pathological chaperone”, catalysing the formation of 
fibrils of Aß, increasing the rate of polymerisation by 10 fold (Ma et al., 1994).  
Amino acids 1-12 of Aß42 closely resemble the conserved active site of serine 
proteases, which is the target of the RSL of ACT.  ACT is able to form a stable 
complex with Aß by interacting with these residues (Ma et al., 1996), moving 
from the stressed to the relaxed conformation.  This increases the 
thermostability of ACT as the residues N-terminal to the cleaved bond insert 
into the major ß sheet of Aß (Whisstock et al., 1998).  It is also possible for the 
ß-sheet of another Aß molecule to insert into ACT (Ma et al., 1996).  During 
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this process ACT moves through four conformations, from a native, uncleaved 
state through two intermediates into an unfolded form.  This occurs relatively 
quickly given the size of ACT (Pearce et al., 2000), and results in the loss of 
inhibitory activity (Whisstock et al., 1998). 
 
1.3.2 Alpha-1-Antichymotrypsin as a Serpin 
Alpha-1-Antichymotrypsin (ACT), also called SERPINA3 (Silverman et al., 
2001) is a member of the serine protease inhibitor (serpin) family of acute phase 
proteins. It has a molecular mass of 55 – 66 kDa (Bao et al., 1987; Kalsheker, 
1996; Travis and Salvesen, 1983) of which approximately 25% is carbohydrate. 
The mature protein consists of 394 amino acid residues.  ACT has a very well 
ordered three-dimensional structure, consisting of eight well-defined alpha 
helices and three large ß-pleated sheets (Kalsheker, 1996). ACT is present in the 
blood at relatively low concentrations in the normal physiological state, but 
during the acute phase the levels in the blood increase dramatically and rapidly. 
During inflammation the increase in concentration is five fold (Kalsheker, 
1996), and the concentration can double within eight hours of trauma (Travis 
and Salvesen, 1983). 
The ACT gene (Fig. 1.3.2), located on chromosome 14q32.1 (Billingsley et al., 
1993), is approximately 12,000 base pairs in length, and organised into five 
exons and four introns (Bao et al., 1987), and shows sequence homology with 
a1-antitrypsin, and antithrobin III, suggesting a common ancestry (Bao et al., 
1987; Chandra et al., 1983; Kalsheker, 1996; Travis and Salvesen, 1983). 
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Figure 1.3.2: A scale diagram of the ACT  gene and 5' regulatory regions.  Scale bars shown 
in red.  Hatched boxes indicate the positions of regulatory regions in the 5’ region, and are 
shown in large scale at the bottom of the diagram.  Shown in the enhancer region are the 
two nuclear factor -?B (NF-?B) sites and the Activating protein-1 (Ap-1) site.  The 
promoter region shows the positions of the Signal Transducer and Activator of 
Transcription (STAT) binding sites and TATA box in relation to the –51bp promoter 
polymorphism, shown as G/T.  Shaded regions within the coding sequence of the ACT gene 
represent exons The product of exon 1, the signal sequence, shaded blue, does not feature 
in the mature protein. 
 
ACT is mainly synthesised in the liver, but it’s mRNA is also expressed in a 
variety of other organs, such as the heart, lung, kidney, brain, breast and 
prostate (Kalsheker, 1996). There are three known biological functions of ACT. 
The first is the inhibition of mast cell chymases, neutrophil cathepsin G and 
proteases that convert angiotensin I to the biologically active vasoconstrictor 
angiotensin II (Bao et al., 1987; Kalsheker, 1996; Travis and Salvesen, 1983). 
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This means that one of the main functions of ACT may be the regulation of 
angiotensin II production.  As mentioned above, ACT accelerates the formation 
of Aß fibrils (Ma et al., 1994), and uniquely amongst serpins it is able to bind 
DNA. This is achieved at a stretch of three basic lysine residues 212 – 214, but 
the significance of this is as yet unknown (Kalsheker, 1996). 
The inhibition of neutrophil cathepsin G and mast cell chymases means that 
ACT plays a part in protecting the lower respiratory tract from damage by 
proteolytic enzymes, and it has been found in high concentrations in the 
bronchial secretions of patients with chronic bronchitis (Travis and Salvesen, 
1983).  The signal sequence polymorphism of ACT has been shown to associate 
with lung disease in smokers (Ishii et al., 2000). Complexed ACT is removed 
from circulation by receptor-mediated pathways, but cleaved ACT is a powerful 
chemoattractant for neutrophils.  Cleaved and complexed ACT can induce the 
synthesis of IL-6, which may provide a mechanism for it’s rapid production 
during the acute phase (Kurdowska and Travis, 1990), since IL-6 upregulates 
the synthesis of ACT. 
 
1.3.3 Regulation of the a1-Antichymotrypsin Gene 
The expression of ACT in the liver is enhanced by IL–6 and glucocorticoids, 
and to a lesser extent by IL-1 (Baumann et al., 1987; Castell et al., 1989).  ACT 
is also found in the brain, but as it is too large to pass the blood brain barrier it is 
instead synthesised by astrocytes (Kordula et al., 1998; Lieb et al., 1996).  
Subsequently it was found that expression of ACT in astrocytes is induced most 
potently by oncostatin M (OSM) and IL-1, while tumour necrosis factor-a 
(TNF–a) has a modest effect (Machein et al., 1995).  On its own IL-6 is 
ineffective in inducing ACT expression, but co-treatment of astrocytes with 
soluble IL-6 receptor (sIL-6r) and IL-6 is a potent activator of ACT expression 
in astrocytes (Kordula et al., 1998; Lieb et al., 1996). This suggests that 
astrocytes may express specific OSM receptors.  The expression of ACT mRNA 
in astrocytes is further enhanced by glucocorticoids working in concert with IL-
1 and IL-6 without sIL-6r (Kordula et al., 1998; Nilsson et al., 2001b; Potter et 
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al., 2001).  In lung epithelial cells OSM, IL-1 and the glucocorticoid analogue, 
dexamethasone have been shown to stimulate ACT production individually, but 
particularly, together, and it appears that the OSM II receptor may be utilised in 
these cells.  This is due to the fact that leukaemia inhibitory factor (LIF) which 
binds to the OSM I receptor does not alter production of ACT (Cichy et al., 
1995; Cichy et al., 1998) 
OSM was found to activate two Signal Transducer and Activator of 
Transcription (STAT) elements, that are located at –125bp to –117bp and at 
-96bp to –87bp away from the ACT transcription start site.  These STAT 
elements were identified as STATA and STATB, with the STATB element 
responding first, followed later by STATA (Kordula et al., 1998).  The STAT 
elements do not appear to interact with IL-1 or TNF-a, suggesting that other 
regulatory elements must be able to influence the ACT gene.  A 413bp-long 
element that conferred a response to IL-1 and TNF-a was identified 13kbp 
upstream of the transcription start site.  This site, the 5’ distal IL-1/TNF-
responsive enhancer, contains three transcription factor-binding sites, two 
nuclear factor ?B (NF-?B) sites, at –13213bp to –13202bp and at –12831bp to 
-12820bp and an activating protein 1 (AP-1) site at –12985bp to –12979bp 
(Kordula et al., 2000).  Investigation of signal transduction pathways (Lieb et 
al., 1996) and mutational analysis of these sites indicates that the 5’ NF- ?B 
element contributes the most to the responsiveness of the ACT gene, the AP-1 
site contributes to the response of both IL-1 and TNF, but the effect of the 3’ 
NF-?B site is minimal (Kordula et al., 2000).  In hepatoma HepG2 cells, IL-1 
and TNF has only a slight effect on ACT mRNA synthesis, indicating that the 
-13kb enhancer element is not fully functional in hepatoma cells (Kordula et al., 
2000).  It is interesting to note that the APP gene flanking sequence also 
contains two NF- ?B binding sites that respond to IL-1ß, resulting in the 
upregulation of APP (Grilli et al., 1996; Grilli and Memo, 1999; Grilli et al., 
1995).  IL-1ß is upregulated in AD brains and interacts with a number of 
proteins associated with AD in addition to ACT and APP, such as ApoE and a2-
macroglobulin (Mrak and Griffin, 2000). 
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1.4 Alpha-1-Antichymotrypsin in Alzheimer’s Disease 
 
1.4.1 Beta-Amyloid Fibril Formation 
As mentioned above, one of the characteristics of AD are the senile plaques 
observed in the brain.  The major component of senile plaques is amyloid-ß 
(Aß), which is a proteolytic product of the amyloid precursor protein (Eriksson 
et al., 1995; Fraser et al., 1993; Mucke et al., 2000). The Aß surrounds a core of 
degenerating nerve endings. However, Aß is not the sole protein associated with 
senile plaques in AD. In addition a number of other proteins are found in 
association with senile plaques, such as apolipoprotein E, extracellular ma trix 
proteins, amyloid P component, complement factors and cytokines (Atwood et 
al., 2002; Bradt et al., 1998; Luterman et al., 2000; Mucke et al., 2000; Namba 
et al., 1991; Ohm et al., 1995; Rebeck et al., 1995).  The acute phase protein, a1-
antichymotrypsin is also associated with senile plaques, as it binds tightly to Aß, 
and specifically co-localises to AD plaques and blood vessels in the brain of 
patients with AD (Fraser et al., 1993; Janciauskiene et al., 1996; Janciauskiene 
et al., 1998; Licastro et al., 2000a; Ma et al., 1994; Pasternack et al., 1989). 
There are several conditions that result from the dysfunction or inappropriate 
regulation of acute phase proteins, such as a deficiency of the serpin a1-protease 
inhibitor, which can result in cirrhosis or emphysema (Trowbridge and Emling, 
1997).  ACT is an acute phase protein, and  the potential role of ACT in the 
pathogenesis of AD has been the subject of considerable interest. 
Aside from the presence of ACT at the site of amyloid deposits in AD, there is 
further evidence to implicate ACT in AD, for instance Aß is known to activate 
microglia, which then secrete a variety of cytokines, including interleukin (IL)-
1ß and IL-6, and IL-1ß is known to stimulate ACT expression (Abraham et al., 
2000; Kordula et al., 1998; Licastro et al., 2000b; Vandenabeele and Fiers, 
1991). It is also known that while many of the proteins that associate with Aß in 
senile plaques bind to other forms of amyloid, ACT is associated primarily with 
Aß amyloidosis (Mucke et al., 2000). 
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There is also evidence that ACT is produced in the region of senile plaques, 
rather than in the liver and then migrating to the brain. Northern analysis of the 
grey matter of AD brains revealed ACT mRNA expression. In addition, in situ 
radiolabelled mRNA probing and astrocyte specific immunostaining has 
demonstrated that ACT mRNA was originating from astrocytes in AD brains, 
something that rarely happens in the brains of control subjects (Pasternack et al., 
1989).  In addition, studies using double transgenic mice, that is mice that 
produce both human APP and human ACT in their brains, and mice that express 
hACT or hAPP alone generate evidence to link ACT to plaque production. Mice 
expressing hACT alone do not develop senile plaques, whereas mice expressing 
hAPP alone, or hAPP and hACT together, do develop AD-like plaques in the 
hippocampus.  The plaque burden of mice expressing hACT and hAPP was 
greater than that of mice expressing hAPP alone (Mucke et al., 2000).  Further 
studies revealed that amyloid was being deposited particularly in the 
hippocampus, where ACT expression was at its highest, and Aß peptide levels 
were raised from an early age, before amyloid was being deposited (Nilsson et 
al., 2001a).  Taken together, these models provide compelling evidence for the 
involvement of ACT in AD. 
It has been demonstrated that ACT has a strong stimulatory role in the 
polymerisation of Aß (Ma et al., 1994). Polymers of Aß form Aß fibrils, 
something which happens spontaneously, but in the presence of ACT and 
apolipoprotein E this will happen more rapidly, within hours, rather than days. 
There is a variation in the catalytic effect of apolipoprotein E between its 
isoforms. The greatest effect is seen with apolipoprotein E ε4, which is also 
known to be the strongest genetic risk factor for AD.  Apolipoprotein E e2 when 
combined with e4 has an inhibitory effect on the formation of amyloid fibrils, 
and apolipoprotein E ε2 is believed to be a negative risk factor for AD (McGeer 
and McGeer, 1995).  
The amino- and carboxyl-termini of Aß strongly resemble the conserved active 
site of serine proteases, and this region is recognised specifically by ACT, and 
can apparently act as a pseudosubstrate (Fraser et al., 1993; Janciauskiene et al., 
1998; Potter et al., 1992). It is these regions that interact with ACT, and they 
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insert into one of two ß-sheets, destroying the inhibitory function of the serpin. 
This also causes ACT to undergo a transition from the stressed to the relaxed 
state, and is accompanied by an increase in thermostability (Eriksson et al., 
1995). 
The role of ACT in fibril formation, is however, somewhat complicated by the 
finding that it may play a part in destabilising Aß fibrils (Eriksson et al., 1995; 
Fraser et al., 1993; Janciauskiene et al., 1998). At a molar ratio of 1 : 10 (ACT 
to Aß) the serpin inhibits the formation of ß-amyloid fibril formation, and at an 
equimolar level ACT promotes the rapid disaggregation of pre-formed Aß 
fibrils (Eriksson et al., 1995; Fraser et al., 1993). It would appear that there is a 
threshold ratio of ACT to Aß below which aggregate formation is stimulated 
(Janciauskiene et al., 1998). There are at least two explanations for the 
discrepancies between the findings that ACT destabilises and disaggregates Aß 
fibrils at high concentrations, but that ACT is found in higher concentrations in 
AD brains compared with normal brains (Janciauskiene et al., 1996). One is that 
these studies were in vitro, using synthetic ACT, and that in vivo ACT 
undergoes some processing that does not occur with the synthetic form, or that 
there are other factors in the brain that have a bearing on the behaviour of ACT, 
such as the length of the amyloid fibril or the pH at which the reactions occur.  
It has been demonstrated that fibrils form faster at lower pH (Eriksson et al., 
1995). The second explanation is that when ACT destabilises or disaggregates 
Aß fibrils it exposes new domains within the amyloid fibril that may undergo 
additional proteolysis, or interact with cell-surface receptors (Fraser et al., 
1993). 
Another mechanism by which ACT may affect the concentration of Aß in the 
brains of AD patients involves the clearance of Aß. It has been reported that Aß 
clearance is dependent on metallopeptidase E.C.3.4.24.15, or MP24.15 (Yamin 
et al., 1999). MP24.15 appears to activate a serine protease that cleaves Aß 
(Yamin et al., 1999). Aß1-42, in comparison with Aß1-40, is degraded slowly by 
the MP24.15 pathway and aggregated Aß1-42 showed almost no degradation. In 
the presence of serine protease inhibitors Aß degradation is partially or 
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completely inhibited. ACT achieves a 60% inhibition of this process (Yamin et 
al., 1999). 
Another report has suggested a further mechanism by which ACT and Aß42 can 
interact in AD.  The exact role of Aß in AD pathology is unclear, and it has 
been speculated that its neurotoxic effects may be a result of interacting with 
other molecules to produce complexes with biological activities that promote 
neuroinflammation.  Microglia and astrocytes in brain regions exhibiting 
abundant AD plaques over-express both pro- and anti- inflammatory reactants.  
The ACT-Aß complexes that are found in AD plaques are known to have lost 
the protease inhibitor activity of ACT, however, when ACT is incubated with 
Aß it has been shown to demonstrate pro- inflammatory properties (Sun et al., 
2002).  These experiments showed that Aß alone induced TNF-a and IL-6 
levels in glioma cells, but a 1:10 molar ratio mixture of ACT:Aß42 mixture 
under the same experimental conditions showed no effect on IL-6 levels, but 
had an even greater effect on TNF-a induction in the same cells.  With Aß 42 
alone TNF-a levels rose by 55% compared to controls, but with the mixture of 
ACT and Aß42 the TNF-a activity rose by 190% against the controls. 
Studies have shown that AD patients have an increased concentration of ACT in 
the CSF and plasma (Janciauskiene et al., 1996; Licastro et al., 2000a). This has 
led to an examination of the factors that cause overexpresion of ACT, to see if 
these factors have an effect on the risk of developing AD. IL-1ß is known to 
stimulate the expression of acute phase proteins in the liver, and it promotes 
overexpression of ACT mRNA in activated astrocytes (Kordula et al., 1998; 
Lieb et al., 1996). Common polymorphisms of the ACT and IL-1ß genes affect 
the plasma levels of ACT or IL-1ß. Patients who had the ACT signal sequence 
or IL-1ß T/T genotypes were shown to have the highest plasma levels of ACT 
or IL-1ß in plasma, and the presence of these genotypes increased the risk of 
AD (Licastro et al., 2000a; Licastro et al., 2000b). It has also been reported that 
the A (threonine) allele of this ACT polymorphism, a biallelic (A/G) mutation at 
position –17, can work in concert with the apolipoprotein E ε4 allele (Kamboh 
et al., 1995) which agrees with the earlier findings that ACT and apolipoprotein 
E together have a stimulatory effect on fibril polymerisation (Ma et al., 1994). A 
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further biallelic polymorphism has been located in the promoter region of ACT 
(-51, G/T), which has an effect on the rate of ACT expression (Licastro, 2002; 
Morgan et al., 2001).  The T allele of the ACT promoter polymorphism was 
shown to be in 95% linkage disequilibrium with the signal sequence threonine. 
1.4.2  Genetics of a1-Antichymotrypsin in Alzheimer’s Disease 
In the search for genes that might predispose to AD, an early candidate was the 
apolipoprotein E (APOE) gene.  Antibodies to ApoE bind to the amyloid 
plaques of Alzheimer’s disease (Namba et al., 1991) and ApoE was soon found 
to bind to synthetic Aß (Strittmatter et al., 1993).  It was found that the e4 allele 
of APOE correlated with amyloid plaque density, both in AD and normal brains 
(Berr et al., 1994).  Although further studies demonstrated that APOE e4 is 
neither necessary, nor sufficient for AD to develop (Polvikoski et al., 1995) it is 
a risk factor (Kamboh et al., 1995; Roses, 1996; Saunders et al., 1993).  The 
search began for other genes associated with AD, which might work in 
conjunction with, or independently of APOE. 
Previously, it had been demonstrated that ACT had been found associated with 
amyloid deposits in AD (Abraham et al., 1988), and it had also been shown that 
Aß fibrils form more rapidly in the presence of ApoE and ACT (Ma et al., 
1994).  Studies of the ACT gene have revealed a number of polymorphisms in 
coding and non-coding regions (Byth and Cox, 1993; Morgan et al., 2001; 
Poller et al., 1993; Samilchuk and Chuchalin, 1993; Tsuda et al., 1992; Wang et 
al., 2002).  (See figure 1.4.1 and table 1.4.1).  In mouse models, as well as in 
AD brains the APOE e4 allele has been linked with higher levels of ACT 
(Licastro et al., 1999a). 
Most attention has been focussed on the signal sequence polymorphism located 
17 bp upstream of the ACT start site.  This is an A? G substitution that results 
in the substitution of a threonine with an alanine at amino acid -15, which has a 
more hydrophobic character than threonine.  This, it has been suggested, may 
enhance ACT secretion (Wang et al., 2002). The A-17G polymorphism is 
unable to affect ACT function, as the signal peptide it generates is cleaved from 
ACT.  Several studies have attempted to prove an association between either 
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allele of the ACT signal sequence polymorphism and AD, either alone (Wang et 
al., 2002), or acting in concert with APOE e4 (DeKosky et al., 2003; Kamboh et 
al., 1997; Licastro et al., 1998; Licastro et al., 1999b; Nacmias et al., 1996; 
Scacchi et al., 1999), with IL-1ß T (Licastro, 2001; Licastro et al., 2000b), 
presenilin 1 allele 1 (PS1*1) (Wang et al., 1998).  These studies have failed to 
show a consistent association with the signal sequence polymorphism and AD, 
either alone or in concert with other genes.  Less attention has been given to the 
reported associations between ACT –17G and IL-1ß T or PS1*1, but a number 
of reports have been published that contradict the finding that APOE e4 and 
ACT –17G are associated with AD (Didierjean et al., 1997; Ezquerra et al., 
1998; Fallin et al., 1997; Haines et al., 1996; Helisalmi et al., 1997; Lamb et al., 
1998; Muller et al., 1996; Murphy et al., 1997; Tysoe et al., 1997; Yoshizawa et 
al., 1997).  It cannot be argued that the contradictions between these reports are 
due to differences in the populations studied, as studies reporting an association, 
and those that showed no association have been performed on a wide range of 
populations, from Europe (United Kingdom, Italy, Germany, Spain, Finland, 
and France), North America (United States of America), Asia (Japan) and 
Africa (Nigeria).  There were no regional differences between the findings of an 
association between APOE e4 and ACT -17G.  Experimental methodologies, 
such as sample size, and classification of AD, differed between studies, but the 
majority of reports used the NINCDS-ADRD method of diagnosing AD, and 
samples sizes varied between all of the papers.  It is possible that the effect of 
the ACT –17G and APOE e4 haplotype is to lower the age of onset of AD, and 
therefore in a comparison of AD patients against controls would show no 
association with this haplotype (Talbot et al., 1996).  If this is correct, patients 
would have to be age-matched with controls, and results stratified by age. 
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Figure 1.4.1: A cartoon showing the ACT gene with positions of known polymorphisms 
(excluding microsatellite) shown as vertical lines underneath. 
Region Nucleotide 
Position 
Base 
Substitution 
Amino Acid 
Position 
Amino Acid 
Substitution 
Reference Population 
Enhancer -12779 G/T N/A N/A * Caucasian 
Promoter -596 G/A N/A N/A * Caucasian 
Promoter -501 G/A N/A N/A * Caucasian 
Promoter -51 G/T N/A N/A Morgan, 2001 Caucasian 
Exon 1 -17 A/G -15 Thr ? Ala Thome, 1995 Caucasian 
Exon 2 2398 A/G 25 Alu? Asn Meng, 2000 Han 
Exon 2 2440 G/A 39 Leu? Leu Meng, 2000 Han 
Exon 2 2484 T/C 53 Leu? Pro Poller, 1993 Caucasian 
Exon 2 2552 A/G 76 Lys? Lys Wang, 2002 Caucasian 
Exon 2 2701 G/A 128 Asp? Asn Wang, 2002 Caucasian 
Exon 2 2745 C/G 142 Ala? Gly Poller, 1993 Caucasian 
Exon 3 7505 C/G 227 Pro? Ala Poller, 1993 Caucasian 
Exon 3 7559 G/A 241 Leu? Leu Wang, 2002 Caucasian 
Exon 3 7580 C/T 250 Ser? Ser Wang, 2002 Caucasian 
Intron 4 7698 G/A N/A N/A Wang, 2002 Caucasian 
Exon 4 10804 T/C 301 Leu? Pro Wang, 2002 Caucasian 
Exon 4 11071 A/G 324 Thr? Thr Wang, 2002 Caucasian 
Exon 5 12794 A/G 389 Met? Val Muramatsu, 1996 Japanese 
3’ UTR 11998 C/A N/A N/A Wang, 2002 Caucasian 
3’ UTR 12013 C/T N/A N/A * Caucasian 
Table 1.4.1 : Previously discovered SNPs in the ACT gene, and the population in which 
they were first discovered.  * indicates SNPs discovered in our laboratory, as yet 
unpublished. 
Promoter 
1.4 Alpha-1-Antichymotrypsin in Alzheimer’s Disease 
60 
  
Another variable sequence of the ACT gene is the polymorphic microsatellite 
located in the 5’ flanking region, 2.5kb from the start of the ACT gene.  This 
microsatellite consists of a variable number of (TA)n(GA)n repeats (Byth and 
Cox, 1993).  Although no significant difference in microsatellite allele 
frequency was reported between AD cases and controls, when the APOE allele 
was taken into account it was shown that with the APOE e4 allele, the A10 
(called B10 in Byth and Cox, 1993) allele frequency was lower in controls, 
compared to AD cases (Morgan et al., 1997).  This study also found no 
association between the APOE e4 allele and the ACT –17G allele of the signal 
sequence polymorphism.  Another study, on a smaller sample, with younger 
sporadic AD patients, again showed an association between the APOE e4 allele 
and AD, but did not show an increased risk for AD in individuals possessing 
both APOE e4 and ACT A10 (Durany et al., 1998).  This may be due to a 
number of factors.  Although AD was confirmed histologically by the CERAD 
criteria (Mirra et al., 1993) in both cases, and the control groups were of 
equivalent age (72.8±9.0 years, (Morgan et al., 1997) against 72.2±8.8 years, 
(Durany et al., 1998)), the ages of AD patients were different (80.8±9.8 years, 
(Morgan et al., 1997) against 72.4±9.2 years, (Durany et al., 1998)).  It has been 
suggested that the ACT –17G allele of the signal sequence polymorphism may 
be associated with a lower age-at-onset of AD (Talbot et al., 1996).  It may be 
possible that a similar effect could account for the differences in the two studies.  
Another possible reason could be the difference in sample sizes.  The Durany 
study contained less than a third of the number of AD cases compared to the 
earlier Morgan study.  It may be that the combined effects of the APOE e4 and 
ACT –17G alleles are too small to be detected with a sample size as small as in 
the Durany study. 
Another study (Bass et al., 1998), looking at the same combined effect of APOE 
e4 and ACT –17A in AD casts doubt on the possibility of an interaction between 
these alleles in AD.  Although this study did not examine the brains of AD 
patients histologically, and probably examined a different population, it seems 
to contradict the previous findings (Morgan et al., 1997).  There was no 
association found between the microsatellite A10 allele and the ACT signal 
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sequence –17A allele to lower the age of onset of Alzheimer’s disease.  In 
addition, there was no significant difference found in microsatellite allele 
frequencies between AD cases and controls, either alone or with APOE e4. 
It has been reported that ACT regulates the formation of Aß-fibrils (Eriksson et 
al., 1995), and that there may be an increase in ACT levels in the brains 
(Licastro et al., 1998), and blood (DeKosky et al., 2003; Gabriel et al., 1998; 
Hinds et al., 1994; Lieberman et al., 1995; Matsubara et al., 1990; Wang et al., 
2002) of AD patients.  In cerebrospinal fluid some studies have shown a 
correlation between ACT levels and AD (Matsubara et al., 1990), others have 
not, but suggest that there may be an involvement between AD and ACT 
(Pirttila et al., 1994).  Studies of the ACT coding region have not provided 
conclusive evidence of a mutation that might enhance the secretion of ACT 
from cells producing ACT.  Some laboratories have begun looking at non-
coding, regulatory regions of the ACT gene.  A promoter and an enhancer for 
ACT have been found, and functional activity has been determined as described 
above. 
A polymorphism has been discovered in the promoter region of the ACT gene, 
located 51 bp upstream of the starting codon (Morgan et al., 2001).  This 
polymorphism, a G ?  T transversion, is located 21 bp upstream of the putative 
ACT TATA box, and 36 bp downstream of the STATB site.  TATA boxes bind 
nuclear proteins, specifically transcription factors, and transcription initiation 
complexes form around them (see figure 1.4.2).  It has been demonstrated that 
that the T allele results in a greater expression of ACT with and without 
stimulation by OSM.  This effect was shown in the human liver cell- line, Hep 
G2 as well as in a mixed population of astrocytes and glial cells, T98G (Morgan 
et al., 2001).  In a sample of elderly subjects with a clinical diagnosis of AD, 
patients with a GG genotype were found to have lower plasma ACT 
concentration than those with a GT genotype, which again was lower than those 
with a TT genotype.  This study found that there was a significant difference in 
plasma ACT concentration between G allele carriers and T allele carriers.  A 
third finding of this study was that the ACT promoter polymorphism G allele is 
in almost complete linkage disequilibrium with the ACT –17 signal sequence G 
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allele, and the T allele of the promoter polymorphism with the A allele of the 
signal sequence polymorphism. 
These findings are interesting for a number of reasons.  Firstly, it provides a 
mechanism for the elevated ACT levels seen in AD brains.  In contrast to the 
theories about the signal sequence polymorphism having an effect on the rate of 
secretion of ACT, the promoter polymorphism demonstrates that more ACT is 
being produced, which would have an effect on the rate of fibrilisation of Aß in 
AD brains.  In addition, several studies looking at polymorphisms in the ACT 
gene have suggested that alleles reported in some studies have an association 
with AD, and others contradict that.  It has been suggested that these alleles 
could be in linkage disequilibrium with an allele that does directly affect ACT 
release, and it appears that the promoter polymorphism fits this description. 
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Figure 1.4.2: Cartoon outlining initiation of transcription in eukaryotic cells.  Upstream 
TATA boxes bind transcription factors to form a pre-initiation complex.  a) The TATA 
box is located upstream of the gene.  b) Two transcription factors (TF), TFIIA and TFIID 
bind to the TATA box. c) TFIIB binds to the TATA box and proteins.  d) RNA polymerase 
II binds to the complex.  d) With the addition of TFIIE and F the pre-initiation complex is 
complete.  (Brown, 1993) 
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1.4.3  Alpha-1-Antichymotrypsin and it’s Potential for Therapy 
As discussed above, a1-antichymotrypsin plays a role in modulating Aß fibril 
formation in Alzheimer’s disease in a concentration-dependent manner. If 
lowering the amount of Aß fibrils is proved to be of benefit to patients with AD, 
then ACT would be an extremely useful target for therapy.  Using a competitor 
or inhibitor of ACT would mean less ACT would be available to catalyse the 
fibrillisation of Aß.  This alone makes it worthy of study, but other reports have 
suggested that ACT may have a role to play as a biomarker in the diagnosis of 
AD (DeKosky et al., 2003; Sun et al., 2003). There is a clear need to develop 
better diagnostic tools for the study of AD. At present AD can only be 
diagnosed reliably post mortem, so many studies recruit patients with dementia 
that may ultimately prove not to be Alzheimer’s disease. This has undoubtedly 
hampered progress in the understanding of this condition. If a reliable clinical 
test for AD can be developed, then research will be more conclusive, and the 
treatment of this disease should benefit as a result. 
The criteria of a good biomarker have been defined by Gracon and Emmerling, 
2001. In brief, it should measure a fundamental contributor to AD 
neuropathology, be clinically accessible, be relevant to the clinical outcome, and 
must be validated in cross-section and longitudinally. The potential sources of 
such a marker are the brain, CSF, plasma, serum, platelets, lymphocytes, or 
other cellular components of the blood or other tissues. Potential markers 
include APP, or APP secretases, total Aß, or Aß1-40, or Aß1-42, tau protein, 
apolipoprotein E, cholesterol, inflammatory cytokines, or antioxidant capacity. 
ACT fits many of the criteria for a good biomarker. It is clinically accessible, as 
it can be measured in the serum or CSF and it has been postulated to play a 
fundamental role in AD (DeKosky et al., 2003; Lieberman et al., 1995; Sun et 
al., 2003). There have been several proposals for the use of ACT as a biomarker 
(Brugge et al., 1992; Hinds et al., 1994; Matsubara et al., 1990). Several studies 
have been completed in order to test the efficacy of ACT as a biomarker of AD. 
It has been reported that a concentration of 60 mg/dL of serum ACT can 
separate putative AD patients from control groups (Lieberman et al., 1995), and 
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taking several measurements of serum or CSF ACT over time was effective in 
differentiating AD-type patients from controls and patients with other dementias 
and degenerative disorders (Matsubara et al., 1990). This study also revealed 
that CSF ACT levels tended to correlate with the degree of dementia being 
suffered. Other reports have not been able to demonstrate the effectiveness of 
ACT as a biomarker, however, it would appear that those that did not support 
the evidence of ACT being a suitable biomarker utilised different 
methodologies in measuring ACT levels. When radial immunodiffusion assays 
(RIA) were used they were able to support this theory (Furby et al., 1991; 
Lieberman et al., 1995; Matsubara et al., 1990; Pirttila et al., 1994). 
The problem with using ACT as a biomarker is that it tends to produce an 
unacceptably high level of fa lse positives, making it unsuitable for population 
screening (Lieberman et al., 1995). RIA does not appear to be extremely well 
suited for individual diagnosis either, as it is somewhat expensive and time 
consuming to use on a small scale. Having to repeat the assay over a period of 
time, to observe persistently elevated ACT, which appears characteristic of AD 
(Matsubara et al., 1990) further reduces the suitability of this test. At present, 
serum ACT levels can be used only to add weight to a putative diagnosis of AD 
made with the help of clinical observation and testing, such as with the Mini 
Mental State Examination (MMSE). 
 
1.5 Summary 
 
Central to the pathology of AD is the peptide ß amyloid.  The physiological 
role, if any, of this peptide is currently unknown.  It is derived from the 
proteolytic processing of the membrane associated amyloid precursor protein.  
Recent evidence suggests that the development of the neurotoxic form of Aß is 
critical in the aetiology of AD.  This results from cleavage by ?-secretase, a 
protein complex that includes the presenilin 1 and 2 proteins.  Most mutations 
associated with the familial form of AD alter the cleavage site of APP, or the 
presenilins. 
1.5 Summary 
66 
  
Evidence from various sources supports the theory that a chronic 
neuroinflammation develops during AD.  Brain tissue from AD patients have 
elevated levels of inflammatory molecules, such as cytokines, complement 
factors and serpins.  Drugs that are used in the treatment of inflammation may 
have some effect in slowing the onset of AD.  If this is the case, controlling 
neuroinflammation through drugs may help to slow the onset and progression of 
the disease. 
To develop therapies that will prevent or halt the damage caused by AD it will 
be necessary to learn more about the disease.  More research is needed to 
explain what causes AD, how it progresses, and precisely how it results in cell 
death in neurones.  Much of this research has centred on senile plaques.  These 
plaques are composed of fibrils of Aß, which had been thought to be responsible 
for the neurological damage seen in AD.  More recently, it has been shown that 
smaller Aß molecules seem to be responsible for the pathology of AD.  These 
Aß oligomers are the focus of a great deal of attention, but the wider issues of 
Aß generation and clearance should also be addressed.  If AD is the result of an 
imbalance between Aß generation and clearance, it is possible that the senile 
plaques provide a reservoir of Aß, caused by too little Aß clearance relative to 
generation.  The molecule that binds amyloid in the fibrillar form is the serine 
protease inhibitor, a1-antichymotrypsin. 
ACT is synthesised in the brain as part of the inflammatory response.  It is able 
to bind to two Aß molecules, which can result in the formation of insoluble 
fibres, which are found in senile plaques.  There have been conflicting reports 
that polymorphisms in the ACT gene are associated with AD.  If it can be 
demonstrated that polymorphisms in the ACT gene do associate with AD then 
this could be useful in developing a diagnostic tool for AD. 
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1.6 Research Aims 
 
The aim of this project is to further the understanding of the function of the a1-
antichymotrypsin promoter: specifically the effect the G? T transversion has on 
that function and its role in disease.  Achieving these aims will involve an 
investigation of the functional activity of the promoter and the production of 
mRNA in different cell lines and also a characterisation of the mechanism of 
promoter activity.  In addition the relevance of ACT as a risk modifier of AD 
has not been firmly established, and this is to be explored in more detail. 
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2 MATERIALS AND METHODS 
 
2.1 Dual-Luciferase Reporter® Assays 
 
The Dual Luciferase Reporter® (DRL) assay provides a way of determining the 
functional activity of any DNA segment.  It can be used to demonstrate that a 
putative regulatory region does have a functional effect, to determine if a 
regulatory region responds to a cytokine, or, as in this case, to compare the 
effect of two variant promoters.  The putative promoter is coupled to the 
luciferase gene, from the firefly, Photinus pyralis, and transfected into cultured 
cells.  Three commercially available constructs were used for this work, pGL3 
enhancer, pGL3 control and pRL (Promega).  The pRL construct does not 
contain the luc reporter gene, instead it contains the Renilla gene, taken from the 
sea pansy Renilla reformis. 
pGL3 control is used as a positive control in the DRL assays.  The luc gene is 
flanked by the SV40 promoter and enhancer, ensuring that the luc gene is 
constitutively active at a high level.  The pGL3 enhancer construct is used to 
determine the “background” level of expression, as the luc gene is active at a 
low level with this construct.  The pRL construct contains all the regulatory 
elements to activate the Renilla gene at a steady level, and acts as a transfection 
control.  This construct is co-transfected with the other constructs. 
In addition, two experimental constructs were prepared pGL3E ‘G’ and pGL3E 
‘T’, containing the G and T alleles of the ACT promoter.  These were based on 
the pGL3 enhancer construct, but the ACT promoter was inserted just before the 
luc gene (see figure 2.1.1).  This  should enable the reporter gene to be activated 
by the same mechanism as the ACT gene in vivo, allowing the luc gene to act as 
a surrogate for ACT.  The luciferase protein emits light, allowing it to be 
measured more conveniently than ACT. 
The cells used for the DRL assays were grown in 12-well plates, and typically 
one experiment required at least three wells each to be transfected with control, 
enhancer, pGL3E ‘G’ and pGL3E ‘T’, all co-transfected with pRL (see figure 
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2.1.1).  Once they were transfected, the cells could then be stimulated, as 
required, with human recombinant oncostatin M, OSM (R and D Systems), 
incubated for the time required, then harvested.  The harvesting lysed the cells, 
allowing light output to be measured.  Both luciferase and Renilla were 
measured separately on the same luminometer.   
The light measured by the luminometer was dependent on the amount of 
luciferase present, which was dependent on the activity of the luc gene.  The 
firefly luciferase reading was normalised by the Renilla luciferase, to allow for 
differences in transfection efficiency.  The luminescence ratio of both ACT 
constructs is then normalised to the enhancer activity alone, to remove the effect 
of the SV40 enhancer present in the ACT promoter constructs.  This ratio gives 
an idea of how active each ACT promoter allele is under basal conditions, or 
after stimulation with OSM in a variety of different cell lines. 
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Figure 2.1.1: Maps of the constructs used in the DLR assays, showing functional regions, 
luciferase genes, antibiotic resistance genes and restriction sites.  The pGL3 Enhancer 
vector was modified to include the ACT promoter thereby generating constructs pGL3E 
‘G’ and ‘T’.  Figure is reproduced with kind permission of www.promega.com, the 
suppliers of these constructs. 
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2.1.1 Tissue Culture 
2.1.1.1 General Cell Culture Materials and Methods 
The growth of cells for the DLR assays has a number of common elements, 
which will be described here, to avoid unnecessary repetition later. 
There were four cell lines used in the DLR assays. HepG2 (ECACC), human 
liver hepatoma, isolated from a liver biopsy of a 15 year old male Caucasian, 
T98G, human glioblastoma, a mixed glial / neuronal cell line derived from a 
multiform tumour from a 61 year old Caucasian male (ECACC), U373 MG, 
astrocytes (ECACC) and SH-SY5Y, a neuronal cell line, derived from a human 
neuroblastoma.  The SH-SY5Y cells were a gift from Dr. Ellen Billett of 
Nottingham Trent University.  Cells were always grown at 37ºC, in a 
humidified atmosphere containing 5% CO2.  Unless specifically mentioned, 
they were grown in complete media, although the media varied between cell 
lines.  Complete media contains a number of additives not included by the 
manufacturer, listed in table 2.1.1. 
 
Additive Stock 
Concentration 
Dulbeco’s Modified 
Essential Medium, 
DMEM (Invitrogen) 
Eagles Minimum 
Essential Medium, 
EMEM (Sigma) 
Cell Type  T98G Hep G2, U373 MG 
Foetal Bovine Serum 
(Invitrogen) 
100% 50ml 50ml 
L-Glutamine (Invitrogen) 200mM 5ml 10ml 
Penicillin – Streptomycin 
(Invitrogen) 
10,000 U/ml 5ml 5ml 
Amphotericin B 
(Invitrogen) 
250µg / ml 5ml 5ml 
Tetracycline 10µg / ml 250µl 250µl 
Non-essential amino acids 
(Sigma) 
100x - 5ml 
Sodium Pyruvate (Sigma) 100mM - 5ml 
Table 2.1.1 : Table showing the additives required to make up 500ml of complete media.  
 
 Serum-free media contains all the above additives except FBS. 
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In addition, the SH-SH5Y cells were cultured in complete Ham’s F12/EMEM.  
This contained the following media and supplements, at the same concentrations 
given in table 2.1.1. 
 
Supplement Volume 
EMEM 214.88ml 
Ham’s F12 (Sigma) 214.88ml 
FBS 50ml 
L-Glutamine 5ml 
Penicillin - streptomycin 5ml 
Ampicillin 5ml 
Tetracyline 250µl 
Non-essential amino acids 5ml 
Table 2.1.2: Supplements added to make complete Ham's F12 / EMEM 
 
All media was filtered through a 0.5µm filter, stored at 4ºC, and warmed to 
37°C before use. 
2.1.1.2 Thawing Cells 
The DLR assays were performed on the cell lines listed above (section 2.1.1.1).  
Whilst some of these cells were supplied commercially, others were taken from 
liquid nitrogen storage, from our own stocks, or from other laboratories.  In the 
case of cells stored in liquid nitrogen, before use they needed to be defrosted in 
such a way as to minimise damaging the cells. 
Cells that had been frozen in liquid nitrogen were usually stored in aliquots of 1 
– 1.5ml, in freezing media.  The cells need to be warmed as quickly as possible 
to prevent damage, so after ensuring the cryo-vials were sealed, they were 
incubated at 37°C until defrosted.  After this the cell suspension was mixed with 
5ml complete medium (see table 2.1.1) and 5ml FBS.  This suspension was 
transferred to a 25cm2 flask and incubated at 37°C. 
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2.1.1.3 Maintaining Cell Lines 
To keep cultured cells growing, the same techniques were used for all cell lines, 
although cells were grown in the appropriate medium.  This involved removing 
the old medium, washing the cells, and replacing the medium.  When the cells 
reached 90% confluency, they were removed and allowed to grow on a surface 
area three times bigger, so cells in a 25cm2 flask would be moved to a 75cm2 
flask, or cells from one 75cm2 flask would be divided into three 75cm2 flasks. 
Cells were fed every two to three days with complete medium.  The old medium 
was removed, the cells were washed twice with 3ml filter sterilised phosphate 
buffered saline (PBS, Oxoid) and then an appropriate volume of medium was 
added.  For cells growing in 25cm2 flasks, this was 10ml, for 75cm2 flasks, 
25ml, then the cells were incubated at 37°C.  When cells were nearly confluent, 
they were split.  The first time this was done after defrosting the cells, they were 
split into three 25cm2 flasks.  When the cells in these flasks had almost reached 
confluence they were transferred to 75cm2 flasks. 
To split cells the medium was removed, and the cells were washed twice in 
PBS.  3ml of 1x trypsin-EDTA were added to the cells, which were then 
incubated for 5 minutes.  The cells were observed through a microscope to 
confirm that they had detached from the flask after this time.  If they had not, 
they were incubated for longer.  Once the cells had detached, the trypsin was 
stopped by the addition of 10ml complete medium.  The suspension was 
thoroughly mixed, and 5ml of it added to one of three new flasks.  These were 
topped up with 20ml of complete medium, and gently mixed, before being 
incubated.  
2.1.1.4 Preparing Tissue Cultured Cells for Transfection 
Each experiment was carried out at least three times, and each experiment 
obtained three measurements under the same conditions.  The cells were 
transferred to 12-well tissue culture plates, which were arranged as three rows 
of four columns.  Cells in each column were transfected with the same 
constructs, and were incubated for the same time before harvesting. 
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Cells, grown to approximately 70% confluence, in 75cm2 flasks were used to 
seed four 12-well plates.  The cells were washed twice with PBS, then 3ml 1x 
trypsin-EDTA was added.  The cells were incubated at 37°C for five minutes, 
and then the trypsin was stopped with 10ml complete medium.  This cell 
suspension was mixed thoroughly, and divided into four 3.8ml aliquots, which 
were then made up to 14.4ml with complete medium.  The aliquots were again 
mixed thoroughly, and 1.2ml was added to each well of the 12-well tissue 
culture plates.  The plates were then incubated for 24 hours at 37°C. 
 
2.1.2 Preparing Reporter Gene Constructs 
2.1.2.1 Amplifying DNA for Plasmid Construction 
To investigate the effects of the ACT promoter T and G alleles in different cell 
lines, it was necessary to introduce reporter genes, coupled with the ACT 
promoter (T/G), into the cells.  To achieve this, the two forms of the ACT 
promoter were cloned into the pGL3 enhancer vector.  ACT promoter DNA 
from homozygous TT and GG samples was therefore amplified to provide 
enough material to clone into the vectors. 
To prepare a 365bp fragment of sufficient quality, a template was amplifed from 
genomic DNA.  This DNA template was a 646bp PCR product, that had 
previously been amplified with the primers F1, 5’ TGT CTC TAC GAA AAA 
TAC AA 3’ and R1, 5’ AGG ATG TAA AAC ATC ATG G 3’.  An aliquot of 
this product was taken and digested with the restriction enzyme Van91I, this 
digestion product was used to verify the promoter genotypes (see figure 2.1.2).  
GG and TT genotypes were used for generating the pGL3E ‘G’ and pGL3E ‘T’ 
constructs, respectively. 
The PCR reactions (646bp product) were carried out in a final volume of 25µl 
containing 200ng genomic DNA; 0.5µM of each primer, 200µM dNTPs; 10mM 
Tris-HCl, pH8.8; 50mM KCl; 1.5mM MgCl2 : 0.08% Nonidet P40 and 1 unit 
Taq polymerase.  Reactions were overlaid with mineral oil and subjected to 35 
cycles of 30 seconds at 94ºC, 30 seconds at 57ºC, 60 seconds at 72ºC, followed 
by 10 minutes at 72ºC. 
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A 345bp fragment of the ACT 5’ flanking region (see Appendix 1), containing 
known regulatory elements (Kordula et al., 1998) and each allele of the 
polymorphism was amplified, and cloned into the pCR®-2.1 TOPO vector 
(Invitrogen).  This region was then sub-cloned into the pGL3E vector, so that 
two experimental constructs, pGL3E ‘T’ and pGL3E ‘G’, differing by a single 
base, were produced.  These constructs were verified by sequencing. 
The 345bp fragment of the ACT gene promoter region was amplified us ing 
primers F2, 5’ GGA GGT ACC CAC ATG TTA GCT 3’ and R2, 5’ AAG CTT 
ATT TAT TCG TGA GA 3’.  These primers were designed with engineered 
restriction sites for the enzymes KpnI and HindIII , respectively.   
The genotypes of the PCR products were verified by restriction digest.  The 
PCR products (7.5µl) were incubated, with 5U of Van91I, at 37ºC for 2 hours, 
then resolved through a 2.5% agarose gel stained with ethidium bromide.  The 
G allele lacks a site for the restriction enzyme while the T allele is cleaved into 
fragments of 511bp and 135bp. 
To produce the 345bp fragment for insertion into the pCR®-2.1 TOPO vector 
50ng of undigested PCR product (646bp) was amplified with 0.8µM each of F1 
and R1, 200µM dNTPs; 10mM Tris-HCl, pH8.8; 50mM KCl; 1.5mM MgCl2 : 
0.08% Nonidet P40 and 1 unit Taq polymerase.  Reactions were overlaid with 
mineral oil and subjected to 35 cycles of 30 seconds at 94ºC, 30 seconds at 
58ºC, 60 seconds at 72ºC, followed by 10 minutes at 72ºC. 
2.1.2.2 Cloning PCR Products into pCR®-2.1 TOPO Vectors 
Approximately 10ng of the 345bp PCR products were cloned into the pCR2.1-
TOPO vector using the TOPO TA cloning kit (Invitrogen) according to 
manufacturer’s protocol in XL1-Blue E. coli (Stratagene).  CG-agar plates, 
containing 50 µg / ml ampicillin, were prepared and pre-warmed to 37°C.  To 
enable blue/white screening, 40µl of 40mg/ml X-gal was spread onto these 
plates.  Approximately 10µl transformation mix, containing the pCR2.1-TOPO 
vector was spread onto a plate and incubated overnight at 37°C.  Positive clones 
(white colonies) were selected and cultured overnight in CG broth containing 
50µg/ml ampicillin.   
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Plasmid DNA was extracted by the modified QIAfilter method (see section 
2.1.2.3) and analysed by restriction digest with 5 units KpnI and 5 units HindIII 
restriction enzymes in 1x One-Phor-All Buffer PLUS (Pharmacia; 10mM Tris-
acetate, pH 7.5; 10mM magnesium acetate; 50mM potassium acetate) in a final 
volume of 10µl at 37°C for 2 hours.   
The products of the restriction digest were run on a 2% agarose gel, and 
visualised by staining with ethidium bromide.  Confirmation of successful 
cloning came by the appearance of a 330bp insert band. 
2.1.2.3 Isolation of Plasmid by Modified QIAFilter (QIAgen) Technique 
A 15ml overnight culture, containing XL-1 blue cells transformed with 
pCR2.1-TOPO plasmid of each ACT promoter allele was centrifuged at 
14,000g for 5 minutes at 4°C.  The resulting supernatant was discarded, and the 
cell pellet was gently resuspended in 4ml resuspension buffer, P1.  To this was 
added 4ml lysis buffer, P2, and the solution was mixed by gently inverting 6 
times, before incubation at room temperature for 5 minutes.  During this 
incubation, a QIAfilter cartridge was prepared, by closing one end with a 
removable cap.  Next, 4ml of chilled neutralisation buffer, P3 was added, and 
the lysate was mixed by gentle inversion 6 times.  The lysate was then added to 
the QIAfilter cartridge, and incubated at room temperature for 10 minutes.  
During this incubation the QIAgen-tip 100 was prepared by the addition of 4ml 
endotoxin-free buffer QBT.  This buffer was allowed to pass through the tip by 
gravity flow.  Once the lysate had been incubated, the plunger was added to the 
QIAfilter cartridge, and the lysate was gently filtered into the QIAgen-tip.  The 
filtered lysate was allowed to pass through the QIAgen cartridge by gravity 
flow.  Once the tip had cleared, it was washed twice with 10ml endotoxin-free 
buffer QC.  After washing the DNA was eluted by the addition of 5ml 
endotoxin-free buffer QN.  The DNA was precipitated by adding 3.5ml 
isopropanol and mixed.  This solution was centrifuged at 4,600g for 90 minutes 
at 4°C, and the resulting supernatant was carefully decanted.  The pellet that 
remained was washed with 2ml 70% endotoxin-free ethanol, and centrifuged 
again at 4,600g, for 30 minutes, at 4°C.  The supernatant was carefully decanted 
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and the pellet was air-dried for 10-15 minutes.  The DNA was re-dissolved in 
100µl endotoxin-free 1x TE buffer (pH 8.0) for 10 minutes.  The yield was 
determined by spectrophotometry. 
2.1.2.4 Preparing a1-Antichymotrypsin Insert for Cloning into pGL3 Enhancer 
Vector 
The TA clone DNA prepared as mentioned in section 2.1.2.3 was digested in a 
final volume of 15µl containing 15 units KpnI and 15 units HindIII in 1x One-
Phor-All-Buffer PLUS at 37°C for approximately 5 hours. 3 digests of 15µl 
were prepared for both the G and T alleles of the TA clones.  The fragments of 
DNA resulting from the restriction digest were electrophoresed on 2% agarose, 
stained with ethidium bromide, and the resulting 330bp insert bands were 
removed from the gel.  Insert DNA was extracted from the gel slices using the 
QIAquick gel extraction kit (QIAgen), according to the manufacturer’s protocol, 
pooling 3 gel slices per column.  DNA was eluted from the column in 30µl Tris-
HCl (pH 8.5). An estimation of the DNA concentration was made by 
electrophoresis of gel-purified insert DNA on 2% agarose stained with ethidium 
bromide. 
2.1.2.5 Preparing pGL3 Enhancer Vector for Cloning 
Approximately 2µg of pGL3E vector was digested with 5 units each of KpnI 
and HindIII in 1x One-Phor-All-Buffer PLUS in a final volume of 10µl at 37°C 
for at least 2 hours.  After this, the restriction enzymes were inactivated by 
heating them to 85°C for 15 minutes.  The linearised vector was then 
precipitated in 2.5 volumes of 100% ethanol, and chilled to –20°C for 1 hour.  
The DNA was then pelleted by centrifugation at 10,000g for 10 minutes, 
followed by a wash with 70% ethanol, to remove the excess salt.  The pellet was 
air-dried, before being resuspended in 17µl distilled H2O. 
There is a risk that the cut pGL3E vector will re-circularise, preventing ligation 
of cut vector fragments.  To prevent this the vector was dephosphorylated after 
ethanol precipitation.  This was achieved using shrimp alkaline phosphatase, 
SAP (USB), which removes the 5’ phosphate groups from the DNA.  The 
presence of 5’ phosphate groups on the insert DNA allows for efficient ligation. 
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The dephosphorylation reactions were performed with 1U SAP enzyme made 
up to a final volume of 20µl with 1x SAP buffer (USB).  The reaction was 
carried out by incubating at 37°C for 30 minutes, after which the enzyme was 
de-activated by heating to 85°C for 15 minutes.  An estimation of the 
concentration of dephosphorylated linear vector was made by electrophoresis of 
a 3µl sample through a 2% agarose gel with ethidium bromide staining. 
2.1.2.6 Ligations 
The linear pGL3E vector and T/G inserts, prepared as described above were 
ligated in a final volume of 20µl.  The solution contained 200ng pGL3E vector, 
200ng insert and 5 units of T4 DNA ligase enzyme.  Ligation reactions were set 
up to prepare vectors containing the T allele and the G allele, and a control 
reaction was performed with water replacing the inserts.  This control reaction 
was to assess the level of background ligation, in the absence of insert.  All 
ligation reactions were incubated at 22°C for 1 hour. 
2.1.2.7 Transformation of XL-1 Blue Cells with pGL3E Vectors 
The plasmids prepared by ligation were transformed into XL-1 Blue super 
competent E. coli cells (Stratagene).  For each transformation 40µl of competent 
cells were required, and 1µl of ligation reaction was inoculated into the cells.  
The cells were chilled on ice for 30 minutes after inoculation, and were then 
heat shocked at 42°C for 45 seconds.  After this, they were put back on ice for a 
further 2 minutes, and then 450µl SOC medium (20g Bacto-tryptone, 5g Bacto-
yeast extract, 0.5g NaCl, 10ml 250mM KCl, 5ml 2M MgCl2, 20ml 1M glucose 
per litre) was added.  The transformation mix was incubated at 37°C for 1 hour, 
with 225 rpm shaking, before being spread onto a pre-warmed CG-agar plate 
containing 50µg / ml ampicillin.  The plates were cultured at 37°C overnight.  
Two plates were cultured for each transformation, one plate was spread with 
50µl undiluted transformation mix, the other with 50µl of a 1 in 10 dilution, 
with SOC medium being used to dilute the solution.  After overnight incubation, 
single colonies were picked from plates inoculated with neat or diluted 
transformation mix, whichever was most convenient. 
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2.1.2.8 Analysis of Transformed XL-1 Blue Cells 
After being picked, single colonies were inoculated into 5ml CG broth 
containing 250µg ampicillin, and incubated at 37°C overnight with 225rpm 
shaking.  The plasmids were extracted using a modified version of the QIAfilter 
protocol described above.  Presence of the insert was determined by restriction 
in a final volume of 10µl, containing 5 units each of KpnI and HindIII, 1x One-
Phor-All-Buffer PLUS at 37°C for 2 hours.  After digestion, the DNA fragments 
were separated by electrophoresis through a 2% agarose gel stained with 
ethidium bromide.  The presence of a 330bp insert band determined which were 
the positive clones (see figure 2.1.2).  Positive clones were preserved as glycerol 
stocks by combining an equal volume of glycerol with overnight culture and 
thoroughly, but gently, resuspending. 
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Figure 2.1.2: Verifying the insertion of the ACT promoter region into pGL3E vectors.  M = 
100 bp ladder, brightest band is 500bp.  Lanes 1 and 2; 646bp PCR product of ACT  
promoter region PCR.   Lanes 3 and 4; products from lanes 1 and 2 were digested with 
Van91I to genotype.  Lane 3 shows no digestion, confirming GG genotype.  Lane 4 has 
been cleaved to give fragments of 511bp and 135bp, confriming TT genotype.  Lanes 5 and 
6; after 330bp PCR product amplified from product shown in lanes 1 and 2 were inserted 
into pGL3E vectors the vector was digested with KpnI and Hind III to show vector at the 
top of the lane and insert.  To verify the allele inserted vectors were sequenced.   
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2.1.2.9 Determining pGL3E Clone Sequences 
It was important to confirm that the clones held in glycerol contained the correct 
sequences, which differed by a single base (see figure 2.1.3 and figures 6.1.2 
and 6.1.3, Appendix 1.).  Plasmid DNA was sequenced by PCR using the RV3 
primer (Promega) which anneals to the pGL3E vector.  The reactions were 
performed in a final volume of 10µl, which contained 4µl Big Dye Ready 
Reaction mix (Applied Biosciences) approximately 500ng plasmid DNA and 
1.5 pmol RV3.  Reactions took place over 25 thermal cycles of 30 seconds at 
96°C, 15 seconds at 50°C, 4 minutes at 60°C, followed by 1 minute at 28°C.  As 
the sequencing dyes are photo- labile reactions were carried out in the dark. 
After cycling the products were cleaned by adding 124µl of 25:5:1 ethanol : 3M 
sodium acetate : water solution.  This was mixed, then incubated on ice for 10 
minutes, the mixture was centrifuged at 13000g for 15 minutes, and the 
supernatant was discarded.  The pellet was dried by heating to 94°C for a couple 
of minutes, then stored, in the dark, at -20°C before being automatically 
sequenced on an ABI sequencer.  Once confirmed the reporter gene constructs 
could be stored at –20°C, or used immediately for Dual-Luciferase Reporter® 
assays (see section 2.1.3). 
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Figure 2.1.3:  Confirmation of the correct allele in pGL3E constructs.  Arrow shows 
position of polymorphism.  For longer sequences, showing position of primer R2 site see 
Appendix 1. 
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2.1.3 Dual-Luciferase Reporter® Assays 
2.1.3.1 Co-transfecting Cells with Reporter Gene Constructs 
Plasmid DNA (pGL3 and pRL) was diluted in serum-free medium and mixed 
with a transfection reagent, either Tfx-20 or Tfx-50 (Promega).  These are 
cationic lipid based reagents which allow DNA to associate more closely with 
the cell membrane as they form a lipid / nucleic acid complex with anionic 
DNA.  The optimum Tfx reagent and charge ratio was determined for each cell 
line prior to use.  For T98G, U373 MG and SH-SY5Y cells, Tfx-20 was the 
appropriate choice, while Tfx-50 allowed efficient transfections for Hep G2 
cells.  For T98G cells a 4:1 charge ratio was used, for the U373 MG cells and 
SH-SY5Y cells and Hep G2 cells a 2:1 ratio was used. 
For each experiment, two 12-well plates of cells at 60-70% confluence were 
used.  A master mix was made up containing 400µl serum-free medium and 
20ng pRL for each well.  This was mixed well and divided into four aliquots, to 
which were added 200ng per transfection of pGL3 enhancer, pGL3 control, 
pGL3E ‘G’ and pGL3E ‘T’.  The appropriate amount of transfection reagent 
was added to these transfection mixes, which were thoroughly mixed and 
incubated at room temperature for 15 minutes.  While the transfection mixes 
were incubating, the cells were prepared.  The medium was removed and the 
cells were washed twice with PBS.  To each well in the plates, 400µl of 
transfection mix were added.  The cells were incubated at 37ºC for one hour and 
800µl complete medium was added.  The cells were then incubated at 37ºC for 
24 hours. 
2.1.3.2 Cytokine Stimulation 
24 hours after transfection the cells were stimulated with 50ng/ml OSM.  In 
different experiments, cells were exposed to OSM for different periods of time.  
Unstimulated cells, those that were not exposed to OSM, were used to represent 
the basal level of luciferase production, and therefore ACT promoter activity. 
The transfection mixes were removed from the cells, which were then washed 
twice with PBS, to remove all traces of growth medium, taking care to remove 
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medium from the walls of the wells.  Once all traces of PBS had been removed 
from the wells, 1ml of serum-free medium containing 2.3pmoles OSM for the 
cells to be stimulated, or 1ml serum-free medium for cells used to measure basal 
activity was added.  The cells were then allowed to grow at 37ºC for the 
required time (3 – 48 hours) prior to harvesting. 
2.1.3.3 Harvesting Cells for Dual-Luciferase Reporter® Assay 
After the cells had been stimulated with cytokine, they were harvested.  Growth 
medium was removed and the cells were washed twice with PBS.  Again, it was 
important to remove all traces of medium and PBS from the wells.  Once this 
had been done 200µl 1x Passive Lysis Buffer, PLB (Promega) was added to 
each well.  The cells were incubated at room temperature for 15 minutes, and 
the resulting lysates were transferred to 1.5ml eppendorf tubes.  Whilst it is 
possible to store this lysate at -20ºC at this point, the DLR assays were 
performed immediately. 
2.1.3.4 Dual Luciferase® Reporter Assays 
Luciferase Assay Reagent II, LARII, and 1x Stop & Glo® reagent (Promega) 
were prepared according to the manufacturer’s instructions.  DLR assays were 
performed on a Turner Designs Model TD-20/20 Luminometer, as 
recommended by Promega, allowing sequential readings of firefly and Renilla 
luciferases.  The luminometer was programmed to allow a 2 second delay 
period prior to quantification of light output over 10 seconds for both firefly and 
Renilla luciferases. 
One tube per reaction was prepared containing 50µl LARII and 20µl cell lysate 
was added.  The firefly luciferase activity was quantified and then quenched by 
the addition of 50µl 1x Stop & Glo®, allowing the Renilla luciferase activity to 
be determined. 
The luminometer output reading is a measurement of light emitted, expressed as 
relative luminescence units (RLU), and is a measurement of firefly and Renilla 
luciferase activities.  The ratio of firefly to Renilla luciferase activity represents 
firefly activity normalised for transfection efficiency. 
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2.1.4 Statistical Analysis 
The values used to compare functional effects of promoter polymorphisms are 
the fold increase over the pGL3 enhancer alone, and have no units.  Log10 of the 
fold increases were used to compare reporter gene activity between different 
transfected vectors in order to obtain normally distributed values. The 
comparison between alleles was made using the 2-tailed paired Student’s T-test, 
with statistical significance being defined as p<0.05.  The comparison of 
activity after different periods of stimulation with OSM were made by 
univariate analysis of variance, using SPSS v11.0 to provide and overall 
measure of statistical significance, followed by post hoc 2-tailed paired 
Student’s T-test.  For ANOVA and post hoc T-testing statistical significance 
was defined as p<0.05. 
 
2.2 Reverse-Transcriptase PCR (RT-PCR) 
 
Reverse transcriptase PCR (RT-PCR) is a technique that demonstrates the 
presence of specific mRNA sequences in a sample.  The technique involves 
creating DNA from mRNA, which can then be amplified by PCR.  The 
production of this complementary DNA, is a reversal of the normal eukaryotic 
transcription process, and relies on reverse transcriptase, an enzyme produced 
by retro-viruses to insert the viral RNA-based genome into the host’s DNA 
based genome. 
The technique can be quantitative, to give a measure of how much mRNA is 
present, semi-quantitative, giving a comparison of mRNA levels between 
samples, or qualitative.  In these experiments, qualitative RT-PCR was used, to 
demonstrate that in vivo the cells used for the DLR assays and in the EMSA and 
supershift assay do actively synthesise ACT mRNA. 
 
2.2.1 mRNA Isolation 
Cultured cells were grown to 90% confluence, as described above.  The cells 
used were Hep G2, U373 MG, SH-SY5Y and T98 G cells.  The growth media 
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was removed, and the cells were washed twice with PBS.  10ml of serum-free 
growth medium, with or without 2.3 pmoles OSM as appropriate, was added 
and the cells were incubated at 37°C for the appropriate length of time.  After 
this, the medium was removed and the cells were again washed twice with PBS.  
The cells were then removed from the flasks by adding 10ml PBS, containing 
1.5ml 1xtrypsin-EDTA, and incubating at 37°C for 5 minutes.  The cell solution 
was then transferred to a 15ml tube and centrifuged at 1000g for 5 minutes at 
4°C.  The supernatant was removed, and the total mRNA was isolated using the 
SV Total mRNA Isolation kit (Promega) according to the manufacturer’s 
instructions.  Some care was taken to ensure that the mRNA, which degenerates 
rapidly, was used immediately, but where this was not possible it was stored at 
–80°C before being used.  Prior to use as the template for cDNA synthesis, the 
concentration of mRNA was measured with a spectrophotometer. 
 
2.2.2 cDNA Synthesis 
In order to amplify the ACT region, the mRNA needs to be converted to cDNA.  
The method used produced cDNA counterparts to all of the mRNA isolated. 
The cDNA synthesis was a two-stage reaction, performed in a reaction mix 
containing 200ng random hexamers (Promega), 1µg mRNA and water to a final 
volume of 26µl. This reaction mix was incubated at 70ºC for 10 minutes then 
cooled on ice. The volume was increased to 40µl by the addition of the 
following: 50mM Tris-HCl, pH 8.0; 50mM KCL; 4mM MgCl2; 10mM DTT; 
1mM dNTPs and 20U ribonuclease inhibitor (MBI Fermentas).  This was 
incubated at 25°C for 5 minutes before the addition of 200U RevertAid M-
MuLV Reverse Transcriptase (MBI Fermentas). The reaction was incubated at 
25ºC for 10 minutes, 42ºC for 1 hour and 70ºC for 10 minutes, and finally 
chilled on ice.  As cDNA is more stable than mRNA the cDNA could be stored 
at -20°C, if not used immediately. 
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2.2.3 RT-PCR 
Two PCR reactions were set up for each cDNA sample.  One reaction amplified 
the housekeeping gene, hypoxanthine guanine phosphoribosyltransferase 1 
(HPRT), which is constitutively active in all cell lines.  This is used as an 
internal control, and also serves to demonstrate that cDNA has been 
synthesised, which in turn proves that mRNA was successfully extracted.  The 
second PCR amplifies the ACT gene.  The primers must be 
different to those used to amplify the promoter polymorphism region, as this 
region is not transcribed into mRNA. 
The HPRT gene was amplified with primers F3; 5’ GAC CAG TCA ACA GGG 
GAC AT 3’ and R3; 5’ CGA CCT TGA CCA TCT TTG GA 3’.  PCR reactions 
were carried out in a final volume of 25µl containing cDNA; 0.5µM of each 
primer; 200µM dNTPs; 10mM Tris-HCl, pH8.8; 50mM KCl; 1.5mM MgCl2 : 
0.08% Nonidet P40 and 1U Taq polymerase.  Reactions were overlaid with 
mineral oil and subjected to 35 cycles of 30 seconds at 94ºC, 60 seconds at 60ºC 
and 60 seconds at 72ºC followed by 10 minutes at 72ºC. 
The ACT gene was amplified with primers F4; 5’ CAG AGA TTC TCA AGG 
CCT CGA GTT 3’ and R4; 5’ GAC CCC CAA GAT ACT CAT CAG T 3’.  
PCR reactions were carried out in a final volume of 25µl containing cDNA; 
0.5µM of each primer; 200µM dNTPs; 10mM Tris-HCl, pH8.8; 50mM KCl; 
1.5mM MgCl2 : 0.08% Nonidet P40 and 1U Taq polymerase.  Reactions were 
overlaid with mineral oil and subjected to 35 cycles of 30 seconds 94ºC, 60 
seconds at 61ºC and 60 seconds at 72ºC followed by 10 minutes at 72ºC. 
Following amplification, PCR products were run through a 2% agarose gel, and 
stained with ethidium bromide. 
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2.3 Electrophoretic Mobility Shift Assays (EMSA) 
 
The electrophoretic mobility shift assay is designed to demonstrate the ability of 
specific DNA sequences to form complexes with nuclear proteins.  Having 
previously demonstrated the functional effect of the alleles with the DLR 
assays, the EMSA was used to provide an insight into the mechanisms involved 
in generating the functional effect.  Short DNA probes of each ACT promoter 
allele were radiolabeled, in order to permit visualisation.  They were then 
allowed to interact with nuclear proteins extracted from cultured cells.  If the 
DNA sequence is recognised by DNA-binding proteins, a complex will form.  
The proteins were then separated by electrophoresis, and the gel exposed to an 
X-ray film.  This film was then developed, and the positions of the free DNA 
probes and DNA-protein complexes were revealed.  Large molecules (DNA / 
protein) are retarded by the molecular structure of the gel to a greater extent 
than the smaller molecules (probes alone).  EMSA autoradiographs can be 
compared to see if the same complexes occur when the nuclear proteins are 
isolated from stimulated or unstimulated cells, or between different cell lines.  It 
is also possible to see if certain proteins bind more strongly to one DNA 
sequence than another. 
The supershift assays are a variation on this technique.  An antibody that is 
expected to bind to the protein likely to bind DNA is introduced to the nuclear 
extract.  The labelled probe is then added to the nuclear extract, where it binds 
with the antibody-protein complex.  When these complexes are run through a 
gel the antibody-protein-DNA complex is much larger than the protein-DNA 
complexes, and so does not move as rapidly through the gel.  On the 
autoradiograph, the protein recognised by the antibody appears “shifted”; that 
is, its position has changed relative to the complex not involving antibody.  In 
this way it is possible to identify the DNA-binding proteins associated with the 
DNA sequence under investigation. 
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2.3.1 Preparing Probes for EMSA 
2.3.1.1 Amplifying the ACT Promoter Region 
Two samples, homozygotes for the ACT promoter polymorphism, representing 
each allele, were amplified by PCR over the promoter region.  The PCR product 
was 80bp long, with the polymorphic site 29bp downstream of the start of the 
amplicon (see Appendix 1).   
The 80bp fragment of DNA from the 5’ flanking region of the ACT gene was 
amplified, using a forward primer, F5: 5’ CTT GGT TGT CCT GGC ATT TC 
3’ and reverse primer, R5: 5’ TGG ATT TTC ATG AAT GCT GA 3’.  PCR 
reactions were carried out in a final volume of 25µl containing 200ng genomic 
DNA; 0.5µM of each primer; 200µM dNTPs; 10mM Tris-HCl, pH8.8; 50mM 
KCl; 1.5mM MgCl2 : 0.08% Nonidet P40 and 1U Taq polymerase.  Reactions 
were overlaid with mineral oil and subjected to 35 cycles of 30 seconds at 94ºC, 
60 seconds at 55ºC and 60 seconds at 72ºC followed by 10 minutes at 72ºC.  
After amplification, the PCR product was cleaned by gel extraction, using the 
QIAquick Gel Extraction kit (QIAgen) following the manufacturer’s 
instructions.  A small amount of the resulting product (5µl) was mixed with the 
same amount of 15% Ficoll and run on a 2% agarose gel. 
2.3.1.2 Radiolabeling DNA Probes for EMSA 
The probes to bind nuclear protein were end- labeled with ?32P-ATP.  The 
following solution was prepared; ~1.8pmol allele-specific probe, 1µl of 10x T4 
polynucleotide kinase reaction buffer (Forward reaction) (45.5mM Tris-HCl 
(pH7.6 at 25°C), 9mM MgCl2, 4.5mM DTT, 0.1mM spermidine, 0.1mM 
EDTA, MBI Fermentas), 3.6pmol ?32P-ATP (20µCi), 5 units polynuclear kinase 
(MBI Fermentas), made up to 10µl with de-ionised water.  This was incubated 
at 37°C for 30 minutes, before 40µl water and 50µl phenol:chloroform was 
added.  This solution was centrifuged briefly and the aqueous phase was run 
through a Sephadex G50 spin column.  The eluant was retained and if it not 
used immediately, the labelled probe was stored at –20°C, for no more than one 
week. 
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2.3.1.3 Isolation of Cell Nuclear Proteins 
Cells were grown in the appropriate medium, as detailed above (section 
2.1.1.3).  Once the cells were 70 – 80% confluent they were washed twice with 
PBS, then covered with 10ml serum-free medium, with or without 2.3pmoles 
OSM as appropriate. The cells were incubated with OSM for a length of time 
determined by the maximum response seen in the DLR assays.  Nuclear proteins 
were extracted using the NucBuster Nuclear Extraction kit (Novagen).  The 
protocol was modified as described below, and the cells, reagents and nuclear 
extracts were kept on ice throughout the procedure. 
After cytokine stimulation, the cells were harvested.  The medium was 
removed, and the cells were washed twice with PBS.  The cells were then 
trypsinised by the addition of 10ml PBS containing 1.5ml 1x trypsin-EDTA 
followed by incubation at 37°C for 5 minutes, or until the cells had detached 
from the flasks.  Once the cells detached the solution of PBS and trypsin, 
containing the cells was transferred to a 15ml tube.  This was centrifuged at 
4°C, for 5 minutes at 500g.  The supernatant was removed, and the pellet was 
resuspended in 150µl NucBuster Reagent A per 50µl of cell pellet.  After gentle 
resuspension, the solution was mixed by vortex for 15 seconds, then incubated 
on ice for 5 minutes.  After another 15 seconds vortexing, the solution was 
centrifuged, at 4°C, for 5 minutes at 14,000rpm.  The supernatant was removed, 
and for each 50µl of the original cell pellet 75µl NucBuster Reagent B was 
added, and the cell pellet was gently resuspended, then vortexed for 15 seconds.  
Once the cell solution was homogeneous, it was incubated on ice for 5 minutes, 
vortexed for 15 seconds, and then centrifuged at 4°C, for 5 minutes at 
14,000rpm.  The supernatant, containing nuclear proteins, was placed in 
labelled tubes, previously cooled on ice, in 8µl aliquots.  The aliquots were snap 
frozen on dry ice, and stored at –80°C.  The nuclear proteins degrade fairly 
rapidly, even at -80°C, so the nuclear extracts were used within 4 weeks of 
preparation, at the latest, but where possible, they were used in gel-shift assays 
as soon as they were extracted.   
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2.3.1.4 EMSA 
The radiolabeled probes were allowed to interact with proteins from nuclear 
extracts.  The following solutions were prepared; 0.03pmol end- labeled probe, 
8.5µl low salt binding buffer, LSB  (100mM NaCl, 30mM MgCl2 and 50mM 
Tris base), 1µg poly(dI):poly(dC) (Sigma), and 0.25 - 3µl of nuclear extract was 
titrated.  The solution was mixed by gentle pipetting and incubated on ice for 30 
minutes then the reaction was stopped by adding 2µl 6x loading dye (MBI).  
DNA-protein complexes were separated by running through a 4% 
polyacrylamide gel at 20mA for 17 – 20 minutes in 0.25x TAE buffer (10mM 
Tris-HCL (pH8.0), 10mM acetate, 0.25mM EDTA).  The gel was then dried at 
80°C and exposed to an X-ray film. 
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2.3.1.5 Supershift EMSA 
Since the ACT promoter region under investigation contained a putative binding 
site for transcription factor II B (TFIIB), an antibody against this protein was 
used. 
DNA probes and nuclear proteins were prepared as above.  The following 
solut ion was made up; 8.5µl LSB, 1µg poly(dI):poly(dC), and a titration of 0.25 
– 3µl nuclear extract, 2µg anti-TFIIB (Autogen Bioclear).  This was incubated 
on ice for 30 minutes, then 0.03pmol 32P end-labeled probe was added, and the 
solution was incubated on ice for a further 30 minutes. The reaction was 
stopped by adding 2µl 6x loading dye (MBI).  The sample was electrophoresed 
through a 4% polyacrylamide gel at 20mA for 17 – 20 minutes in 0.25x TAE.  
The gel was then dried at 80°C and exposed to an X-ray film. 
 
2.4 Genotyping the a1-Antichymotrypsin Gene  
 
The genotyping was performed at the MRC’s Geneservice facility in 
Cambridge, and the data was confirmed by restriction enzyme digestion or 
sequencing of a selected number of samples.  The samples used were from two 
centres, the University of Nottingham and the University of Oxford.  The 
assistance of Professor James Lowe at the University of Nottingham’s 
Histopathology Department and Dr. Donald Lehmann of the OPTIMA study 
(Oxford) was invaluable in recruiting patients, making clinical and pathological 
observations and supplying material.  Dr. Louise Tilley extracted DNA from the 
Nottingham samples for an earlier study. 
Genotyping polymorphisms by restriction enzyme digestion is a relatively quick 
and cheap two-step process.  It relies on the polymorphism under investigation 
altering the digestion site such that each allele produces a different pattern of 
DNA bands when run on an agarose gel.  For the ACT promoter polymorphism, 
the G allele has no restriction site that can be recognised by the enzyme Van91I, 
while the T allele can be cleaved. 
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The first step in this process is to amplify the region of DNA incorporating the 
polymorphism.  The PCR product is then digested with the restriction enzyme, 
so that the DNA can be cut completely at the correct site.  The PCR is designed 
in such a way that a clear distinction can be made between digested and 
undigested DNA.  If a sample is homozygous for the allele that retains the 
restriction site, one larger band will appear when run through an agarose gel.  
Heterozygotes will appear as two bands, and homozygotes for the other allele 
appear as one smaller band. 
Aside from producing data about the frequency of different alleles, genotyping 
was used as a way of selecting DNA to make constructs for the functional 
assays, and probes for the EMSA and supershift assays. 
 
2.4.1  Alpha-1-Antichymotrypsin Promoter Polymorphism 
One third of the samples were randomly selected for repeat genotyping to 
ensure accuracy of the MRC data. The DNA used came from 729 subjects, 
divided into three groups, control (n=335, mean age 75.00±9.39 years), 
probable AD (n=86, mean age 69.50±9.17 years) and confirmed AD (n=308, 
mean age 77.31±10.09 years). Of the 729 samples, 240 (32.9%) were genotyped 
by RFLP, prior to receiving data from MRC Geneservice.  Discrepencies in 
genotypes obtained using the two methods was found in 11 (4.6%) cases.  On 
sequencing, genotypes from all 11 cases agreed with data provided by the MRC.  
Confirmed AD status was determined following the CERAD criteria (Mirra et 
al., 1993), probable AD status was determined by the Mini Mental State 
Examination.  
A 646bp region of the 5’ flanking sequence of the ACT gene was amplified with 
primers F1; 5’ TGT CTC TAC GAA AAA TAC AA 3’ and R1; 5’ AGG ATG 
TAA AAC ATC ATG G 3’ (see Appendix 1).  The template was genomic DNA 
and PCR reactions were carried out in a final volume of 25µl containing 200ng 
DNA; 0.5µM of each primer; 200µM dNTPs; 10mM Tris-HCl, pH8.8; 50mM 
KCl; 1.5mM MgCl2 : 0.08% Nonidet P40 and 1U Taq polymerase.  Reactions 
were overlaid with mineral oil and subjected to 35 cycles of 30 seconds at 94ºC, 
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30 seconds at 57ºC and 60 seconds at 72ºC followed by 10 minutes at 72ºC.  To 
determine that the amplification was satisfactory, 5µl of PCR product was run 
on a 2% agarose gel and visualised with ethidium bromide. 
To genotype the PCR products 10µl was digested with 5U Van91I at 37°C 
overnight.  The digestion product was run through a 2.5% agarose gel and 
stained with ethidium bromide.  Genotypes were verified by two observers.  The 
undigested DNA was 646bp long and could be distinguished from the cut DNA 
that had fragments of 511bp and 135bp (see figure 2.4.1). 
 
 
 
 
 
 
 
 
Figure 2.4.1 Genotyping ACT -51 Promoter Polymorphism by RFLP.  M shows 100bp 
ladder, U/D is undigested PCR product 646bp in length, lane 1 contains a known GG 
genotype, lane 2 contains a known GT genotype and lane 3 contains a known TT genotype.  
Arrow shows position of 500bp. 
 
M M U/D 1 2 3 U/D 
2.4 Genotyping the a1-Antichymotrypsin Gene 
95 
  
2.4.2 Apolipoprotein E Genotyping 
A 172 bp region of the APOE  gene was amplified with primers F6; 5’ TCC 
AAG GAG CTG CAG GCG GCG CA 3’ and R6; 5’ ACA GAA TTC GCC 
CCG GCC TGG TAC ACT GCC A 3’.  PCR reactions were carried out in a 
final volume of 25µl containing 200ng DNA; 0.5µM of each primer; 200µM 
dNTPs; 10mM Tris-HCl, pH8.8; 50mM KCl; 1.5mM MgCl2: 0.08% Nonidet 
P40 and 1U Taq polymerase.  Reactions were overlaid with mineral oil and 
subjected to 35 cycles of 30 seconds at 94ºC, 30 seconds at 65ºC and 60 seconds 
at 72ºC followed by 10 minutes at 72ºC.  To determine that the amplification 
was satisfactory, 5µl of PCR product was run on a 2% agarose gel and 
visualised with ethidium bromide. 
To genotype the PCR products 10µl was digested with 5U Hin61 at 37°C 
overnight.  The digestion product was run through a 10% polyacrylamide gel 
and stained with ethidium bromide and two observers verified genotypes.  The 
e2 allele generated bands of 91bp and 81bp; the e3 allele, bands of 91bp, 48bp 
and 33bp; the e4 allele, bands of 72bp, 48bp and 33bp.  The 33bp bands were 
not visible on the 10% polyacrylamide gels. 
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Figure 2.4.2:  ApoE genotyping.  Lane 1 contains a known e2/e2 genotype, lane 2 contains 
a known e2/e3 genotype, lane 3 contains a known e2/e4 genotype, lane 4 contains a known 
e3/e3 genotype, lane 5 contains a known e3/e4 and lane 6 contains a known e4/e4.  Arrows 
show, from top, 91bp, 81bp, 72bp, 48bp.  Known e2/e4 was used as a marker when scoring 
unknown genotypes. 
 
1 2 3 4 5 6 
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2.4.3 Automated Sequencing of the a1-Antichymotrypsin Gene Promoter 
Polymorphism 
In addition to confirming the ACT genotyping results by “in house” restriction 
analysis, two samples of each genotype were sequenced across the ACT 
promoter polymorphism site.  One reason for doing this was to confirm that the 
results obtained by restriction enzyme genotyping were correct, but more 
importantly, to verify that the sequence was as expected.  These samples were 
used later, to produce constructs for the functional assays, and probes for the 
EMSA.  It was important that the samples chosen did not contain unreported 
polymorphisms that might interfere with these experiments, as well as being 
absolutely sure that the correct genotypes were used. 
2.4.3.1 Cleaning PCR Products for Sequencing 
PCR products for the 646bp 5’ flanking sequence of the ACT gene were 
obtained, as described above.  The PCR products (0.2µg) were then cleaned 
with 5U exonuclease I, exoI (USB), 1U shrimp alkaline phosphatase, SAP 
(USB), in a final volume of 6µl.  This was incubated at 37°C for 15 minutes, 
and then the enzymes were inactivated by incubating at 80°C for 15 minutes.  
Following this, the products were chilled on ice and centrifuged briefly at 
15,000rpm. 
2.4.3.2 Sequencing Reaction 
The reverse primer, R1 (see section 2.4.1, or Appendix 1) was used to sequence 
the ACT flanking region using the Big Dye protocol (ABI). 
Sequencing reactions took place in a final volume of 10µl which contained 4µl 
Big Dye Ready Reaction mix version 3.1 (Applied Biosciences), 1.5pmol 
primer, and approximately 50ng enzyme treated PCR product.  This was 
overlaid with mineral oil and centrifuged, then subjected to 25 cycles of 30 
seconds at 96°C, 15 seconds at 50°C, 240 seconds at 60°C, after which there 
was 60 seconds of incubation at 28°C. 
The sequencing reaction was purified by filtration through AGTC Spin 
Columns (VH Bio) following the manufacturer’s instructions.  The cleaned 
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product was heated to 90°C for approximately 5 minutes, or until the liquid had 
evaporated, leaving dry DNA at the bottom of the tube.  The tubes were then 
delivered to a sequencing laboratory. 
 
2.5 Statistical Analysis 
 
The alleles were counted to provide an estimation of allele frequencies.  The 
frequencies could then be compared between AD and control groups by χ2 
testing.  Due to the small sample sizes, Yates continuity correction was used.  
To determine if genotypes were in Hardy-Weinberg equilibrium, the following 
equation was used: 
1 = p2 + 2pq + q2 
where p and q are the observed frequencies of the two alleles, determined by 
counting.  This equation gave the expected genotype frequencies, which could 
be compared against the observed frequencies by ?2 testing.  In both cases, the 
level of statistical significance was defined as p<0.05. 
Comparisons between discrete variables, such as allele frequencies and AD 
status were made using the ?2 test, and comparisons between ranges of values, 
such as mean age, were made using ANOVA.  These statistical analyses were 
performed using the statistical software package SPSS for Windows v11.01. 
Power calculations were performed using Quanta 0.5 software, assuming a 
recessive inheritance of the allele under investigation, with a 5% error rate.  
Odds ratios were calculated using the equation: 
a x d 
b x c 
where a is the number of cases possessing the allele investigated, b is the 
number of controls possessing the same allele.  c is the number of cases not 
possessing the allele under investigation, and d is the number of controls not 
possessing this allele.  95% CI was derived using the equation: 
 
95% CI = LnOR±1.96 SE(LnOR) 
2.5 Statistical Analysis 
99 
  
 
where SE(LnOR) =  
 
1 
a 
1 
c 
1 
b 
1 
d + + + 
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3 RESULTS 
 
3.1 Functional Assays 
 
The functional assays were performed using four different cell lines, Hep G2 
(hepatocyte), T98G (mixed population), U373 MG (astrocytes), and SH-SY5Y 
(neuronal cells).  The experiments were performed over a defined time course, 
to demonstrate each allele’s response both with and without exposure to 
oncostatin M (OSM).  Each experiment was performed at least three times, in 
triplicate. 
 
3.1.1 Effect of the ACT Promoter Polymorphism on Reporter Gene Activity in 
Hep G2 Cells 
Reporter gene activity was higher in Hep G2 cells transfected with the T allele 
by an average of 187% compared with the G allele when data from stimulated 
and unstimulated cells were combined; this was to be expected from previous 
observations.  The greatest difference in reporter gene activity between the two 
promoters occurred after twenty-four hours, when the difference in reporter 
gene response was 427% (see figure 3.1.1 and table 3.1.1).  Under basal 
conditions there was a significant difference in activity between alleles.  The T 
allele showed a 90% higher response over the G allele.  After three hours of 
OSM stimulation, the T allele response was only 36% greater than the G allele, 
and this difference was not significant.  When the cells had been stimulated with 
OSM for six hours, the difference in reporter gene activity was significant.  The 
difference in reporter gene activity between the two promoters at this time was 
289%.  After twelve hours of OSM stimulation, the difference in reporter gene 
activity between the two promoters was 92% although the difference was not 
significant. 
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The liver is the main site of ACT synthesis (Kalsheker, 1996), and functional 
assays were carried out in hepatocytes, to gain an insight into how circulating 
ACT levels might vary with OSM stimulation.  It can be seen that the functional 
response to 50ng/ml OSM is large and rapid (see table 3.1.2.).  In Hep G2 cells, 
when the ‘T’ allele was present, there was an immediate response to OSM.  The 
reporter gene response increases 10 fold in three hours.  After six hours of OSM 
stimulation, this response had risen by more than 20 fold, before reaching a 
peak of activity, more than 40 times the basal activity, after twelve hours had 
elapsed.  When the G allele was present, the response was slightly different.  
There was an initial rise in activity, with reporter gene activity 14 fold greater 
after three hours of OSM stimulation compared with the basal level.  After six 
hours the response had fallen, but was still over 10 fold higher than basal.  As 
with the T allele response, the G allele saw reporter gene activity peak after 
twelve hours, with a response 40 times higher than basal.  The response dropped 
to basal levels after 24 hours. 
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Figure 3.1.1: Functional response of the ACT promoter polymorphism to OSM stimulation 
in Hep G2 (hepatocyte) cells.  Results of three experiments are shown as mean ± standard 
error of the mean (error bars). 
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 Exp1 Exp2 Exp3 Mean Std. Deviation % Change p value 
T Basal 3.2 2.7 2.9 2.9 0.3 
G Basal 1.6 1.9 1.1 1.5 0.4 
90.3 0.042 
T 3 hrs 35.2 31.9 19.8 29.0 8.1 
G 3 hrs 17.8 22.5 23.7 21.3 0.3 
36.2 0.250 
T 6hrs 72.8 65.6 55.3 64.6 8.8 
G 6 hrs 14.1 18.2 17.5 16.6 2.2 
289.2 <0.001 
T 12 hrs 103.3 165.3 90.9 119.8 39.9 
G 12 hrs 75.2 35.3 76.3 62.3 23.3 
92.3 0.103 
T 24 hrs 4.9 4.2 8.2 5.8 2.1 
G 24 hrs 1.2 1.0 1.1 1.1 0.1 
427.3 0.011 
Table 3.1.1: Difference between activity of the pGL3E ‘G’ and ‘T’ constructs, shown as % 
change in Hep G2 cells basally and following OSM treatment.  The fold increases of 
luciferase activity, over the pGL3 enhancer vector alone are given as mean ± standard 
deviation.  p values are derived using the Student’s t-test on the log of the fold increases. 
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 T Allele G Allele 
Time 
Mean increase 
over pGL3 
enhancer alone 
Fold 
increase 
over basal 
p value 
Mean increase 
over pGL3 
enhancer alone 
Fold 
increase 
over basal 
p value 
Basal 2.9±0.3 - - 1.5±0.4 - - 
3 hrs 29.0±8.1 10.0x 0.006 21.3±0.3 13.9x 0.006 
6 hrs 64.6±8.8 22.3x 0.001 16.6±2.2 10.8x 0.006 
12 hrs 119.8±39.9 41.3x 0.004 62.3±23.3 40.6x 0.011 
24hrs 5.8±2.1 2.0x 0.085 1.1±0.1 0.7x 0.242 
Table 3.1.2: OSM Response of ACT promoter alleles.  Response of the pGL3E ‘T’ and ‘G’ 
constructs in Hep G2 cells, comparing basal response to different OSM exposure times.  
Results (mean ± SD) are the mean of three experiments; % change is the percentage 
difference between activity of the pGL3E ‘G’ and ‘T’ constructs.  Univariate analysis of 
variation of both variation over each time point provided a p value of <0.001.  p values 
shown in table are calculated by performing post hoc Student’s t-test on the log of the fold 
increase ove r the pGL3 enhancer alone. 
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3.1.2 Effect of the ACT Promoter Polymorphism on Reporter Gene Activity in 
T98G Cells 
The T98G cell line is a mixed population of astrocytes and neuronal cells.  Once 
again, the T allele always provoked a greater functional activity in comparison 
to the G allele (see figure 3.1.2 and table 3.1.3).  The difference was greatest 
after twenty-four hours stimulation with OSM at 115%, and the smallest 
difference, 19% was seen after three hours of stimulation.  The mean difference 
in functional activity between the two promoters when transfected into T98G 
cells was 49%. 
The comparison of functional activity of cells stimulated and unstimulated with 
OSM revealed a trend to increasing activation with longer exposure to OSM 
(see table 3.1.4).  When the G allele was present the mean rise in activity was 3 
fold, a rise that began at three hours, increased after six hours, and declined, but 
not to the basal level, after twenty-four hours.  Of these changes, only that 
observed after six hours was statistically significant, according to the t-test.  
When the T allele was present, the mean rise in activity was 4 fold, and once 
more there was a 3-fold rise at three hours.  The peak OSM response of 4-fold 
occurred at six hours.  At twenty-four hours the increase in functional activity 
was 3-fold compared to the basal level.  In each case, the difference was 
statistically significant. 
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Figure 3.1.2: Functional response of the ACT promoter polymorphism to OSM stimulation 
in T98 G (mixed population) cells.  Results of three experiments are shown as mean ± 
standard error of the mean (error bars). 
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 Exp1 Exp2 Exp3 Mean Std. deviation % Change p value 
T Basal 33.5 31.8 35.7 33.6 2.0 
G Basal 23.6 23.0 29.2 25.3 3.4 
32.8 0.044 
T 3 hrs 80.2 120.4 121.9 107.5 23.7 
G 3 hrs 106.0 108.3 56.4 90.2 29.3 
19.2 0.484 
T 6 hrs 148.4 155.9 121.9 142.1 17.9 
G 6 hrs 117.8 106.0 108.3 110.7 6.3 
28.4 0.066 
T 24 hrs 88.3 121.6 107.0 105.6 16.7 
G 24 hrs 61.0 44.8 41.4 49.1 10.4 
115.1 0.007 
Table 3.1.3: Difference between activity of the pGL3E ‘G’ and ‘T’ constructs, shown as % 
change in T98G cells basally and following OSM treatment.  The fold increases of 
luciferase activity, over the pGL3 enhancer vector alone are given as mean ± standard 
deviation.  p values are derived using the Student’s t-test on the log of the fold increases. 
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 T Allele G Allele 
Time Mean increase 
over pGL3E 
enhancer alone 
Fold 
increase 
over basal 
p value Mean increase 
over pGL3E 
enhancer alone 
Fold 
increase 
over basal 
p value 
Basal 33.6±2.0 - - 25.3±3.4 - - 
3 hrs 107.5±23.7 3.2x 0.032 90.2±29.3 3.6x 0.075 
6 hrs 142.1±17.9 4.2x 0.011 110.7±6.3 4.4x 0.003 
24 hrs 105.6±16.7 3.1x 0.019 49.1±10.4 1.9x 0.083 
Table 3.1.4: OSM Response of ACT promoter alleles.  Response of the pGL3E ‘T’ and ‘G’ 
constructs in T98G cells, comparing basal response to different OSM exposure times.  
Results (mean ± SD) are the mean of three experiments; % change is the percentage 
difference between activity of the pGL3E ‘G’ and ‘T’ constructs. Univariate analysis of 
variation of both variation over each time point provided a p value of 0.001.  p values 
shown in table are calculated by performing post hoc Student’s t-test on the log of the fold 
increase over the pGL3 enhancer alone. 
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3.1.3 Effect of the ACT Promoter Polymorphism on Reporter Gene Activity in 
U373 MG Cells 
Since ACT is too large to pass through the blood-brain barrier, it must be 
synthesised by the brain.  The cells that produce ACT in the brain are the 
astrocytes, and U373 MG cells were chosen to study represent a pure astrocyte 
population in this study. 
There was again a difference in the functional response produced between the 
different alleles of the ACT promoter polymorphism (see figure 3.1.3 and table 
3.1.5).  Once again, the T allele provoked higher activity compared to the G 
allele at each time interval.  When the astrocytes were transfected a mean 
difference between the promoter alleles of 167% was seen.  The greatest 
difference in functional effect between the alleles was seen at twelve hours, 
when the difference was 320%, a highly significant difference.  Under basal 
conditions there was a 207% difference in the functional activity of the two 
promoter alleles, although this was not statistically significant.  The difference 
in promoter activity after three, six and twenty-four hours was not significant, 
either, but ranged from a 100% to 140% increase in activity when the T allele 
was present.  After forty-eight hours, the difference between the promoters was 
115%, a statistically significant result.  
As with the Hep G2 and T98G cells, there was a definite response to OSM (see 
table 3.1.6).  There was a mean rise in functional response of 2-fold when the 
hepatocytes were stimulated with OSM whichever promoter allele was present.  
The OSM response in astrocytes differed to that seen in hepatocytes in a number 
of ways.  Firstly, there seems to be a delay in the response.  After three hours 
there was a decrease in activity.  This decrease is not statistically significant, 
and it is more likely that there is no change in promoter activity. After 6 hours 
there is a statistically significant increase in functional activity when the T allele 
is present, then a small, non-significant rise after 12 hours, before activity rises 
to a peak after 24 hours.  When the cells were stimulated with OSM for 48 
hours the functional activity had dropped to approximately basal levels.  This is 
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in contrast to the hepatocytes, which maintained a response to OSM for only 12 
hours.  The mean response to OSM was over 8 times greater in hepatocytes than 
seen in astrocytes.  The hepatocytes showed a much greater mean increase to 
OSM, and at each time interval the activity in response to stimulation was much 
higher in these cells compared to astrocytes.  In hepatocytes the mean increase 
in functional activity with OSM stimulation over the pGL3 enhancer alone was 
18.9 fold with the T allele present, and 16.5 fold when the G allele was present.  
In astrocytes the values were 1.6 and 2.0 fold respectively. 
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Figure 3.1.3: Functional response of the ACT promoter polymorphism to OSM stimulation 
in U373 MG (astrocyte) cells.  Results of three experiments are shown as mean ± standard 
error of the mean (error bars). 
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 Exp1 Exp2 Exp3 Mean Std. Deviation % Change p value 
T Basal 4.6 4.7 2.8 4.0 1.1 
G Basal 1.5 0.6 1.8 1.3 0.6 
207.7 0.054 
T 3 hrs 1.6 3.2 1.2 2.0 1.0 
G 3 hrs 1.2 1.0 0.8 1.0 0.2 
100.0 0.156 
T 6 hrs 8.5 7.5 6.0 7.3 1.3 
G 6 hrs 2.2 2.7 4.9 3.3 1.4 
121.2 0.053 
T 12 hrs 4.1 4.2 4.3 4.2 0.1 
G 12 hrs 1.3 1.0 0.7 1.0 0.3 
320.0 0.014 
T 24 hrs 19.4 13.7 13.8 15.6 3.2 
G 24 hrs 3.6 7.8 8.0 6.5 2.5 
140.0 0.054 
T 48 hrs 2.5 3.8 2.1 2.8 0.9 
G 48 hrs 1.0 1.8 1.2 1.3 0.4 
115.4 0.040 
Table 3.1.5: Difference between activity of the pGL3E ‘G’ and ‘T’ constructs, shown as % 
change in U373 MG cells basally and following OSM treatment.  The fold increases of 
luciferase activity, over the pGL3 enhancer vector alone are given as mean ± standard 
deviation.  p values are derived using the Student’s t-test on the log of the fold increases. 
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 T Allele G Alleles 
Time Mean increase 
over pGL3 
enhancer 
alone 
Fold 
increase 
over basal 
p value Mean increase 
over pGL3E 
enhancer 
alone 
Fold 
increase 
over basal 
p value 
Basal 4.0±1.1 - - 1.3±0.6 - - 
3 hrs 2.0±1.0 0.5x 0.060 1.0±0.2 0.8x 0.724 
6 hrs 7.3±1.3 1.8x 0.019 3.3±1.4 2.5x 0.099 
12 hrs 4.2±0.1 1.1x 0.728 1.0±0.3 0.8x 0.697 
24 hrs 15.6±3.2 3.9x 0.013 6.5±2.5 5.0x 0.083 
48 hrs 2.8±0.9 0.7x 0.105 1.3±0.4 1.0x 0.865 
Table 3.1.6: OSM Response of ACT promoter alleles.  Response of the pGL3E ‘T’ and ‘G’ 
constructs in U373 MG cells, comparing basal response to different OSM exposure times.  
Results (mean ± SD) are the mean of three experiments; % change is the percentage 
difference between activity of the pGL3E ‘G’ and ‘T’ constructs. Univariate analysis of 
variation of both variation over each time point provided a p value of <0.001.  p values 
shown in table are calculated by performing post hoc Student’s t-test on the log of the fold 
increase over the pGL3 enhancer alone. 
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3.1.4 Effect of the ACT Promoter Polymorphism on Reporter Gene Activity in 
SH-SY5Y Cells 
Hepatocytes and astrocytes are known to synthesise ACT, and for that reason, 
the response to OSM of the ACT promoter was tested in these cells, but 
neuronal cells are not known to synthesise ACT.  SH-SY5Y cells are neuronal 
cells, and the response of the ACT promoter to OSM was studied in this cell line 
to provide a contrast with cells involved in the acute phase response with cells 
that do not synthesise acute phase proteins. 
Once more, the functional response of the T allele of the ACT promoter 
polymorphism is higher than the G allele (see figure 3.1.4 and table 3.1.7).  The 
mean difference in functional response between the two promoters is a 44% 
increase in activity when the T allele is present.  The greatest difference 
between the activity of the two alleles is at six hours, a difference of 112%.  
Statistically significant differences were seen until twelve hours of stimulation 
with OSM, when the difference is 21%.  Before this time, the difference, which 
was 36% in unstimulated cells, had risen at each time interval.  The smallest 
difference in functional activity was seen after twenty-four hours, when there 
was only a 5% difference in response between the two alleles. 
There was no trend in increasing functional activity over time when exposed to 
OSM (see table 3.1.8).  The mean response to OSM over each time interval was 
no different to the basal level of activity whichever promoter allele was present.  
In general, there was no significant difference between the functional activity of 
stimulated and unstimulated SH-SY5Y cells. 
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Figure 3.1.4: Functional response of the ACT promoter polymorphism to OSM stimulation 
in SH-SY5Y (neuronal) cells.  Results of three experiments are shown as mean ± standard 
error of the mean (error bars).  
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 Exp1 Exp2 Exp3 Mean Std deviation % Change p value 
T basal 4.7 5.2 4.3 4.8 0.5 
G Basal 3.7 3.5 3.3 3.5 0.2 
36.2 0.015 
T 3 hrs 4.1 4.2 4.2 4.2 0.1 
G 3 hrs 2.9 3.2 2.6 2.9 0.3 
43.5 0.024 
T 6 hrs 6.1 6.4 4.6 5.7 1.0 
G 6 hrs 3.0 2.5 2.5 2.7 0.3 
111.9 0.006 
T 12 hrs 4.0 4.7 5.6 4.7 0.8 
G 12 hrs 3.7 4.5 3.6 3.9 0.5 
21.2 0.199 
T 24 hrs 4.4 3.8 4.1 4.1 0.3 
G 24 hrs 3.7 4.7 3.2 3.9 0.8 
5.3 0.609 
Table 3.1.7: Difference between activity of the pGL3E ‘G’ and ‘T’ constructs, shown as % 
change in SH-SY5Y cells basally and following OSM treatment.  The fold increases of 
luciferase activity, over the pGL3 enhancer vector alone are given as mean ± standard 
deviation.  p values are derived using the Student’s t-test on the log of the fold increases. 
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 T Allele G Allele 
Time Mean increase 
over pGL3 
enhancer alone 
Fold 
increase 
over basal 
p value Mean increase 
over pGL3 
enhancer alone 
Fold 
increase 
over 
basal 
p value 
Basal 4.8±0.5 - - 3.5±0.2 - - 
3 hrs 4.2±0.1 0.9x 0.152 2.9±0.3 0.8x 0.088 
6 hrs 5.7±1.0 1.2x 0.102 2.7±0.3 0.8x 0.020 
12 hrs 4.7±0.8 1.0x 0.957 3.9±0.5 1.1x 0.271 
24 hrs 4.1±0.3 0.9x 0.243 3.9±0.8 1.1x 0.447 
Table 3.1.8: OSM Response of ACT promoter alleles.  Response of the pGL3E ‘T’ and ‘G’ 
constructs in SH-SY5Y cells, comparing basal response to different OSM exposure times.  
Results (mean ± SD) are the mean of three experiments; % change is the percentage 
difference between activity of the pGL3E ‘G’ and ‘T’ constructs. Univariate analysis of 
variation of both variation over each time point provided a p value of 0.138.  p values 
shown in table are calculated by performing post hoc Student’s t-test on the log of the fold 
increase over the pGL3 enhancer alone. 
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3.1.5 Summary of the ACT Promoter  Responses 
It is apparent, even looking at these data in isolation, that the response of the 
ACT promoter to OSM stimulation, and the responses of the two alleles of the 
polymorphism differ between cell lines.  Table 3.1.9 is a summary of the results 
described in section 3.1. 
The most striking observation was that in every cell line, the T allele had a 
higher functional effect than the G allele.  In the Hep G2 cells, the functional 
activity of the T allele was higher than that of the G allele under basal 
conditions and following OSM stimulation.  The difference between the  
functional activities of the alleles was most pronounced after 24 hours of OSM 
stimulation, with the T allele of the promoter showing 427% more activity than 
the G allele.  The difference in functional activity between the two alleles was 
similar when the reporter gene constructs were transfected into T98G cells.  As 
with the Hep G2 cells, the greatest difference between the alleles was after 24 
hours of OSM stimulation (115%).  The U373 MG cells again showed a higher 
functional effect when the T allele was present than the G allele.  In contrast to 
the previous two cell lines, U373 MG cells showed the greatest difference 
between alleles after 12 hours of OSM stimulation, with the T allele showing a 
320% greater functional effect than the G allele.  When the SH-SY5Y cells 
were investigated the greatest difference between functional activity of the two 
promoter polymorphism alleles was seen after 6 hours of OSM stimulation.  
The results of OSM stimulation were not as clear-cut.  In all but the SH-SY5Y 
cells there was, on average, an increase in activity when the cells were 
stimulated compared to basal.  However, the time course of this effect was not 
consistent between cell lines.  In some cases, such as the T98G cells, the effect 
of OSM stimulation was apparent after 3 hours of OSM stimulation, and had 
diminished after 24 hours, whereas U373 MG cells did not show a definite 
response until they had been stimulated for 6 hours.  The difference in activity 
seen between the OSM responses of the ACT promoter polymorphism alleles 
was not uniform either.   
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Although there are some differences in the effect of OSM on the different 
promoter polymorphism alleles in different cell lines, some general points can 
be made.  With the exception of the SH-SY5Y cells, OSM caused an increase in 
functional activity of the ACT promoter, regardless of which allele was present.  
When the T allele was present, the increased functional activity of the ACT 
promoter caused by OSM stimulation was of a longer duration, with the 
response to OSM falling to near-basal levels first when the G allele was present.  
 
Cell line Allele Response OSM Response 
 Basal OSM % Difference   
 T G T G Basal OSM T G 
Hep G2 2.9 1.5 54.8 25.3 90.3 116.6 18.9x 16.5x 
T98G 33.6 25.3 118.4 83.3 32.8 42.1 3.5 3.3x 
U373 MG 4.0 1.3 6.4 2.6 207.7 146.2 1.6x 2.0x 
SH-SY5Y 4.8 3.5 4.7 3.3 37.1 45.5 1.0x 1.1x 
Table 3.1.9: Summary of the functional assay data.  Allele response under basal condition 
is the mean fold increase of both alleles of the ACT promoter over the SV40 enhancer 
alone.  The values for OSM response are the mean of every OSM at each time interval 
combined over the SV40 enhancer alone.  % Differences are the percent differences 
between alleles under basal and mean stimulated conditions.  The OSM response is the 
mean OSM response over basal response. 
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3.2 Reverse-Transcriptase PCR 
 
To confirm that the cell lines under investigation synthesise ACT mRNA, RT-
PCR was performed on mRNA extracted from the four cell lines used in the 
functional assays.  Of these cell lines, Hep G2, U373 MG and T98 G cells are 
known to synthesise ACT (Kalsheker, 1996; Kordula et al., 1998).  The SH-
SY5Y cells are neuronal cells, and it is not known whether they synthesise 
ACT. 
 
3.2.1 RT-PCR in Cultured Cells 
Two RT-PCR reactions were carried out for each cell line being studied.  One 
was a positive control, amplifying cDNA from the housekeeping gene HPRT, 
and the other reaction was for the ACT gene.  The RT-PCRs demonstrate that 
mRNA was being synthesised for both genes in Hep G2, U373 MG and T98G 
cells (figure 3.2.1). There is one strong band in both lanes, in every cell line, 
except SH-SY5Y.  The presence of a band in the HPRT lane of SH-SY5Y 
demonstrates that mRNA was isolated from these cells, and cDNA was 
succesfully produced from this mRNA.  The amplification of ACT cDNA from 
the other cell lines demonstrates that the reaction to amplify ACT cDNA was 
working in three of the four reactions.  These results suggest that SH-SY5Y 
cells do not synthesise ACT mRNA. 
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Figure 3.2.1:  RT-PCR on cDNA from cultured cell lines.  Bands show the products of 
quantitative RT-PCR on cDNA synthesise from mRNA from two genes, HPRT  (180bp) 
and ACT (470bp).  Other lanes show 100bp ladder (M) and negative controls, containing 
no cDNA (-ve). 
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3.3 Electrophoretic Mobility Shift Assays 
 
Having obtained functional data that demonstrates a statistical difference in 
activity between alleles, the EMSAs were used in order to understand the 
underlying mechanism behind these differences.  These assays rely on 
radiolabelled DNA, spanning the region of interest, to bind to nuclear proteins 
extracted from cultured cells.  The cell lines chosen for this work were the Hep 
G2, U373 MG and T98G lines.  The SH-SY5Y cells were not included, as RT-
PCR showed they do not synthesise ACT and DLR assays showed no functional 
response to OSM. 
 
3.3.1 Electrophoretic Mobility Shift Assay with Nuclear Proteins Extracted 
from Hep G2 Cells 
The signal obtained with nuclear extract from stimulated Hep G2 cells is greater 
than that from unstimulated Hep G2 cells (figure 3.3.1).  This is in agreement 
with the functional data, and demonstrates that more nuclear proteins are 
binding to this region of the ACT promoter when the cells are stimulated.  This 
is to be expected, as OSM is known to upregulate ACT in hepatocytes.  It is also 
apparent that more protein is binding to the probe that contains the T allele of 
the ACT promoter.  Again, this agrees with the functional data, which showed 
that this form of the ACT promoter is more active, both under basal conditions 
and when stimulated with OSM. 
There are at least three bands present in the lanes containing nuclear extract.  
The lowest band, which is also present in lanes that do not contain extract, is 
unbound probe.  It is important to note that the amount of unlabelled probe is 
roughly equal in each lane.  The probe is added in excess during the binding 
stage of the assay, and an equal amount of probe at the bottom of the gel 
suggests that the differences in the amount of protein bound to the probe are 
genuine, and not due to differences in loading. 
The other bands (*) are the result of probe binding to proteins of different sizes.  
This is due, either to the ACT probe being able to bind to more than one protein, 
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or, the protein to which the probe binds is able to form a complex.  The band 
closest to the unbound probe (†) is likely to be the result of degraded protein.  
This is possible, as the proteins that initiate transcription not only bind to DNA, 
but also form complexes due to protein/protein interactions. 
Whatever the identity of the protein, or proteins, binding to the ACT probe, the 
signal in each lane is not present in equivalent amounts.  As mentioned before, 
it seems to bind preferentially to the T allele of the ACT promoter, and when 
cells have been stimulated with OSM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1: Electrophoretic mobility assay with nuclear proteins isolated from Hep G2 
cells.  Radiolabelled probes spanning the ACT  promoter polymorphism were allowed to 
interact with nuclear proteins and then separated by size.  ‘+’ Represents lanes containing 
nuclear extract, ‘-’ represents lanes containing radiolabelled probe only. ‘*’ indicates 
position of DNA/protein complexes and ‘†’ indicates unbound probe.  
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3.3.2 Electrophoretic Mobility Shift Assay with Nuclear Proteins Extracted 
from U373 MG Cells 
When nuclear proteins extracted from astrocytes were allowed to interact with 
the radiolabelled ACT promoter probe a marked difference was seen between 
the two alleles (figure 3.3.2).  Under both basal and OSM stimulated conditions 
the strength of the signal coming from the ACT T promoter probe was stronger 
than that obtained with the G allele probe.  There was a large increase in the 
amount of nuclear protein binding to the T probe when the U373 MG cells were 
stimulated with OSM. 
Although it is difficult to resolve the apparent differences between basal and 
stimulated binding patterns it is clear that the ACT promoter probe is interacting 
with protein.  When nuclear protein from stimulated U373 MG cells interacts 
with the T probe under basal conditions, at least three bands are present (*), 
aside from the unlabelled probe band (†).  The band nearest the unlabelled 
probe is most likely to be degraded protein.  When the nuclear proteins were 
extracted from OSM stimulated cells, there are at least 5, possibly 6 bands 
present, including what is probably degraded protein.  There was more protein 
binding to the probe in the stimulated extracts, and also a number of larger 
proteins or protein complexes present.  When the probe to the G allele 
interacted to nuclear proteins, the proteins from the unstimulated cells bound 
less to the G allele probe than proteins obtained from stimulated cells.  As with 
the T allele, a number of higher molecular weight proteins or protein complexes 
were present. 
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Figure 3.3.2: Electrophoretic mobility assay with nuclear proteins isolated from U373 MG 
cells.  Radiolabelled probes spanning the ACT  promoter polymorphism were allowed to 
interact with nuclear proteins and then separated by size.  ‘+’ Represents lanes containing 
nuclear, ‘-’ represents lanes containing radiolabelled probe only.  ‘*’ indicates position of 
DNA/protein complexes and ‘†’ indicates unbound probe. 
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3.3.3 Electrophoretic Mobility Shift Assay with Nuclear Proteins Extracted 
from T98G Cells 
When the T98G cells were stimulated with OSM, there appeared to be similar 
amounts of protein binding to the ACT promoter as seen in the basal state  (see 
figure 3.3.3).  This was true for both alleles of the ACT promoter polymorphism.  
When the T allele was used there was more DNA-protein binding than when the 
G allele was used.  The proteins that bind to the T allele could, on first 
examination, appear to be different than those that bind to the G allele.  These 
appear as faint bands (marked ‘?’), and seem to bind only to the T allele.   What 
is more likely is that the same proteins are binding to both alleles, however, 
only the proteins that bound most strongly to the T allele can be seen.  There are 
at least three bands, representing different sized proteins, or protein complexes 
binding to the ACT promoter DNA, although the band closest to the unbound 
probe (†) is likely to be the result of degraded protein. 
When anti-TFIIB antibody was added to the nuclear proteins from cells 
stimulated with OSM, the banding pattern changed.  The strongest band seen 
when no antibody was present decreased in intensity, and a new band appeared 
near the top of the gel (arrowed).  This indicates a larger protein complex due to 
the increased size of the protein originally present bound with the antibody 
(induced supershift).  This suggests that the strong band is, at least in part, 
TFIIB.  It is difficult to determine whether the other bands present were shifted 
by the addition of anti-TFIIB, so it cannot be said with certainty that each band 
represents a complex of protein that contains TFIIB, but it is clear that TFIIB 
can bind to the ACT promoter. 
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Figure 3.3.3: Electrophoretic mobility assay with nuclear proteins isolated from T98 G 
cells.  Radiolabelled probes spanning the ACT  promoter polymorphism were allowed to 
bind to nuclear proteins and then separated by size.  In the lanes on the left, ‘+’ represents 
lanes containing nuclear extract, ‘-’ represents lanes containing radiolabelled probe only.   
‘*’ indicates position of DNA/protein complex, ‘?’ indicates position of spurious 
DNA/protein complexes and ‘†’ indicates unbound probe.  In the lanes on the right, ‘+’ 
represents lanes containing nuclear extract, radiolabelled probe and anti-TFIIB, ‘-’ 
represents lanes containing radiolabelled probe alone.  Arrow indicates position of 
supershifted DNA/protein complex. 
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3.4 Alpha-1-Antichymotrypsin Promoter Genotyping in AD Cases and 
Controls 
 
Samples from two centres, Oxford and Nottingham, were used in this study 
(table 3.4.1).  All samples were genotyped at the ACT –51 promoter and had 
previously been screened at the APOE polymorphism locus.  The ACT 
genotypes were generated by MRC Geneservices (Hinxton, Cambridge) 
genotyping facility, and one third of samples had their genotype verified by 
RFLP (see figure 2.4.1, p93). 
The numbers used in this study (335 controls, 394 AD) have over 99% power to 
detect an OR of 2 or more when the allele under investigation has a frequency 
of 49%.  The OR of 2 was chosen arbitarily.  The sample sizes are also large 
enough to have a greater than 99% power to detect an OR of 4 or more for the 
APOE e4 allele association.  Previous studies have shown an OR for this 
association to be 4.5 (Lambert et al., 2002). 
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Centre AD Status n Mean age±SD Male Female AD Status n Mean age Male Female 
Nottingham All AD 191 83.3±8.7 69 118 Control 123 72.8±8.9c 78 38 
Oxford All AD 198 70.5±9.1 89 115 Control 212 76.3±9.5d 93 119 
Total All AD 389 75.6±10.4 158 233 Control 335 75.0±9.4 171 157 
Nottingham Confirmed AD 191 83.3±8.7a 69 118      
Oxford Confirmed AD 112 71.1±9.0 51 67      
Total Confirmed AD 303 77.3±10.1 120 185      
Oxford Probable AD 86 69.5±9.2b 38 48      
Table 3.4.1: Demographic information for the two populations examined in the genotyping study.  Each population was divided into groups based on AD 
status.  Note some samples did not posses age or sex data; 
a
7 samples,
 b
3 samples, 
c
2 samples,
 d
5 samples.  
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3.4.1 ACT-51bp Promoter Polymorphism and Alzheimer´s Disease 
Samples from both populations were classified according to disease status, 
confirmed AD, probable AD and control.  Genotype and allele frequencies in 
each group, confirmed AD, probable AD and control, are shown in table 3.4.2.  
In the control groups from Nottingham and Oxford, the distribution of 
heterozygotes were as predicted by Hardy-Weinberg equilibrium.  There was no 
significant difference between confirmed AD cases and controls in either 
population (Nottingham, ?2= 1.808, 1df, p=0.99 OR= 1.15, 95% CI 0.66 to 1.99; 
Oxford, ?2= 0.864, 1df, p=0.649, OR=0.98, 95% CI 0.59 to 1.63).  Also, there 
was no significant difference when the Oxford probable AD group was 
compared with the Oxford control group (?2= 1.848, 1df, p=0.39, OR=1.53, 
95% CI 0.82 to 2.89).  When both populations were combined, there was still no 
significant difference between genotype frequencies in confirmed AD cases and 
controls (?2= 2.76, 1df, p=0.25, OR=1.12, 95% CI 0.79 to 1.58).  The low odds 
ratios derived from these tests meant that the studies were underpowered.  To 
gain 80% power with an odds ratio of 1.19 in a population with a mean age of 
75, 2077 cases would be needed, with the same number of controls, assuming a 
5% two-way error rate (false negatives and positives).  This is assuming a 49% 
frequency of the T allele. 
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Centre AD Status Genotype Frequency Allele Frequency AD Status Genotype Frequency Allele Frequency 
  GG GT TT G T  GG GT TT G T 
Nottingham All AD 39 
(20.5%) 
103 
(54.2%) 
46 
(24.2%) 
181 
(48.1%) 
195 
(50.8%) 
Control 28 
(22.8%) 
57 
(46.3%) 
36 
(29.3%) 
113 
(46.7%) 
129 
(53.3%) 
Oxford All AD 47 
(23.0%) 
105 
(51.5%) 
52 
(25.5%) 
199 
(48.8%) 
209 
(51.2%) 
Control 55 
(25.9%) 
99 
(46.7%) 
58 
(27.4%) 
209 
(49.3%) 
215 
(50.7%) 
Total All AD 86 
(21.9%) 
208 
(53.1%) 
98 
(25.0%) 
380 
(48.5%) 
404 
(51.5%) 
Control 83 
(24.9%) 
156 
(46.8%) 
94 
(28.2%) 
322 
(48.3%) 
344 
(51.7%) 
Nottingham Confirmed 
AD 
39 
(20.5%) 
103 
(54.2%) 
46 
(24.2%) 
181 
(48.1%) 
195 
(50.8%) 
      
Oxford Confirmed 
AD 
31 
(26.3%) 
60 
(50.8%) 
27 
(22.9%) 
122 
(51.7%) 
114 
(48.3%) 
      
Total Confirmed 
AD 
70 
(22.9%) 
163 
(53.2%) 
73 
(23.9%) 
303 
(49.5%) 
309 
(50.5%) 
      
Oxford Probable AD 
16 
(18.6%) 
45 
(52.3%) 
25 
(29.1%) 
77  
(44.8%) 
95  
(55.2%)       
Table 3.4.2: ACT  –51bp promoter polymorphism genotype and allele frequencies in different AD groups in two British populations.  χ2 tests demonstrated no 
association between ACT genotype or allele and AD risk, either when samples were combined or in separate populations. 
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It has been reported that the ACT signal sequence polymorphism, which is in 
linkage disequilibrium with the promoter polymorphism, has a modifying effect 
on age of onset of AD.  For this reason, the confirmed and probable AD groups 
from both populations were combined and the effect of ACT-51 genotype on 
mean age of onset was determined (table 3.4.3).  When age of onset was 
unobtainable, age of death, less 10 years was used to estimate age of onset.  No 
association was observed between ACT promoter genotype and age of onset. 
 
 
     
95% Confidence 
Interval for Mean 
  
ACT 
Genotype 
n 
Mean 
age 
Std. 
Deviation 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Minimum Maximum 
GG 85 75.5 11.5 1.3 73.1 78.0 50.5 95.0 
GT 201 75.6 10.0 0.7 74.2 77.0 51.1 101.0 
TT 96 75.6 10.4 1.1 73.5 77.7 49.3 97.0 
Total 382 75.6 10.4 0.5 74.6 76.7 49.3 101.0 
Table 3.4.3: Mean age of AD samples against ACT  genotype.  AD samples were from the 
confirmed and probable AD subgroups of both the Nottingham and Oxford populations.  
ANOVA test gave a p value of 0.997. 
Although the ACT promoter polymorphism had no apparent effect on mean age 
of onset in the AD groups, there may still be an age-effect of the ACT 
polymorphism.  When the AD cases, both confirmed and probable, are divided 
by age into early onset (defined as AD diagnosis made before the age of 65) and 
late onset (diagnosis of AD after the age of 65), the ACT-51 polymorphism 
genotype frequencies did not show a significant difference (figure 3.4.1). 
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Figure 3.4.1: ACT –51bp promoter polymorphism genotype frequencies in early and late 
onset AD subgroups.  Data labels show sample size and frequencies.  Pearson ?
2
 returns a 
p value of 0.435; there is no significant difference in genotype frequencies between 
subgroups of AD in the two British populations. 
3.4.2 Apolipoprotein E Genotype and AD Status 
Previous studies have suggested that there is an association between ACT and 
Apolipoprotein E in AD.  Although no mechanism has been suggested for this 
possible interaction, it has been suggested that the e4 allele of APOE results in a 
lower age of onset in AD.  A table detailing ACT –51 and APOE genotypes in 
AD cases and control can be found in Appendix 2.  The probable and confirmed 
AD groups were combined into an AD group, as there were insufficient 
probable AD cases for analysis.  Similarly, the APOE genotypes were combined 
into presence or lack of e4, as some genotypes, such as e2/e2 were too rare to 
provide enough numbers for analysis.  It was seen that AD patients were likely 
to have one or more APOE ε4 alleles (table 3.4.4).  The odds ratio of 4.5 (95% 
CI 3.3 to 6.2) was in close agreement with previous studies (Lambert et al., 
2002). 
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APOE Genotype  AD Status 
No e4 e4 Total 
125 183 308 
AD 
(40.6%) (59.4%)  
245 78 323 
Control 
(75.9%) (24.1%)  
Table 3.4.4: Comparison of AD Status with APOE genotype groups.  Samples from 
Nottingham and Oxford were combined, as were the confirmed AD and probable AD 
subgroups, in order to provide enough cases for comparison.   Pearson ?
2
 test returns a p 
value of less than 0.001, d.f = 1, OR= 4.5 (95% CI 3.3 to 6.2).  Note that not all samples 
were categorised, as APOE genotype data was not available for every sample. 
 
As with ACT, APOE has been reported as having an effect on the age of onset of 
AD.  If this was the case, it would be expected that the mean age of AD patients 
in this study would be lower when the ε4 allele is present.  The mean age of AD 
patients with and without APOE ε4 was compared and e4 patients have a 
significantly lower age of onset (table 3.4.5). 
 
     
95% Confidence 
Interval for Mean 
  
APOE 
Genotype 
Group 
n 
Mean 
age 
Std. 
Deviation 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Minimum Maximum 
No e4 158 77.1 10.5 0.8 75.4 78.7 51.7 97.0 
e4 224 74.7 10.3 0.7 73.3 76.0 49.3 101.0 
Total 382 75.7 10.4 0.5 74.6 76.7 49.3 101.0 
Table 3.4.5: Mean age of AD samples against presence of APOE  e4 allele.  To determine if 
APOE genotype influences mean age of AD onset the age of onset was compared between 
confirmed and probable AD cases from Nottingham and Oxford based on presence of 
APOE ε4.  ANOVA test gives a p value of 0.026. 
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It is possible that the lack of association between the ACT –51 polymorphism 
and AD was masked by the strong association between the APOE ε4 allele and 
AD.  When the ACT promoter polymorphism genotype frequencies were 
compared in subjects lacking an APOE ε4 allele no significant difference was 
seen (table 3.4.6).  
 
ACT Genotype Frequency ACT Allele Frequency AD Status 
GG GT TT G T 
37 78 45 152 168 
AD 
(23.1%) (48.8%) (28.1%) (47.5%) (52.5%) 
67 115 62 249 239 
Control 
(27.5%) (47.1%) (25.4%) (51.0%) (49.0%) 
104 193 107 401 407 
Total 
(25.7%) (47.8%) (26.5%) (49.6%) (50.4%) 
Table 3.4.6: Comparison of ACT genotype between AD cases and controls from 
Nottingham and Oxford in the absence of APOE e4.  Pearson ?
2
 generates p value of 0.598, 
the ACT –51 polymorphism had no effect on AD risk in the absence of the APOE  ε4 allele. 
 
Since there have been studies showing that ACT may be a risk modifier for AD 
in combination with the e4 isoform of ApoE, genotype frequencies of the ACT 
promoter polymorphism were compared in subjects, excluding those with no 
APOE e4 allele.  No significant difference was seen in this comparison (table 
3.4.7). 
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ACT Genotype Frequency ACT Allele Frequency AD Status 
GG GT TT G T 
32 93 45 157 183 
AD 
(18.8%) (54.7%) (26.5%) (46.2%) (53.8%) 
10 30 26 50 82 
Control 
(15.2%) (45.5%) (39.4%) (37.9%) (62.1%) 
42 123 71 207 265 
Total 
(17.8%) (52.1%) (30.1%) (43.9%) (56.1%) 
Table 3.4.7: Comparison of ACT genotype between AD cases and controls from 
Nottingham and Oxford in the presence of APOE e4.  Pearson ?
2
 generates p value of 
0.215, the ACT –51 polymorphism had no effect on AD risk in the presence of the APOE  ε4 
allele. 
 
To determine if the ACT –51 polymorphism alters the mean age of AD patients 
in the absence of the APOE ε4 allele, the mean age of patients with each 
genotype of the ACT promoter polymorphism, lacking APOE ε4 allele were 
compared.  There was no association with ACT promoter genotype and age at 
onset of AD in patients lacking APOE e4  (table 3.4.8). 
 
     95% Confidence 
Interval for Mean 
  
 n Mean 
Std. 
Deviation 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Minimum Maximum 
GG 37 76.8 11.9 2.0 72.8 80.7 54.8 94.0 
GT 76 76.8 9.7 1.1 74.6 79.1 52.6 97.0 
TT 45 77.7 10.8 1.6 74.4 80.9 51.7 97.0 
Total 158 77.1 10.6 0.8 75.4 78.7 51.7 97.0 
Table 3.4.8: Mean age of AD samples against ACT genotype in the absence of APOE e4 
allele.   AD samples are the confirmed and probable AD patients from Nottingham and 
Oxford, without an APOE  ε4 allele.  ANOVA test gives a p value of 0.902. 
 
To determine if APOE e4 is a necessary co-factor with ACT -51T in the 
pathology of AD, the mean age of patients with each genotype of the ACT 
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promoter polymorphism, with at least one APOE ε4 allele were compared.  
There was no association with ACT promoter genotype and age at onset of AD 
in patients with the APOE e4 allele (table 3.4.9). 
 
     95% Confidence 
Interval for Mean 
  
 n Mean 
Std. 
Deviation 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Minimum Maximum 
GG 48 74.6 11.2 1.6 71.3 77.8 50.5 95.0 
GT 123 74.9 10.2 0.9 73.1 76.7 51.1 101.0 
TT 51 73.8 9.8 1.4 71.1 76.6 49.3 93.0 
Total 222 74.6 10.3 0.7 73.3 76.0 49.3 101.0 
Table 3.4.9: Mean age of AD samples against ACT genotype in the presence of APOE  e4 
allele.   AD samples are the confirmed and probable AD patients from Nottingham and 
Oxford, with at least one APOE  ε4 allele.  ANOVA test gives a p value of 0.827. 
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4 DISCUSSION 
 
4.1 Functional Activity of the ACT –51 Promoter Alleles 
 
As described previously, the ACT promoter responds to OSM stimulation 
(Kordula et al., 1998).  These experiments have extended previous work by 
demonstrating that the alleles of the –51bp polymorphism modify the functional 
activity of the ACT promoter, both basally and with OSM stimulation.  
Specifically, the T allele of this polymorphism has a higher activity, under basal 
conditions and when stimulated with OSM. 
The acute phase response is the body’s immediate reaction to a range of insults, 
including trauma, and results in a wide-ranging physiological reaction.  This 
includes the generation of acute phase proteins that fulfil a number of 
requirements to co-ordinate a response to the insult, to reduce and repair any 
damage caused.  The acute phase response sees an increase in the concentration 
of acute phase proteins in the circulation, co-ordinated by a range of cytokines 
(Roberts et al., 1995).  These cytokines, which can influence local and distal 
reactions on cells, are tightly regulated, and the responses they provoke are 
strictly controlled (McGeer and McGeer, 1995).  Cytokines often trigger 
cascade responses, whereby the genes they activate synthesise proteins that 
activate, directly or indirectly, other genes, and these cascades can also produce 
a feedback response.  In these situations the product of a gene downstream can 
activate a gene upstream; in effect the system is self-maintaining.  
Polymorphisms in the regulatory regions of acute phase protein genes could 
therefore have a morbid  effect, if they alter the cytokine response of the genes 
small effects could be amplified (Akiyama et al., 2000; McGeer and McGeer, 
2001b). 
Since AD pathogenesis is believed by many researchers to be a product of 
chronic neuroinflammation, the response of the two alleles of the ACT promoter 
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to an inflammatory cytokine was also investigated.  The functional assays were 
chosen as the most appropriate method of testing the hypothesis that the base 
substitution in the ACT regulatory region alters the functional response of the 
ACT promoter. 
The functional assays were used to demonstrate two different, but linked, 
effects.  The difference in functional activity of the two alleles of the ACT 
promoter polymorphism was measured in different cell lines, and also, the effect
 of oncostatin M (OSM) exposure on functional effect was investigated.  As the 
ACT promoter was known to respond to OSM (Kordula et al., 1998), the effect 
of OSM on the two alleles was also shown. 
These effects were demonstrated in four different cell lines.  Hepatocytes are the 
main source of ACT synthesis (Kalsheker, 1996), and the concentration of ACT 
in the circulation is dependent on ACT secretion from these cells.  Hep G2 cells 
represented hepatocytes in this study.  The origin of ACT in the brain is 
dependent on production by astrocytes, as this serpin is too large to pass through 
the blood brain barrier.  Astrocytes were represented in this study by two cell 
lines, U373 MG, which is a pure astrocytic population, and T98G, a mixed 
population of astrocytes and neuronal cells.  For purposes of comparison, the 
pure neuronal cell line, SH-SY5Y, was also included. 
The most active allele in terms of functional activity did not vary according to 
the cell line under investigation.  The T allele demonstrated higher activity, 
regardless of cytokine stimulation or cell line.  There was also a cell-specific 
effect of the ACT promoter to OSM stimulation.  The hepatocytes showed the 
largest response to OSM stimulation compared to the other cell lines, while the 
neuronal cells did not respond to OSM.  The response to OSM in each 
individual cell line was similar whether the T allele or the G allele of the ACT 
promoter polymorphism was present overall. 
Although these are in vitro data, if these trends reflect what occurs in vivo, the T 
allele of the ACT promoter polymorphism may result in a higher expression of 
ACT and this change will vary between cell types and tissues.  This result is 
interesting as in AD amyloid plaques are localised to certain regions of the 
brain.  It may be that the difference in ACT promoter activity leads to localised 
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differences in ACT concentration, causing Aß fibrilisation to increase in these 
regions. 
 
4.2 Protein Interactions with the ACT –51 Promoter Alleles 
 
The functional assays, described above, demonstrated that the different ACT 
promoter alleles have cell-specific functional effects and confirmed that the 
ACT promoter responds to stimulation by OSM.  The mechanism by which 
these effects are mediated is unknown, although one possibility is that the 
promoter polymorphism alters the binding affinity of nuclear proteins 
responsible for initiating transcription.  The electrophoretic mobility assay 
provides a qualitative demonstration of the differences in DNA-protein binding 
activity of the two promoter alleles.  In this assay, DNA probes covering the 
polymorphic site of the ACT promoter interact with nuclear proteins extracted 
from cultured cells.  The greater the affinities to the nuclear proteins, the more 
the probes will bind to them.  Since the probes are labelled with a radioisotope 
the more probe that binds to the proteins, the more radioactive the DNA-protein 
complexes will be.  The assumption being tested is that the polymorphism alters 
the binding affinity to nuclear proteins, and this will be revealed by differences 
in signal strength on the autoradiograph.  If the probes for the different alleles 
bind to different proteins then the size of the DNA-protein complex will differ, 
and this will be revealed by the position of the complexes on the EMSA gels. 
In general, all the EMSA patterns show a similarity in that the T allele probe of 
the promoter polymorphism binds nuclear proteins more avidly than the G allele 
probe.  There does not appear to be a correlation between the increase in 
functional activity after OSM stimulation and increased DNA-protein binding.  
There are a number of possible reasons why this may be the case, for example 
the different complexes binding to the EMSA probes may be responsible for the 
magnitude of the OSM response. 
The EMSA gels all show that the radiolabelled probes have bound protein 
complexes.  One of the DNA-protein complexes appears to be common to all 
4.2 Protein Interactions with the ACT –51 Promoter Alleles  
141 
  
cell lines.  When nuclear extract obtained from T98G cells was incubated with 
radiolabelled probe and anti-TFIIB antibody the predominant band shifted, 
towards the top of the gel as a result of its increased size due to recognition by 
the antibody.  This is evidence that the protein present in this band was at least 
in part TFIIB, which forms a core component of the RNA polymerase II 
transcription complex.  By extension, it is possible that TFIIB is bind ing to all 
of the probes shown.  Unfortunately, due to the presence of higher molecular 
weight complexes in the Hep G2 and U373 MG cells lines, it was not possible 
to test with the anti-TFIIB antibody, as the band would be shifted into the 
position of these bigger complexes.  These higher order complexes either did 
not exist, or were present at levels difficult to detect in nuclear extracts from 
T98G cells. 
Other complexes were also present, although different complexes were present 
in each cell line.  These additional complexes appeared to bind less strongly, as 
their intensities varied.  Without further study, isolating and identifying these 
proteins, it is difficult to state with any certainty what these bands could be, and 
what relevance, if any, they could have to the regulation of the ACT gene.  It is 
known that a large number of proteins complex with TFIIB in the initiation of 
transcription.  These additional bands could be the transcription initiation 
complex in different stages of assembly, either missing factors, or containing 
additional proteins.  They may be the result of a non-specific binding, proteins 
that bind normally to a similar, perhaps related, DNA sequence.  However, this 
is unlikely as all reactions were conducted using an optimal concentration of 
poly dI-dC, which minimises non-specific binding.  What is interesting is the 
fact that there appear to be different proteins binding to the ACT promoter.  This 
raises the possibility that this region could bind to different proteins depending 
on the cell line thereby modulating cell-specific expression and contain, as yet 
unidentified tissue-specific factors.  Further work is required to determine if this 
is the case, or whether the bands represent the transcription initiation complex in 
different stages of assembly. 
The EMSA assays add some detail to the results of the functional assays.  It can 
be seen in all cases that the T allele appears to have a higher affinity than the G 
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allele for proteins isolated from cell nuclei.  Although it is not possible to say 
definitely that the ACT promoter is binding TFIIB several results suggest that 
this is the case.  The ACT promoter region contains sequence which matches the 
predicted sequence of a TFIIB-binding domain; binding is a function of the 
DNA sequence, which is changed by the polymorphic site.  The evidence to 
suggest that TFIIB is involved comes from the antibody shift experiment.  
Knowing that the promoter potentially binds TFIIB in T98G nuclear extract 
suggests a possible mechanism for the difference in ACT promoter activity, and 
makes it more likely that the functional data is a true reflection of what occurs 
in vivo.  TFIIB is more likely to bind to the T allele than the G, such that a 
transcription initiation complex forms more readily when the T allele is 
available.  This implies that ACT mRNA will be present at higher levels when 
the T allele is found in the ACT promoter than the G allele.  There is no data on 
mRNA splicing, or on translation, but if the level of ACT protein is dependent 
on the concentration of mRNA then differences in the ACT promoter 
polymorphism sequence will result in a greater transcription of the ACT gene, 
which will result in more ACT protein. 
 
4.3 ACT –51 Promoter Polymorphism and AD 
 
When the results of the binding assay are considered in the light of the 
functional data, bearing in mind the caveats mentioned above, it could be said 
that hepatocytes and astrocytes could produce a higher level of ACT depending 
on which form of the polymorphism is present.  This would mean that 
individuals that have the T allele of the promoter polymorphism would produce 
more ACT, during an inflammatory response, compared to individuals without 
the T allele.  Since hepatocytes appear to produce more ACT when the T allele 
is present, whether or not there is OSM stimulation, this would show up as an 
increase in plasma ACT compared to CSF ACT when there is no inflammation.  
This is precisely what has been shown in some studies to determine the viability 
of ACT as a biomarker in AD (Licastro et al., 2000a; Sun et al., 2003).   
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The functional and DNA-protein binding data suggest that the ACT –51 
promoter polymorphism alters the functional activity of the ACT gene.  Since 
the T allele of this promoter has a higher affinity for TFIIB, it is possible that 
this effect is mediated through the transcription initiation complex.  If this has a 
role in the pathology of AD, it could be expected that the T allele might 
segregate with AD.  To demonstrate this, DNA was genotyped from over 700 
subjects with confirmed and probable AD as well as controls.  In the control 
groups, both from Nottingham and Oxford as well as the combined populations, 
the genotypes were found to be in Hardy-Weinberg equilibrium, meaning that 
alleles are being distributed at random, not as the result of some selective 
pressure.  This is an important point, as it suggests that any differences found 
when comparing cases with controls are due to alleles segregating with AD.   
When comparing the frequencies of the ACT promoter alleles between AD cases 
and controls no significant differences were found.  This was true both of 
genotype frequency and allele frequency, in both populations separately and 
combined, and when considering confirmed AD, probable AD, or both. 
That the TT genotype does not segregate with AD does not mean that the ACT 
promoter polymorphism has no effect on AD.  It is possible that this 
polymorphism alters the pathology of AD, rather than the risk.  One way the 
pathology could be altered is increasing the aggressiveness of the disease.  
Should this hypothesis be correct, there need not be a change in ACT promoter 
genotype frequencies in AD cases, but such a change would increase the 
severity of AD once it develops.  However, the ACT promoter genotype 
frequencies did not show a significant change with age of onset in AD cases.  
When the AD cases were split into early onset and late onset, according to age 
at diagnosis, there was again no significant difference in the ACT genotype 
distribution. However, the numbers for this sub-analysis were very small and 
must be treated with caution in the light of other studies that show a potential 
involvement in early onset AD, for example, as shown in an Italian population 
(Licastro et al., 1999b). 
The absence of an association between ACT genotype and AD is perhaps 
unsurprising.  This study was designed to detect associations between alleles 
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and disease with an odds ratio of 2 or more, but on calculating the odds ratio for 
the association of the ACT T allele with AD, this was found to be less than 2, 
therefore not enough patients were included in the study.  As the ACT promoter 
polymorphism is a recent discovery, no data was available for the risk 
associated with the T allele of this gene with AD.  Overall in this study the odds 
ratio was 1.19 (95% CI 0.77 to 1.62), when all cases of AD were compared in 
both populations, without accounting for the APOE e4 allele.  Using the Quanto 
0.5 software, the number of cases required to gain a power of 80% for such a 
small effect can be computed.  The number of cases needed would be 2800, 
with an equal number of controls for a population of 75-year olds. 
 
4.4 Apolipoprotein E, Interactions with ACT and AD 
 
Previous studies have demonstrated that apolipoprotein E is a major risk factor 
for AD.  In particular, the e4 allele of APOE is associated with an increased risk 
of AD and e2 appears to have a protective effect.  It has also been reported that 
ACT may have an effect on AD risk in association with APOE e4.  The work of 
Licastro, et al. demonstrated that in both a mouse model, and in a human AD 
population, APOE e4 and the T allele of the ACT signal sequence polymorphism 
were associated with an increased risk of AD (Licastro et al., 1999a; Licastro et 
al., 1999b).  A positive correlation was found between brain ACT levels and the 
APOE e4 allele in AD patients (Licastro et al., 1998).  Other studies have either 
failed to show this effect (Durany et al., 1999; Helisalmi et al., 1997; Muller et 
al., 1996; Nacmias et al., 1996), or failed to prove or disprove an association 
(Axelman et al., 1999; Durany et al., 1999; Fallin et al., 1997; Kamboh et al., 
1997; Nacmias et al., 1998; Scacchi et al., 1999; Scacchi et al., 2001). 
The apolipoprotein E genotypes of the 405 AD patients and 307 controls were 
available.  These were divided into e4 allele carriers and non-e4 carriers.  The 
frequency of these allele groups in cases and controls were compared, and it was 
shown, in agreement with previous stud ies, that there was a greater number of 
e4 carriers in the AD groups (confirmed AD and probable AD) than in controls.
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It has been reported that the apolipoprotein E e4 allele is associated with 
lowering the age of onset of AD.  To demonstrate this effect the 382 AD 
patients for whom age was known were divided into e4 carriers and non-e4 
carriers and the mean age was compared.  It was shown that the e4 allele was 
associated with a lower mean age of onset. 
In contrast to the ACT promoter polymorphism AD risk associated with the 
APOE e4 allele is very much higher.  This was observed in this study, and 
agrees with data from previous studies.  Since the association of APOE with AD 
is so large, the number of samples needed to effectively demonstrate an 
association between allele and disease is much lower.  Due to this large effect 
on AD risk, the APOE genotyping had a very high power (greater than 99%), 
and the effect could have been reliably demonstrated with far fewer samples. 
 
4.5 ACT –51 Promoter Polymorphism in AD Patients Lacking APOE e4 
 
To demonstrate that the ACT –51 promoter polymorphism has an effect on the 
risk of AD, the ACT genotype frequencies were compared in 244 controls and 
160 AD patients lacking the apolipoprotein E e4 allele.  By excluding subjects 
with the APOE e4 allele, which has been shown to alter risk of AD, it is possible 
to look at the effect of the ACT polymorphism in isolation.  The ACT –51 
polymorphism genotype frequencies were not significantly different between 
cases and controls. 
No association with AD and ACT genotype in the absence of APOE e4 was 
demonstrated, so the hypothesis that the ACT -51 promoter polymorphism may 
have an effect on the age of onset of AD was tested.  The supposition was made 
that a lower age of onset would result in a mean lower age of diagnosis or death.  
This was again assuming that while the ACT promoter polymorphism does not 
alter the risk of developing AD it may alter the pathology of pre-existing AD.  
The 158 AD cases with data for APOE and ACT genotype together with age 
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were analysed.  There was no significant difference between the mean ages of 
AD patients with any ACT –51 genotype. 
The association of the ACT promoter polymorphism with AD in a population 
without the APOE e4 allele could not be demonstrated, but the number of 
samples used in the study was too low.  To conclusively demonstrate a small 
effect such as this, 1590 cases and an equal number of controls would have to be 
included to gain 80% power. 
 
4.6 General Discussion 
 
Previous studies looking at association of the ACT gene with AD have not 
conclusively demonstrated a link (Axelman et al., 1999; Bass et al., 1998; 
Didierjean et al., 1997; Durany et al., 1999; Durany et al., 1998; Egensperger et 
al., 1998; Ezquerra et al., 1998; Fallin et al., 1997; Haines et al., 1996; Helisalmi 
et al., 1997; Itabashi et al., 1998; Kamboh et al., 1998; Kamboh et al., 1997; 
Kamboh et al., 1995; Kim et al., 2000; Licastro et al., 2000b; Licastro et al., 
1999b; McGeer and McGeer, 2001b; McIlroy et al., 2000; Meng et al., 2000; 
Morgan et al., 1997; Muller et al., 1996; Muramatsu et al., 1996; Murphy et al., 
1997; Nacmias et al., 1998; Nacmias et al., 1996; Rodriguez Martin et al., 2000; 
Scacchi et al., 2001; Talbot et al., 1996; Tang et al., 2000; Tysoe et al., 1997; 
Wang et al., 1998; Yamanaka et al., 1998; Yoshiiwa et al., 1997; Yoshizawa et 
al., 1997). The signal sequence polymorphism of ACT, believed to influence the 
secretion of ACT into the extra-cellular matrix, has been reported to modify the 
risk of AD, but there have been contradictory reports with some studies being 
unable to find such a link (Licastro et al., 1999b; Nilsson et al., 2001b; Wang et 
al., 2002). Using the ACT microsatellite there was some evidence for an 
increased risk of AD when the microsatellite allele A10 was present, but the 
presence of Apolipoprotein E allele e4 was also required.  This thesis 
investigates the recently discovered ACT promoter polymorphism, and attempts 
to demonstrate if there is a link between this polymorphism and AD.  This work 
was designed to prove that the ACT promoter polymorphism does alter the 
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functional activity of the promoter in various cell lines, to give an insight into 
how this activity might be modified, and to determine if there is a relationship 
between the alleles of the polymorphism and AD risk. 
The functional assays performed in the course of this study have not only 
confirmed results of previous work, that OSM increases the activity of the ACT 
promoter in astrocytes (Kordula et al., 2000; Kordula et al., 1998), but also, that 
the –51bp polymorphism in the promoter region of the ACT gene modifies the 
activity of the promoter.  These effects were demonstrated in hepatocytes and 
astrocytes, both of which have previously been shown to produce ACT (Castell 
et al., 1989; Yoon et al., 2002).  The main difference between the two cell lines 
is that Hep G2 cells containing either allele show an immediate response to 
OSM stimulation.  In the liver cells, the response to OSM is rapid, but short-
lived.  In astrocytes, there is a stronger response to OSM when the T allele is 
present than when the G allele is present, it is slower to appear, but persists 
longer.  This is interesting in the context of AD.  If neuroinflammation is a 
feature of AD, as is a current belief amongst some researchers, the presence of 
the T allele might result in an elevated synthesis of ACT, which would not be 
the case if this allele were absent.  This in turn would mean that the balance of 
Aß between the form of oligomers and polymers may possibly be altered, which 
could result in differences in the pathology of AD between individuals, such as 
earlier onset, or faster progression of the disease. 
The response to OSM in the mixed population T98 G cells is broadly similar to 
that of astrocytes.  This, perhaps, could be expected, as astrocytes are present in 
the T98 G population.  During an inflammatory response a range of signalling 
molecules are produced from a range of different cells.  These molecules, such 
as cytokines, influence other cells and modulate the inflammatory response.  
The difference in activity between a pure astrocyte population and a mixed 
population containing astrocytes is important when considering 
neuroinflammation.  In vivo cells do not exist in isolation, and communicate in 
varied and often subtle ways.  This well illustrates the problems of studying a 
model system and trying to draw conclusions about a more complex organism.  
At the very least, one can conclude that the choice of tissue used to study a 
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functional polymorphism is critical in generating meaningful results.  The 
response of the promoter polymorphism is different when the reporter construc t 
is transfected into Hep G2, U373 MG or T98 G cell lines, each of which could 
be chosen to study such a response.  There is no known tissue specific element 
in the regulatory region of the ACT gene, but these results show that the 
promoter response varies in different tissues anyway. 
The neuronal cells, SH-SY5Y, were included as a negative control.  These cells 
are not involved in inflammation, and RT-PCR showed that these cells were 
producing no ACT mRNA.  This is reflected in the comparison of reporter gene 
response to OSM, which is non-existent.  There is, however, still a difference 
between the response shown by each allele.  Although in previous cell types the 
basal activity was measured over different times, and showed no significant 
variation (data not shown), in these cells there is no response to OSM, so that at 
each time point the results are consistent with the basal activity.  There is still a 
difference between the promoter activity of each allele, and that difference is 
consistent: the T allele is more active than the G allele.  This is the case in every 
cell line, regardless of the effects of cytokine stimulation. 
Having demonstrated that the polymorphism does have a functional effect, in an 
experimental model, there are legitimate grounds to question whether this 
polymorphism could have an effect on the risk and pathology of AD.  The 
limitations of this model should be considered before going on to ask these 
questions.  What is being measured is the effect of a cytokine on a reporter gene 
construct, not on chromosomal DNA.  There are almost certainly other features 
of chromosomal DNA that are not present in these experimental vectors.  The 
vectors used are modified plasmids, structures not found in mammalian cells.  
The regulatory elements of the ACT gene are found up to 13,000bp upstream of 
the transcription start site, while the DNA in the vector is only 345bp, or 2% of 
the regulatory elements (Kordula et al., 2000).  While not every base of those 
13kbp may be needed for the regulation of the ACT gene, there are other 
elements that do modify the activity of the ACT gene.  These were not included 
in the reporter construct used in these experiments, and their effects were 
therefore ignored.  This is not a fatal flaw, however, as the purpose of these 
4.6 General Discussion 
149 
  
experiments was to look at the promoter polymorphism.  Further 
polymorphisms can be examined in the future, and the combined effects can be 
investigated then.  What is more important is that the chromosomal version of 
the ACT promoter does not exist, in vitro, as naked DNA.  Genomic DNA 
cannot be considered as structurally uniform; it may be methylated, or wrapped 
around histones, or made inaccessible by its location on coiled DNA.  The 
structure of genomic DNA is not static, as DNA can coil and uncoil, associate 
and dissociate with proteins that support, repair and replicate it.  The 
experimental vectors are at best are a highly simplified model of the true picture 
of the mechanisms found in the nucleus. 
In addition to this, the protein produced using the reporter gene constructs is not 
ACT, but luciferase.  ACT, as it is found in the extracellular matrix, is the 
product of transcription, translation and post-translational modification.  
Although these events may take place to create a mature luciferase protein, they 
will not mimic exactly what occurs to ACT in the tissues.  These experiments 
only show what effect the polymorphism has on promoter activity; they do not 
and cannot show what happens beyond this.  Other changes that could occur at 
the level of transcription, translation, and secretion of ACT, all of which may 
have an effect on ACT levels in the brain, or CSF, or plasma, are not revealed.  
For example, it may be the case that an increase in promoter activity may result 
in a higher level of ACT mRNA being transcribed, but if there is no increase in 
translation, and this may be more dependent on ribosome availability, then the 
level of ACT protein might not vary.  Whether this is the case or not is beyond 
the scope of this type of experiment to determine.  What is shown is that there is 
a functional effect of the ACT promoter polymorphism, and that is worthy of 
further investigation. 
It should be added that the OSM used in these assays is human recombinant 
OSM, synthesised in E. coli.  While this form of OSM does produce a 
demonstrable response in functional activity, it was used at nanomolar 
concentrations.  In vivo, the protein is matured in eukaryotic cells, and is present 
in picomolar concentrations (Slaviero et al., 2003).  The differences between the 
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experimental model and the conditions found in living tissue could be 
significant. 
The functional data appear to fit a model of AD rather well.  There is a chronic 
inflammatory response in the brains of AD patients which results in cytokine 
signalling that, in turn, provokes the secretion of acute phase proteins.  These 
result in alterations in the homeostasis of Aß, leading to neurodegeneration, and 
progression of AD.  This is the basis on which the polymorphism might have an 
influence on the risk of AD, or the age of onset.  According to the genotyping 
data, it would appear that the ACT promoter polymorphism alone is not 
sufficient to alter the risk of developing AD.  It has been suggested that the 
polymorphisms in the ACT gene associate with polymorphisms in the 
apolipoprotein E gene and that together they modulate the risk of AD (Axelman 
et al., 1999; Kamboh et al., 1997; Kamboh et al., 1995; Lamb et al., 1998; 
Licastro et al., 1999b; Nacmias et al., 1996; Potter et al., 2001; Rodriguez 
Martin et al., 2000; Scacchi et al., 2001; Yoshiiwa et al., 1997).  In the data 
presented in this thesis, a strong association was shown between APOE 
genotype and AD, and the e4 allele was associated with a lower age of onset.  
The effect of APOE e4 was so strong that it was difficult to determine if any 
allele of the ACT promoter polymorphism contributed to it.  In the absence of 
the APOE e4 allele, however, there was still no association between ACT 
genotype and AD, nor was there a link between lower age of onset and ACT 
genotype.  The number of subjects available to test this hypothesis was too low 
to make a definitive statement about this.  A recent study has shown an 
increased risk of EOAD associated with the ACT TT genotype in an Italian and 
English population independently of the presence of the APOE e4 allele.  In 
existing AD cases, the ACT TT genotype was also associated with faster 
cognitive decline in patients with the APOE e4 allele (Licastro, et al, submitted 
2004). 
It would seem that while there is a functional effect of the ACT promoter 
polymorphism, this does not correlate with an association in AD.  There are 
several possible reasons for this.  It could be that, as mentioned above, a change 
in promoter activity does not necessarily result in a change in protein level in 
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the extracellular matrix.  However, patients with the TT genotype have been 
shown to have a higher serum ACT level compared to the GG genotype, so this 
is unlikely to be true (Licastro et al., 2000b).  This could be due to events that 
occur after the initiation of transcription.  The polymorphism may well 
influence the rate of transcription, and this effect could be exacerbated by 
cytokine stimulation, but if some other process alters the result of that 
transcription, this effect may be irrelevant to the level of protein found in the 
extracellular environment.  One research group has suggested that another 
polymorphism, the ACT signal sequence polymorphism, influences the rate of 
protein secretion (Wang et al., 2002).  If the rate of protein secretion were 
altered independently of the rate of transcription, the effect of the promoter 
polymorphism on extra-cellular ACT would be diminished.  Linkage analysis 
has shown that the higher expressing T allele of the promoter polymorphism is 
tightly linked to the –17A signal sequence allele (Morgan et al., 2001). 
Sequence analysis of the ACT regulatory regions has revealed more than one 
SNP, and at least one, in the enhancer region, may also have functional activity, 
although this is yet to be confirmed.  If the –51bp polymorphism is one of a 
number of functionally active SNPs that alters the rate of ACT transcription then 
studying one SNP in isolation may not reveal an association between one 
genotype and AD.  Haplotype analyses, looking at a number of SNPs in diseases 
clearly represents the way forward, as the technology for mass screening 
becomes more readily available (Dennis, 2003; Gabriel et al., 2002; Koch et al., 
2002; Martin et al., 2000; Patil et al., 2001; Salisbury et al., 2003).  A recent 
hypothesis states that several sporadic forms of neurodegenerative diseases may 
all be due to variation in the regulatory region haplotypes, and the difference in 
quantity of proteins produced by such variation is an important factor in the 
genetic risk of these diseases (Singleton et al., 2004).  An investigation into 
haplotypes of the ACT regulatory regions in AD has already begun.  It is 
possible that the –51bp polymorphism is part of a more complex picture.  If the 
odds ratio associated with a haplotype is higher than that of a genotype of a 
single polymorphism then the number of samples required for 99% power in a 
study will be reduced.  If there is a functional effect of each SNP in regulatory 
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region being studied, then the cumulative effect of all the SNPs in the haplotype 
will be considered. 
Another layer of complexity is added when the interactions of cells under 
inflammatory conditions are considered.  Unlike in the functional model used 
here, cells are not subject to the influence of one cytokine at a time during 
inflammation (McGeer and McGeer, 1995).  A number of cytokines as well as 
other signalling molecules are involved.  While the one-cytokine model used in 
the functional assays might produce a certain response in cultured tissues, the 
response of cells bathed in a cocktail of cytokines, in contact with different cell 
types, in a living organism is almost certain to be different.  It has been shown 
that IL-1ß can inhibit activation of the a2-macroglobulin promoter by IL-6 
(Bode et al., 2001).  IL-1ß activates NF-?B, which can competitively bind to 
STAT responsive elements, preventing binding by STAT3.  The activation of 
the ACT enhancer by IL-6 can also be inhibited by NF-?B, mediated by IL-1ß 
(Bode et al., 2001).  An NF-?B consensus site is essential for IL-6-induced 
transcription (Bode et al., 2001) and it may be the case that the interplay 
between IL-1ß inhibition and IL-6 activation is more important than the effect 
of a single cytokine when considering the regulation of the ACT gene.  If AD 
does result in a state of chronic neuroinflammation, it is possible that cells 
undergo changes to adapt to pathological conditions, resulting in a different 
response to stimulation in pathological tissues than healthy tissues (Black, 2002; 
Slaviero et al., 2003).  Conversely, the effect of the ACT promoter 
polymorphism could influence other genes that might have an effect in AD.  
ACT is known to have DNA binding properties (Kalsheker, 1996), and while 
the ability of ACT to enter the nucleus and have a direct effect on DNA is 
unproven, ACT is known to have more properties than simply inhibiting serine 
proteases.  Complexed ACT is removed from the circulation by receptor-
mediated pathways, where it is presumably degraded.  Is it possible that the 
DNA-binding domain once liberated from ACT-protein complexes could enter 
the nucleus?  Preliminary data suggest that several genes in cells incubated with 
ACT and Aß are activated in the presence of these proteins together, but not 
separately (Baker and Morgan, unpublished data).  This would again suggest 
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that the ACT promoter polymorphism is one SNP in a chain of genetic 
alterations needed to provoke AD.  This situation is similar to that seen with the 
involvement of several proto-oncogenes in cancers.  An environmental effect, 
coupled with several polymorphisms is required for the development of a 
disease.  In the case of AD it could be that an initial trauma would trigger an 
inflammatory reaction, which, when certain alleles are present in different 
genes, would lead to the development of self-perpetuating neurodegenerative 
state.  As mentioned in the introduction, a large number of genes have been 
investigated and shown to have an influence on the risk of AD.  Some of these 
genes could very well be involved in the aetiology of AD, and although no 
single combination of polymorphisms in these genes may be needed to produce 
AD, a combination of some may be necessary, in some cases, to trigger this 
disease.  The most obvious example of this is the apolipoprotein E 
polymorphism.  It has been shown that while the e4 allele does influence the 
risk of AD, it is neither necessary nor sufficient to cause AD (Laws et al., 2003).  
This is compatible with a model where a number of different polymorphisms 
have a small effect on the likelihood of developing AD.  The more “proto-AD 
genes” present, the greater the risk, with APOE e4 having the greatest effect of 
all these polymorphisms.  This would also suggest the possibility that there is no 
one Alzheimer’s disease, but a range of sub-types of Alzheimer’s diseases, each 
having the same symptoms, but being caused by different polymorphisms.  
These subtypes could be more or less aggressive, depending on which genes 
were involved; the age of onset could vary, depending on when the disease is 
triggered and which genes are involved.  The inheritance of AD would follow a 
non-Mendelian model, as several genes are necessary in this scenario.  This is, 
of course, what is seen in AD, with sporadic and familial forms of the disease, 
as well as early- and late-onset subgroups.  The familial form of AD is 
dependent on inheriting disease-associated forms of one of three genes: the 
amyloid precursor protein gene, presenilin 1 and presenilin 2, while the genetic 
cause of the sporadic form, if any, is unknown (Rocchi et al., 2003). 
If sporadic AD is a polygenic, multifactorial disease, it could alter the prospect 
for developing treatments.  While there may be an underlying basis for the 
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aetiology, for instance, every polymorphism could alter the inflammatory 
response, then a treatment that targets the abnormal inflammatory response 
could be effective in every form of AD.  If there is no commonality between 
subgroups, other than the end results, it may be difficult to design one treatment 
that is effective in each case.  In this case, the pathway that leads to senile 
plaques might be different to that which causes tau pathologies, for instance.  In 
some cases a treatment might prevent amyloidosis, but not avert development of 
tauopathies.  Recent work on the aetiology of AD suggests this might not be the 
case, as it is starting to look as though there is a common pathway that produces 
both amyloid plaques and tau fibrilisation (Mudher and Lovestone, 2002).  
Determining which gene pathways are involved in AD, and to what extent, and 
how they influence the progression of AD is still likely to be extremely 
important to reach the goal of a cure, or even improved treatment of AD. 
Whether or not these hypotheses are true, it is clear that further work is needed 
before a definitive conclusion can be made on the involvement of ACT in AD.  
Some of this work has already begun. 
A search for new polymorphisms in the regulatory regions of the ACT gene has 
started, looking at both the 5’ and 3’ flanking regions of the gene.  Once found, 
and some have already been discovered, they must be investigated to determine 
functional activity.  Once this has been done, genotype and haplotype analyses 
can be made, to see if any are associated with AD.  It is more likely that a group 
of functionally active SNPs will show an association with AD than one SNP 
considered alone (Martin et al., 2000).  Even a SNP that has a large functional 
effect may be modulated by alleles at other loci, which means the overall 
functional effect of the haplotype is greater than the effect of the individual 
genotype.  The “signal” of an association between alleles of any single SNP and 
AD may well be lost in the “background noise” of the effect of the other SNPs 
being investigated on an individual basis. 
Following on from this, the post-transcriptional events will need investigation.  
It remains to be seen whether changes in DNA-protein binding results in 
changes in mRNA levels.  The level of mRNA needs to be measured, for 
instance by quantitative RT-PCR and compared to either the ACT –51bp 
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polymorphism genotype or the haplotype of a range of ACT regulatory SNPs.  If 
there is no difference between mRNA level, there could be differences in 
mRNA length, due to differences in splicing, which might alter the mRNA 
stability, although there is no evidence yet for alternative splicing in the ACT 
gene.  If the mRNA half- life varies, this may have a greater effect on translation 
than the concentration of mRNA, for instance, if a particular form of mRNA is 
unlikely to survive long enough to reach a ribosome, or if it can be translated 
repeatedly. It is possible to determine mRNA stability and this might be an 
interesting line of research for the future. 
As well as post-transcriptional events, there are post-translational events to be 
considered.   Most proteins undergo modifications before becoming mature 
proteins.  While it is implausible that a SNP in the non-coding, regulatory 
regions of the gene would influence post-translational modification, a regulatory 
SNP could be in linkage disequilibrium with a coding SNP.  The –51bp 
polymorphism, for instance, is in almost complete linkage disequilibrium with 
the signal sequence polymorphism found in exon one of the ACT gene (Morgan 
et al., 2001).  While the amino acids coded for by this exon are not present in 
the mature protein, it does influence the secretion of the protein.  If there were 
other SNPs that do result in a modified form of the mature protein, which are in 
partial linkage disequilibrium with a functionally active regulatory SNP, the 
effects on AD would be worth investigating. 
Changes in ACT activity and function alone do not cause AD.  It would seem 
that ß-amyloid is a key protein in the development of AD, and there are many 
other proteins that are involved in the processing of amyloid precursor protein to 
Aß, and still more proteins that have an effect on the APP gene.  In the case of 
APOE, there is a demonstrable effect on AD risk, but there are many other 
candidate proteins, and therefore genes, which may modify the risk of AD 
(Rocchi et al., 2003).  With recent improvements in technology to allow rapid 
sequencing and comparison of sequences, it is easier than ever to search for 
SNPs in candidate genes for AD (Chandra et al., 1983; De Quervain et al., 2004; 
Sun et al., 2000).  The growing availability and improvements of micro-arrays 
means that it is becoming easier to test for functional activity of such 
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polymorphisms in the presence of several cytokines.  Similarly, the effects of 
novel molecules, such as Aß, on gene regulation can be investigated with 
greater ease than before.  Where, only a few years ago, investigating the 
functional effects of one cytokine on one gene was a time consuming affair, 
studying the expression of an entire gene pathway can now be achieved in the 
fraction of the time (Lee et al., 2000).  As more data are obtained, the 
computational models for predicting regulatory regions from sequence data will 
become more accurate and powerful (Rodriguez-Antona et al., 2003; 
Schlotterer, 2003; Segal et al., 2003).  This will make it easier to find regulatory 
regions to test, and it may one day be possible to predict the functional activity 
of regulatory region of DNA by computer analysis alone, although it would be 
advisable to confirm this experimentally.  Until that day arrives, new ways of 
studying the genetic involvement of AD are becoming available. 
A transgenic strain of Caenorhabdis elegans has been developed which 
expresses human Aß (Link et al., 2003).  The C. elegans model has several 
advantages over previous model organisms, such as rodents and primates.  It is a 
simple, multi-cellular organism, with a short lifespan.  The lifespan of C. 
elegans is considerably shorter than mice, which means that the effects of Aß 
over a lifetime can be studied in a shorter time than previously.  It is also easier 
to produce and house large numbers of offspring, so that experimental groups 
can be larger, generating more reliable data, at a lower cost.  Finally, while more 
complex than tissue culture, the C. elegans approach is far simpler than mouse 
models, so there are fewer interrelated genes and environmental factors to take 
into account with this model.  This means that the effect of one gene on the 
organism may be demonstrated more clearly in the worm than the mouse.  If a 
transgenic worm can be produced that expresses Aß, a worm that produces ACT 
is also possible, as has been achieved with mouse models (Nilsson et al., 
2001a).  Genes can then be studied in relation to each other, and their effects 
demonstrated more clearly than before, and more rapidly. 
The results of these experiments have shown that a functional effect of a 
polymorphism in the regulatory region of the ACT gene might have a bearing on 
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AD.  While they do not demonstrate that this polymorphism does influence the 
risk of AD, it is one small part of a much greater, complex web of cause and
 effect.  Newer technology is emerging that will in future make it far easier to 
study more of these integrated networks.   The results obtained in this study 
have not closed the door on the possibility that this polymorphism is a risk 
factor for AD, but neither has this been demonstrated.  What has been shown 
indicates that there is still a need for further work that might demonstrate some 
role for ACT in AD, although this could be one factor amongst many that 
contribute to the disease process.  A recent report has shown that, in transgenic 
mouse models, the process of Aß fibrilisation is more neurotoxic than 
monomeric, oligomeric or fibrillar Aß (Nilsson et al.), possibly due to the 
formation of a neurotoxic intermediary between the different forms of Aß.  ACT 
and ApoE are pathological chaperones crit ical to the process of Aß fibrilisation. 
 
4.7 Conclusions  
 
These experiments have confirmed previous observations that the ACT promoter 
responds to oncostatin M stimulation.  In addition, they have shown that the T/G 
polymorphism located in the promoter region at –51bp is also functional.  The T 
allele of this polymorphism is responsible for increased activity of the promoter, 
both under basal conditions and when stimulated by OSM.  The G allele is 
functionally less active, but responds to OSM in the same fashion as the T 
allele.  The response of the promoter polymorphism varies between different 
cell lines. 
The polymorphism appears to alter the binding afinity of TFIIB to the ACT 
promoter with the T allele having a greater afinity for this transcription initiation 
complex subunit than the G allele. 
No genetic association between the ACT –51bp polymorphism and late onset 
AD was detected, and there was no apparent effect of this polymorphism on 
influencing age of onset of AD in the two UK populations studied.  However, 
the small size of the study means that the question of any risk associated with 
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the ACT –51 promoter polymorphism and early onset AD remains to be 
established. 
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6 APPENDIX ONE 
 
6.1 The 5’ Flanking Sequence of ACT 
 
CTGAGGTGGGCAGATCACGAGGTCAGGAGGTCGAGACCAGTCCGGCCGACAAGGTGAAACCCTG 
F1 
TCTCTACGAAAAATACAAAAATTANCTGGGCGTGGTGGTGTGTGCCTGTAGTCCCAGCTACTCG 
 
GGAGTCTGAGGCAGAAAGTTGCTTGAACCCGGGAGTCAGAGGTTGCAGTGAGCTGAGATCACGC 
 
CACTGCACTCCAGCCTGGGCAACAAAGCAAGACTCTGTCTCAAAATAAAAATAATAAATAAAAA 
                 F2 
GAAATAAAAAAGAAATATACCCACATGTTAGCTGGGGTCTTCTCTGGGTAGTAAAGTGCTGGGG 
 
GATATTTTCCAAAGTCCTTCTTTACATTCTCTGAGTTTTTCCATGTTCTTCAATGAGTATTTAA 
 
TAAGCAGATAAAAACTAATACAACAAAGGATTTTTTCTGTGTGCTTTTTTGACCTTTGGAGGAA 
 
GAGATTAGAGCTAGTCCCATAACCAGGTTATTTGAGTAGGTCTAATAAGCCCGTATTACCAGAA 
                                     F5 
ATTATCATCTGGTCATTTCCAGTCCGAGAACAGAACACTTGGTTGTCCTGGCATTTCCCAAGCA 
              R2                   R5               +1 
GGGGGAGGAGTTCTCTGCAGGAATAAATAAGCCTCAGCATTCATGAAAATCCACTACTCCAGAC 
                                                  R1 
AGACGGCTTTGGAATCCACCAGCTACATCCAGCTCCCTGAGGCAGGTAATCCATGATGTTTTAC 
 
ATCCTGGGAGCGGAGGAATCTGTTTTTCCAGGAGAGTTTTAGGCAGCAGCCTGGAGTGTGTGGA 
 
GTGTGAGGGGTAAGCAGAG 
Figure 6.1.1: The 5' Region of the a1-antichymotrypsin gene.  Highlighted sequence shows 
primers and the TATA box, +1 is the transcription start site, G is the -51 polymorphism. 
TATA box 
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Figure 6.1.2:  The 330bp ACT  promoter region insert in pGL3E construct.  Arrow shows 
the position of the G allele, and underlined bases shows the position of the R2 primer. 
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Figure 6.1.3The 330bp ACT promoter region insert in pGL3E construct.  Arrow shows the 
position of the T allele, and underlined bases shows the position of the R2 primer. 
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7 APPENDIX TWO 
7.1 Apolipoprotein E and a1-Antichymotrypsin Genotyping Data 
 
APOE ACT Confirmed AD Probable AD Total AD Control Total 
GG 26 6 32 51 83 
GT 54 13 67 96 163 e3/e3 
TT 31 8 39 49 88 
GG 0 0 0 0 0 
GT 0 1 1 1 2 e2/e2 
TT 0 0 0 1 1 
GG 26 6 32 10 42 
GT 78 15 93 30 123 e3/e4 
TT 33 12 45 26 71 
GG 4 1 5 16 21 
GT 7 3 10 18 28 e2/e3 
TT 3 3 6 12 18 
GG 9 2 11 1 12 
GT 16 7 23 2 25 e4/e4 
TT 4 2 6 0 6 
GG 5 1 6 1 7 
GT 8 1 9 4 13 e2/e4 
TT 2 0 2 3 5 
Table 7.1.1: Frequencies of Apolipoprotein E and a1-antichymotrypsin genotypes in AD and 
control subjects. 
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APOE ACT Mean Age n 
GG 78.83 32 
GT 76.63 66 e3/e3 
TT 77.48 39 
GG 74.28 31 
GT 75.06 91 e3/e4 
TT 74.26 43 
GG 76.37 5 
GT 78.20 9 e2/e3 
TT 78.81 6 
GG 74.69 11 
GT 70.37 23 e4/e4 
TT 67.99 6 
GG 75.92 6 
GT 84.80 9 e2/e4 
TT 82.26 2 
GG 0 0 
GT 78.57 1 e2/e2 
TT 0 0 
Table 7.1.2: Mean Age of AD Onset in Apolipoprotein E and a1-Antichymotrypsin 
Genotypes 
 
